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1 Abstract 
The transport of compounds around the body has been a topic of 
interest for many years, and the advent of non-invasive biological 
imaging in living tissue has made huge advances in the characterisation 
and localisation of cellular receptors for use in drug targeting.  
However, there remains a significant paucity of knowledge regarding 
how the majority of drug molecules are transported about the body, 
when they often exhibit negligible aqueous solubility and the body 
expresses no trans-membrane pumps or chaperone proteins that 
recognise them and facilitate their movement.  This leads to large 
attrition rates in drug discovery programmes, as compounds with high 
binding constants or inhibitive activity in vitro fail to perform in vivo, 
due to poor bioavailability or non-specific sequestration away from the 
tissue of interest. 
In this study, the interactions between a number of drug and lipid 
molecules were investigated and the effects upon both the lipids’ 
chemical and bulk membrane structures were analysed.  This revealed 
some of the mechanistic causes of the previously observed hydrolytic 
activity a number of common drug compounds exhibit toward lipid 
membranes and identified parameters affecting the observed rates of 
reaction.  The findings also suggest approaches by which this behaviour 
might be predicted, or even tuned to deliver optimum pharmacological 
characteristics.  
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3 Introduction  
(Adapted from A. Seddon, D. Casey et al., Chem. Soc. Rev., 2009, 38, 2509–25191) 
Understanding the mechanism at the molecular level by which drugs interact with cell 
membranes is of critical importance in pharmacological science.  Many drugs, displaying a wide 
range of applications and with diverse structures, can cross or bind to lipid membranes and 
potentially modulate the physical properties of that membrane. However, the cell membrane is 
a carefully balanced environment and any changes inflicted upon its structure by a drug 
molecule must be considered in conjunction with the overall effect that this may have on the 
function and integrity of the membrane. 
 
3.1 The Cell Membrane 
3.1.1 Eukaryotic cell membranes 
The plasma membrane of all cells is comprised of a double leaflet of lipids organised into a 
bilayer structure, and maintains the difference in electrolyte concentrations and electric field 
gradient between the extracellular environment and the cytosol within the cell.  In eukaryotic 
cells, the interior of organelles such as the endoplasmic reticulum, the Golgi and the 
mitochondria are separated from the cytosol by a second membrane. This allows cells to 
maintain differences in pH or ionic strength inside organelles, especially in the case of 
mitochondria which rely on their internal membranes to isolate the harmful reactive oxygen 
intermediates formed during the synthesis of ATP. 
 
3.1.2 Lipid composition of membranes 
Biological membranes consist of a back-to-back arrangement of amphiphilic lipid molecules.  
The interior of the plasma membrane is comprised of hydrophobic fatty acid tails, with the 
hydrophilic lipid head-groups pointing outwards to the extracellular and cytosolic regimes. 
Although the hydrophobic interior acts as a barrier to the passage of polar molecules and ions in 
or out of the cell, a modulated flux of these species is required for the cell to function, meaning 
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regulated mechanisms by which molecules can cross the membrane are vital. The mechanisms 
by which molecules can enter or leave the cell will be discussed in detail below.  
 
Figure 1: The fluid lipid bilayer structure is comprised of a variety of phospholipids, sphingolipids and sterols and 
contains channels and membrane-associated proteins. (A) membrane channel; (B) surface associated membrane 
protein; (C) transmembrane protein; (D) the lipid bilayer, with the hydrophilic lipid head-groups represented as coloured 
circles and the fatty acid tails as black lines
1
. 
 
The lipids that make up biological membranes are highly varied in terms of their head-group, 
chain length and degree of saturation.  These membranes are approximately 5nm thick and are 
studded throughout with a range of trans-membrane and membrane-associated proteins, as 
shown above in Figure 1.  The role of lipids in vivo extends beyond that of structural 
compartmentalisation as they are involved in cell signalling pathways and implicated in a 
number of disease pathologies.  Furthermore, the composition of cellular membranes can be 
altered rapidly in response to environmental stimuli2.  A comprehensive overview of biological 
membranes and their structure has been written by van Meer et al. and references cited 
therein2.   
Recent research has shown that there is greater underlying structure to the lipid bilayer and 
that lateral ordering within the bilayer may play an important role in certain biological 
processes.  The formation of microdomains, (or rafts), for example, is hypothesized to be 
involved in signalling complexes3.  While the existence of rafts has been demonstrated in model 
membranes, their existence in vivo remains controversial. A full discourse of the intricacies of 
membrane structure is beyond the scope of this thesis and the interested reader is directed to 
recent reviews on this topic.  
The structure of the cell membrane is maintained by enzyme activity both within the membrane 
itself and in the cytosol, synthesising or digesting lipid molecules in order to conserve its 
integrity.  The plasma membrane of eukaryotic cells consists predominantly (~50%) of the 
glycerophospholipid phosphatidylcholine, with smaller fractions of phosphatidylethanolamine, 
phosphatidylserine, phosphatidylinositol and phosphatidic acid.  An example is presented below, 
A B C D 
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in Table 1.  To add to the complexity, each lipid class contains fatty acid chains of varying length 
and degree of unsaturation4.  These can contribute significantly to the curvature of each 
individual lipid: double bonds in lipid biosynthesis are almost exclusively cis, meaning that a 
single unsaturated bond can dramatically increase the volume occupied by the fatty chain 5.   
Phospholipid class % of total lipid phosphorus 
Acylphosphatidylglycerol <0.1 
Bis(monoacylglycero) Phosphate 0.32 
Diphosphatidylcglycerol 6.25 
Phosphatidylcglycerol 0.22 
Phosphatidylethanolamine 26.3 
Phosphatidylcholine 46 
Phosphatidylinositol 9.88 
Phosphatidylserine 3.19 
Sphingomyelin 3.92 
Lysophosphatidylcholine 0.86 
Others 3.07 
Table 1: The relative composition of the phospholipid membranes found in rat liver homogenates
6
. 
By contrast, bacterial membranes such as that of E. Coli are 70% phosphatidylethanolamine with 
phosphatidylglycerol species constituting the remaining majority 2.  Literature values for the lipid 
compositions of different tissue and organelle membranes within an organism are available but 
these are often unreliable and subject to considerable variation between measurements. The 
search for the ‘lipidome’ is particularly hampered by its dynamic nature in response to external 
stimuli2.   
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Another class of structural lipids are the sphingolipids are another class of structural lipids, 
which contain a ceramide backbone. Sphingomyelin is the major sphingolipid component of 
mammalian cells, as well as the glycosphingolipids containing mono-, di-, or oligosaccharides 
based on glucosyl or galactosylceramide. Sterols comprise the major class of non-polar lipids in 
cell membranes. In mammals, the predominant sterol is cholesterol2.  These common head-
groups are illustrated in Figure 2, and their phase behaviour is discussed in depth below.  A 
comprehensive review on the different lipids found in both eukaryotic and prokaryotic 
membranes is given by Dowhan7, and for an in-depth discussion of their structures and 
nomenclature see Fahy et al.8. 
 
Figure 2: Head-group structures of commonly occurring membrane lipids and the structure of cholesterol. R indicates an 
alkyl chain. 
 
3.1.3 Phase behaviour of lipids 
Lipids can adopt a range of lyotropic phases in the presence of water, including the fluid 
lamellar, inverse hexagonal and inverse bicontinuous cubic phases 9. In order to understand the 
formation of these phases, the total free energy of the system must be considered. Gruner et 
al.10 hypothesized that the total free energy of bilayer systems (gtotal) is dominated by three 
contributions: the bending energy per unit area, gC, the packing of the hydrocarbon chains, gP, 
and ginter which brings together hydration and electrostatic forces into a single free energy 
interaction term leading to: 
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Equation 1 
10
  
Under certain circumstances, the last term can be assumed to be, or experimentally arranged to 
be negligible, leaving the curvature elasticity and the packing of the hydrocarbon chains as the 
chief terms dictating the free energy of the system. The curvature elasticity is determined by 
reducing the lipid bilayer to an infinitely thin elastic surface. Deforming such a surface has an 
associated energy cost, which depends on changes in the mean curvature (Equation 2) and 
Gaussian curvature (Equation 3), where c1 and c2 are the principal curvatures of the surface 
under consideration and are illustrated in Figure 3.   
       
Equation 2 
    
Equation 3 
 
Figure 3: The radii of curvature of a surface, R1 and R2. The principle curvatures of a surface, c1 and c2, are given by the reciprocal 
of the radii of curvature of that surface, 1/R1 and 1/R2, respectively. 
When combined with the bending modulus κ and Gaussian modulus κ G which describe the 
energy cost per unit area of changing the mean and Gaussian curvature,  this leads to the 
‘Helfrich ansatz’ which describes the curvature elastic energy per unit area g C for a membrane 
(Equation 4)10: 
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Equation 4 
where H0 is the mean curvature (or spontaneous mean curvature) of the surface when relaxed.  
The spontaneous mean curvature depends on the distribution of lateral stresses acting  on the 
membrane at varying depths (Figure 4a).  The lateral pressure in the chain region which occurs due 
to thermally activated trans-gauche conformational changes is balanced by the interfacial tension 
at the polar / non-polar interface where the head-groups are attached to the chains. There will also 
be head-group interactions between lipids which may be repulsive or attractive (electrostatic, steric 
or hydrational). This often represented by a lateral stress profile as shown in Figure 4b which is a 
plot of the lateral stress π(z) against the distance z through the monolayer. The net lateral tension 
across this monolayer (the integral of the stress profile) must equal zero with the spontaneous 
curvature proportional to the first moment of the lateral stress across the monolayer11. 
 
Figure 4: (a) The forces acting on the lipid bilayer at varying depths within the bilayer; (b) the lateral pressure profile. 
The magnitude of each of these contributions is dictated by the steric and electronic structure of 
the head-group and fatty acid tail of each of its component lipids, leading to an average value of 
an otherwise vastly complex system.  Head-group pressure is controlled by its cross-sectional 
area, any charges it contains and the hydration shells that these groups co-ordinate, as well as 
any interactions with neighbouring head-groups.  Fatty acid interactions are dominated by 
hydrophobic effects and Van der Waals forces, meaning that fully-saturated, all-trans systems 
pack the most closely and thus occupy the smallest cross-sectional area.  In order to simplify 
a) 
b) 
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these concepts, the lipids are split into three broad-brush categories, highlighted below in 
Figure 5. 
 
Figure 5: (a) Single chained lipids such as lyso-PCs will self-assemble into micelles; (b) DOPC, a commonly occurring bilayer lipid 
self assembles into a fluid lamellar phase; (c) lipids with a small head-group area and a propensity to hydrogen bond, for example 
DOPE, will tend to adopt curved structures such as the inverse hexagonal structure. 
Commonly occurring lipids in biological membranes, such as 1,2-dioleoyl-sn-
glycerophosphatidylcholine (DOPC) (Figure 5) have a small negative spontaneous curvature (H0 = 
between -1/20 and -1/8.7nm-1), single chained lipids such as lyso-lipids have a positive 
spontaneous curvature (for example, palmitoyl lyso-PC, H0 = 1/6.8nm
-1) (type I lipid; curvature 
away from the aqueous exterior) and double chained lipids with small head-group areas such as 
1,2-dioleyl-sn-glycerophosphatidylethanolamine (DOPE) have a large negative spontaneous 
curvature (H0 = -1/3nm
-1), (type II lipids; curvature towards the aqueous exterior). Sensing and 
regulation of the curvature elastic energy has been shown to be a mechanism by which a variety 
of key biological processes operate: an increased curvature or curvature stress leads to the 
formation of defects within the otherwise relatively uniform membrane surface, leading to 
increased amphiphile binding.  This process was first observed to regulate lipid biosynthesis12, 
but has since been highlighted as a more generic mechanism for the sorting and activation of 
membrane proteins13,14.  This topic is explored in more detail in section 6 (page 147), but if it is 
considered that a number of amphiphilic drug compounds have previously been observed to 
induce serious changes in a membrane’s curvature, rigidity and fluidity 15,16, it appears likely that 
the non-specific detergent effects of drugs within a membrane may play at least some role in 
their transport and biological activity. 
a) b) c) 
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H0 is not expected to be zero, but when two identical monolayers are placed back to back in a 
bilayer, the bilayer spontaneous curvature (H0
b) is zero so as to prevent the formation of 
energetically costly vacuums. If the spontaneous curvature of the monolayers is increased 
(physically achieved by changing the composition of the monolayer) there will come a point at 
which the curvature elastic energy becomes too great and a transition to an inverse phase 
occurs so as to allow the interface to bend, as in Figure 6. Such systems are more likely to be 
able to form the intermediate structures necessary for membrane fusion events to occur 17 by 
lowering the energy required to create voids between the monolayers 18.  
This process is of major biological relevance as the same process must occur to allow the 
budding or fusion of vesicles in intra-cellular communication, for example at synapses in the 
nervous system.  The resting state of such cell membranes lies in the fluid lamellar phase; when 
a budding event is initiated, regions of high curvature are created which closely mimic the 
proposed transition state between the Lα – HII phase transition
19, as shown below in Figure 6.   
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Figure 6: The stalk hypothesis model of phase transition between lamellar and more curved phases.  As the lamellar 
sheets approach one another, either through dehydration or thermal undulation (a), contact points begin to form 
between the lammellae (b).  These can link up to form inverse hexagonal cylinders (d), or can alternatively ‘unzip’ along 
the length of the sheet (c), leading to membrane fission and the creation of daughter vesicles, micelles and cubic phases 
(e).  Adapted from Siegel
19
. 
The void spaces which inhibit the formation of these non-bilayer structures are clearly visible in 
images b, c and d.  The addition of strongly hydrophobic species such as hexane but also 
potentially a range of drug compounds can fill these energetically unfavourable regions, 
promoting the formation of highly curved phases and thus disrupting the morphology of the 
membrane.  These curved phases behave very differently to lamellar sheets: their restricted 
geometry means that they effectively exclude water from all but a very limited volume, shown 
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schematically above in Figure 6d.  The combination of narrow channel widths and static layers of 
water co-ordinated to the lipid head-groups leads to slow diffusion times throughout the 
enclosed water, combined with decreased lateral motion of the lipids themselves due to the 
increased steric stresses upon them.  For a more detailed discussion of this and other mechanics 
of biological membranes see Seddon20, Shearman et al.21 and Zimmerberg et al.22. 
 
 
Figure 7: (a) The effect of monolayer curvature on curvature elastic stress in the bilayer. Monolayers containing type II lipids, such 
as those with PE head-groups, try to curve towards the water; (b) however they are constrained within a bilayer and are forced 
together, leading to an increase in stress within the membrane. 
 
The lipids presented on the inner and outer leaflets of the bilayer differ greatly2 .  This 
transverse asymmetry is believed to be controlled by a family of enzymes, called flippases, 
floppases (both ATP-dependent) and scramblases (calcium dependant), which enable the 
bidirectional translocation of lipids between the two leaflets.  Flippases 23 aid the stereospecific  
movement of lipids from the outer to inner leaflet, displaying a high degree of head-group 
selectivity, with floppases23 aiding translocation in the opposing direction to that of flippases 
(from the inner to outer) and scramblases23 operating in both the ‘flip’ and ‘flop’ directions.  
Inevitably, the physical shape of the molecule and its trans-bilayer diffusion rate, which can vary 
dramatically between species, will also influence this asymmetry.  In vivo, the loss of trans-
bilayer asymmetry results in the exposure of phosphatidylserine to the outer leaflet, triggering 
the activation of a number of cell-lysis enzymes such as Phospholipase A2 (PLA2) and inducing 
apoptosis24. 
  
VACUUM VACUUM 
INCREASED STRESS 
a) 
b) 
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3.2 Moving Molecules across Membranes - Classical Models of 
Transport 
In order to understand the interactions of drug molecules with the plasma membrane of cells, it 
is worth considering some basic biological concepts concerning the mechanisms by which 
molecules can cross cell membranes.  
 
3.2.1 Passive transport 
The mechanism by which small molecules may traverse a cell membrane spontaneously without 
any energy being expended by the cell is referred to as passive transport, (see Figure 8) with the 
simplest example being that of diffusion. Small, hydrophobic molecules will diffuse rapidly 
across membranes, (although a significant percentage may be retained), whereas small but 
uncharged polar molecules will take a greater period of time to cross.  Ions face a very high 
energetic barrier to cross the hydrophobic core of the membrane due to their charge and 
hydration shells and so in practical terms, their rates of transit are generally low. In terms of 
drug molecules, non-ionized forms or neutral drugs like caffeine can readily cross the membrane 
by diffusion25.  The amount of ionized form of a drug versus the non-ionized form available will 
be dependent on the partition function (log P, explained fully in section 3.2.3 below) and pKa of 
the drug and the pH of the medium on either side of the membrane.  If the drug has a fixed 
charge (for example, quaternary amines or some types of antibiotic) the drug is unlikely to enter 
the cell by diffusion alone. In the case of cationic amphiphilic drugs (CADs) (whose cationic 
groups are normally formed by secondary or tertiary amines) and other small amphiphiles, a 
grey area emerges26.  Recent molecular dynamics calculations suggest that for a strong base, 
pKa~12, the pKa can shift by approximately 4.5 units upon entering a membrane
27, although the 
energetic cost associated with such a movement effectively prohibits such action.  For slightly 
weaker, amphiphilic bases such as the CADs under discussion, the situation is less certain but it 
seems likely that the majority of such compounds would have difficulty traversing a membrane 
by diffusion alone.  Should such a CAD enter a cell or cross the blood-brain barrier by simple 
diffusion, it is likely to become ionised almost immediately upon exposure to the intracellular 
environment:  the pH of arterial blood plasma is around 7.4; cerebrospinal fluid is around 7.3 
and cytosol is often around 7.228.  As a result, any such compound is unlikely to be able to 
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diffuse out of a cell via the same mechanism.  Furthermore, organelles such as lysosomes can 
have internal pH values below 5.5 and thus tend to attract basic drugs in high concentrations, 
leading to aggregation29. 
 
Figure 8: Passive transport can occur across membranes in a number of ways, the simplest of which is diffusion. Molecules can also 
cross the membrane without requiring the input of external energy by diffusion through a channel, the opening and closing (or 
‘gating’) of which can be controlled by voltage, ligand binding or mechanical stress. Ion channels are often selective for a particular 
ionic species. Carrier proteins can also facilitate translocation across the membrane by a passive mechanism1. 
 
3.2.2 Measuring diffusion across membranes 
The rate of diffusion of a drug across a membrane will be proportional to the concentration 
gradient, the lipid-water partition coefficient (the equilibrium ratio between the concentrations 
dissolved in water and an immiscible organic phase (typically 1-octanol), assuming the molecule 
is un-ionised) and the diffusion coefficient of the drug within that membrane.  This can be 
summarised by Fick’s Law of Diffusion (Equation 5): 
 
Equation 5 
Where D is the diffusion coefficient of the drug in the membrane, P is the partition coefficient of 
the molecule between the membrane and the external medium, b is the thickness of the 
membrane and X1-X2 is the concentration gradient across the membrane.  Experimentally, 
however, if the lipid-water partition coefficient is too great then the drug is unlikely to leave the 
membrane and may merely be sequestered within it. 
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3.2.3 Binding and partitioning to membranes 
The value of the partition coefficient or log P (see Equation 6), of a compound is often used as a 
crude measure of distribution of a compound in vivo, as Overton’s rule suggests that lipophilic 
compounds will traverse a lipid bilayer faster than hydrophilic species and that this solubility 
was the major rate-determining factor in the species’ permeability coefficient30.  Although this 
has been overtaken by more recent research into ion channels and membrane protein pumps 31 
like those described below, this remains the backbone of many predictive tools in drug-
discovery. 
 
Equation 6 
The classical method of determining the octanol-water partition coefficient for a molecule 
involves dissolving the molecule of interest in a two-phase system containing octanol and water 
and determining the concentration in each fraction, most commonly by UV-Vis spectroscopy or 
alternatively by the addition of a small amount of a radiotracer. 1-Octanol is used as a mimic of 
the lipid environment; data can be extrapolated from the interaction of drug molecules with the 
octanol phase and applied to the partitioning of the drug within a lipid membrane.  A more high-
tech approach can be achieved using HPLC, correlating the retention time of the molecule with 
that of molecules with a known log P value32.  While this method has the advantage of being 
high throughput, it assumes a degree of knowledge about that behaviour of a molecule which 
may not be available for de novo drugs.   
Many drugs have some form of amphiphilic or detergent-like character, in particular the CADs, 
with critical micelle concentrations in the sub-millimolar range33.  This, combined with their 
often high octanol-water partition coefficients, means that they exert an effect upon any 
membrane in which they are resident should they reach a sufficient concentration, causing cell 
leakage, deformation and sometimes lysis due to their detergent-like solubilising effect on the 
membrane.  For a comprehensive review of these effects and their physicochemical and 
biological implications, see Schreier16. 
The distribution function, or log D, is a slightly more refined model34, but one whose 
measurement requires significantly more effort.  Log D is the ratio of the equilibrium 
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concentrations of all species, both unionized and ionized of a molecule dissolved in octanol to 
the same species dissolved in water at a given temperature, normally 25° C. It differs from Log  P 
in that ionized species are considered as well as the neutral form of the molecule  (see Equation 
7). 
 
Equation 7 
In order to find a log D function, the partition function must be measured across a range of pH 
values and thus ionisation states.  This is further complicated by the choice of buffer upon the 
system, and any Hofmeister effects35,36 that may arise as a result.  Again, it gives no indication of 
any interactions the compound may have with proteins resident in the membrane, nor is 1 -
octanol a particularly good model for the often highly charged, amphiphilic lipids which make up 
such a barrier. Despite this, it is often one of the major physico-chemical properties which a 
pharmaceutical company will consider when debating the desired products of a high-throughput 
library. 
At its most basic level, the Hofmeister effect35,36 describes the effect of an ion upon the 
structure of water around it.  Chaotropes such as nitrate and iodide ions have very weak 
interactions with the surrounding water; kosmotropes such as sulphates and phosphates have 
very strong interactions, and tend to co-ordinate water around them, weakening the hydrogen 
bond network that water normally forms.  This means that, at least in concentrated solutions, 
the volume of ‘bulk’ water (as opposed to surface-coordinated water used to solubilise or 
suspend the protein/colloid/membrane of interest) decreases and to compensate the solute is 
precipitated out, thus freeing up the low entropy surface coordinated water.   This obviously has 
major implications for the observed partition/distribution function of a compound in a system as 
described above, as the relative concentrations measured in the two phases of the system are 
based on the assumption that all the solvent in the system is available to contribute to their 
solvation. 
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3.2.4 Non-specific binding 
Labelled drug molecules, such as those used in positron emission tomography (PET) can 
sometimes be found to interact non-specifically with membrane structures. This leads to a high 
background signal as a result of this non-specific binding, which reduces the quality of PET data 
that can be collected from probing a specific receptor. Non-specific binding is thought to be 
correlated in part to a molecule's lipophilicity, or log P value; this is, however, an over-
simplification. A general rule of thumb is that a molecule with a log P below 3 will be a good PET 
ligand.  Within the brain, where a degree of lipophilicity is required to traverse the blood brain 
barrier, a log P value between 1.5 and 3 is preferred37. Whilst the behaviour of many 
radiotracers correlates with these log P regimes, there are also many exceptions. As a result 
there is a need to understand the molecular basis of non-specific binding, in order to improve 
the design of PET ligands and further the fundamental understanding of how drugs interact with 
membranes.  Log P, as discussed earlier, contributes significantly toward non-specific binding, 
but there are also active processes that can lead to the sequestration of drugs within 
membranes.  This sequestration has two major effects.  Firstly, a drug sequestered within a 
membrane will have reduced efficacy, being extremely unlikely to meet its target unless it is 
ubiquitous or the drug was administered topically.  This requires more drug to be administered 
in order to achieve the desired therapeutic effect, thus increasing any side-effects and 
narrowing the therapeutic window of the compound.  Secondly, and more insidiously, the drug 
concentration inside these membranes can become dangerously high (>50mM) 38, causing a 
range of potential effects varying from membrane disruption through to storage disorders such 
as phospholipidosis, which can cause a range of secondary pathologies 39.  For example, 
amiodarone has been observed to cause clouding of the lens and cornea of the eye 40 and 
ketoconazole has been demonstrated to induce long-term hepatic effects through its primary 
metabolite, which is sequestered in the lipid domains it creates and is only very slowly 
metabolised41.  It is clear that non-specific binding is a far more complex process than has been 
previously thought: whilst it can be an unwanted side product of drug-membrane interaction, it 
may be advantageous under certain circumstances to have a drug capable of non-specific 
binding, acting for example as a reservoir of drug bound within a membrane that can be 
released over a period of time.  
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3.2.5 Facilitated transport 
In order for hydrophobic species such as ions, sugars and amino acids to be able to enter and 
leave the cell, transport proteins embedded in the membrane must be utilised: these are 
categorised as either carrier proteins or channel proteins.  As the name implies, carrier proteins 
bind to the transported molecule and by means of conformational changes of the protein, carry 
the molecule across the membrane.  Channel proteins form aqueous pores across the lipid 
bilayer that, when opened, allow the molecule to diffuse through the pore and thus cross the 
membrane. Often these channels will be highly selective, allowing only certain ions to pass 
through them. They are not continuously open, but instead open and close in response to 
stimuli such as voltage, mechanical stress or ligand binding.   Each transport protein is specific 
for a particular class of molecule and often has specificity for a specific substrate within that 
class.  Many transport proteins move molecules in the direction of the concentration gradient: 
as such they require no energy to do so.  This is therefore a form of passive transport, known as 
facilitated diffusion.  For a series of reviews describing each of the families of solute carrier 
proteins such as these, please see Hediger et al. and the accompanying special issue42. 
To move an uncharged molecule across a membrane by facilitated diffusion simply requires a 
concentration gradient across the membrane.  For a charged molecule to cross, the 
concentration gradient and the electrical potential difference across the membrane (the 
membrane potential) are combined to give a net driving force known as the electrochemical 
gradient. 
 
Figure 9: In active transport, molecules are transported against the concentration gradient using proteins as channels or 
transporters. In primary active transport, a substrate can be moved directly (uniport); in secondary active transport, a substrate is 
moved in conjunction with a secondary molecule in the same direction (symport) or in conjunction with a secondary molecule 
moving in the opposite direction (antiport). 
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3.2.6 Active transport 
When a cell needs to move molecules across the membrane against a concentration gradient, 
the process will require an energy input in one of three ways.  This energy can come from the 
hydrolysis of ATP, leading to what is known as primary active transport.  Energy may also be 
derived from the coupling of the transport of a secondary species, usually via an ion gradient 
and is known as secondary active transport.  Finally, the energy required can come from light; 
this is a highly specialised mechanism employed by some organisms and is mediated by light 
transduction proteins such as bacteriorhodopsin43. Methods of active transport are illustrated in 
Figure 9. 
3.2.6.1 Primary active transport 
Primary active transport is driven by proteins which use chemical energy from ATP hydrolysis to 
translocate molecules across the membrane.  Often these proteins are ion pumps, responsible 
for maintaining gradients of ions across the membrane44.  Creating ion gradients is also 
important for secondary active transport.  Some carrier proteins, including the ATP-binding 
cassette (ABC) transporter super-family45 are directly responsible for pumping a variety of 
molecules in and out of the cell. 
Some drugs are actively taken up by cells by primary active transport, although this is the 
exception rather than the norm.  For example, the tyrosine kinase inhibitor imat inib, used for 
the treatment of chronic myeloid leukaemia, is taken up by the human organic cation 
transporter protein hOCT1 as well as being expelled by P-glycoprotein meaning that differences 
in individual patients’ expression levels can lead to the failure of drug therapy46. 
3.2.6.2 Secondary active transport 
During secondary active transport, molecules are translocated across the membrane as the 
result of diffusion of another substance.  The proteins responsible for this coupled transport are 
known as symporters or antiporters.  A symporter moves a second solute in the same direction 
as the primary transport; an antiporter moves the second solute in the opposite direction.  By 
using the energy stored in the electrochemical gradient of one molecule (or ion), symporters 
and antiporters can move a second molecule against the concentration gradient.  Examples 
include the SVCT1 and 2 proteins, which transport vitamin C across the membrane via the 
simultaneous diffusion of Na+ 47. The Na+ - Ca2+ antiporter drives the removal of calcium from the 
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cell against the concentration gradient by using the opposing movement of Na +.  For a range of 
further examples, including structures, physiological distribution and pharmacokinetics, please 
refer to Terada and Inui48. 
3.2.6.3 Drug resistance  
In eukaryotes, ABC transporters have attracted clinical attention as they are able to efflux 
hydrophobic drug molecules from the cell.  In cancer cells, over-expression of P-glycoprotein (P-
gp) and the multi-drug resistance protein (MDR) leads to the expulsion of chemotherapy drugs 
from the cell, conferring resistance to a wide range of therapeutic agents 46.  Drug resistance of 
one type of malaria parasite, Plasmodium falciparum, is also controlled by an ABC transport 
protein, which causes the efflux of the anti-malarial agent, chloroquine49.  An excellent overview 
of the mechanisms and structure of bacterial ABC transporters is given by Moussatova et al45. 
Most secondary multidrug transporters work to efflux drugs using the movement of H+, known 
as the proton motive force, or gradient.  Toxic compounds are expelled from the cell via a 
coupled exchange with protons.  There are four classes of bacterial secondary multidrug 
transporters: the major facilitator super-family (MFS), the small multidrug resistance family 
(SMR), the resistance-nodulation cell-division family and the multidrug and toxic compound 
extrusion family (MATE). These families can transport a variety of substrates, inc luding sugars, 
phosphate esters, small molecule dyes and a range of antibiotics and by extruding compounds 
from the interior of the cell, build up resistance of the cell to that compound. For 
comprehensive reviews on this subject see Putman et al.50 and references cited therein. 
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3.3 An alternative mechanism for drug translocation 
Neither passive nor active transport mechanisms, however, can adequately describe the 
translocation of bulky hydrophobic or amphiphilic molecules not recognised by  the cell (for 
example CADs), across the membrane.  In light of this failure, a third class of mechanism is 
required: one which considers direct chemical or physical interactions between the drug and 
lipid molecules.  Simple examples include the non-specific effects that occur when amphiphilic 
compounds are sequestered or retained within a membrane as described above.  This has been 
most widely studied in the case of anaesthetics, which have been observed to cause significant 
fluidisation and softening of membranes51.  However, the doses at which these effects occur are 
significantly greater than those which are pharmacologically relevant, and later research has 
focussed upon the effects that the compounds have on the lateral pressure profiles of their 
surrounding lipids and proteins52. 
Another candidate for this class was recently observed by Baciu et al.53,54, in which the presence 
of a small molar fraction of CAD within a phosphatidylcholine membrane led to the rapid 
hydrolysis of the lipid molecules via their ester bonds.  This hydrolysis was catalytic with respect 
to the drug, and generates a molecule of lyso-lipid, in this case mono-acyl phosphatidylcholine, 
and the concomitant fatty acid.  The reaction is not believed to be regiospecific (although if it 
were, mono-acyl lipids have been shown to isomerise rapidly, favouring the sn-1 
conformation55).  Furthermore, the reaction is not constrained by a highly specific active site as 
is the case with similar enzyme-mediated reactions.  As a result, the lyso-lipid formed in the first 
reaction can itself form a substrate for hydrolysis, forming a second molecule of fatty acid and 
one of highly hydrophilic phosphatidylglycerol.   
This process rapidly causes dramatic perturbations to the membrane topography, as 
degradation products begin to accumulate.  Fluorescence microscopy studies have revealed that 
drug-bearing membrane fragments are ejected from the membrane within seconds of the 
compound’s administration (see Figure 10, below), and it is therefore possible that this 
mechanism contributes toward its in vivo transport.  These fragments are formed of lyso-lipid 
rich micelles and mixed lamellar bodies, which have been previously observed: Burack et al. 
have previously demonstrated that in gel-phase dipalmitoylphosphatidylcholine/ 
monopalmitoylphosphatidylcholine/palmitic acid mixtures, where the lyso-lipid and fatty acid 
are added at a 1:1 ratio to mimic the effects of PLA2 hydrolysis, a major phase change occurred 
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at ~8% lyso-lipid, as the multi-lamellar vesicles under observation collapsed to form small, disk-
like micelles56. 
 
Figure 10: Fluorescence micrographs showing CAD-catalysed hydrolysis. (A) Fluorescence microscopy images showing 
the effects of labelled spiperone HCl on DOPC giant unilamellar vesicles (GUVs) over time; (B) TM image DOPC GUVs 
with haloperidol HCl; (C) The same experiment performed on ether-PC, showing no reaction. Scale bar = 20μm
53
 
The mechanism of formation of these bodies is still the topic of some debate.  Lyso -PC has a 
relatively low critical micelle concentration of around 5µM, forming small micelles often 
containing as few as 140 monomers each57 and has been observed to cause the formation of 
many such bodies upon its addition to egg-PC multilamellar vesicles58.  However, more recent 
studies contend that as the aqueous solubility of lyso-lipids is significantly greater than that of 
the di-acyl species, they rapidly leave the bilayer as monomers59 and that the effects observed 
are caused by fatty acid and diacyl lipid interactions.  In practice, both phenomena may 
contribute: if it is assumed, as a first approximation, that an exogenously applied drug remains 
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charged at all times and thus does not flip-flop between bilayers, it follows that all hydrolysis 
that it catalyses will also take place in the outer leaflet of  the membrane.  The flip-flop rate of a 
lyso-lipid has been shown by NMR to be negligible (t1/2>12hr)
60, whereas those of fatty acids 
have been shown to be extremely rapid61-63.  This implies that the fatty acids produced by 
hydrolysis will equilibrate across both leaflets of a membrane very quickly, leaving an effective 
2:1 lyso-lipid: fatty acid ratio in the outer shell and local regions of high lyso-lipid 
concentrations, quickly producing regions of high curvature which eventually bud off into 
solution, (shown below in Figure 11).  This hypothesis is somewhat supported by data from PLA2 
studies (described in more detail below), which indicate that after hydrolysis the membrane is 
significantly enriched in fatty acid relative to lyso-lipid64. 
 
Figure 11: The proposed mechanism of drug transport: CAD molecules migrate to the membrane interface, driven by the 
hydrophobic effect, where they intercalate between lipid molecules (A).  They rapidly hydrolyse a number of 
surrounding ester bonds (B), forming a high local concentration of tightly-curved lipid shown in green (C).  This leads to 
changes in membrane morphology and eventually the formation of small micelles and vesicles, each containing a few 
molecules of the drug (D)
1
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3.3.1 Comparisons with enzyme-catalysed hydrolysis 
This process has many similarities to the action of Phospholipase A2, (PLA2), an endogenous 
enzyme responsible for membrane maintenance and specifically in the pancreas for lipid 
metabolism.  However, a number of important differences apply: for example, PLA 2 is highly 
selective in both its choice of substrate and its regiospecificity, only attacking the sn-2 ester65; 
the mechanism described above appears, from our investigations, to apply to any acyl bond at a 
lipid interface.  Furthermore, PLA2 is activated and deactivated in response to specific stimuli, 
leading to ‘lag-burst’ kinetics66,67.  This does not appear to be the case for the CAD-catalysed 
reaction, and indeed there is no reason why it should as no three-dimensional ‘active site’ exists 
on the molecule. 
There are some interesting parallels, however.  Previous experiments have demonstrated that 
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the rate of CAD-catalysed reaction is affected by the lateral stress profile within the membrane: 
very different rates have been observed for membranes made of saturated versus unsaturated 
lipids53.  A similar effect is observed in the activation of PLA2, whereby the full activation of the 
enzyme appears driven by the aggregation of degradation products produced in the low -rate 
‘lag’ phase, either due to the increase in anionic fatty acid concentration 68 or due to the 
formation of membrane defects and/or lateral phase separation as lyso-lipid leaves the 
membrane56,69 and the system attempts to move towards the inverse hexagonal phase 21. 
 
3.3.2 Links to phospholipidosis 
As described above, the hydrolysis of a proportion of the lipid or even the act of introducing a 
number of largely type I drugs70 into a bilayer will attempt to increase the curvature of the 
membrane, leading to an increase in the curvature elastic stress within the bilayer.  This stress 
has been shown to activate the biosynthesis of a number of lipid molecules and others by 
causing a conformational change within a number of membrane-bound proteins71,72.  
Furthermore, it has been shown that the enzymes which normally degrade any excess 
membrane fabric such as the PLA family are inhibited by the presence of a range of such drugs 73-
75.  It is proposed that the effect of these two mechanisms is the build-up of excessive cellular 
lipid concentrations, commonly known as phospholipidosis: a lipid storage disorder commonly 
associated with the administration of a range of CADs.  However, there are some suggestions 
that this ‘disease’ is, in fact, an evolutionary response to protect the cell from unwanted 
amphiphilic compounds by sequestering the CADs away from any sensitive proteins or 
organelles76. 
This sequestration can have a number of secondary effects which have been discussed 
previously in this chapter (see section 3.2.4), in terms of both non-specific binding and out-and-
out toxicity.  The apparent links outlined above have led to the hypothesis that a successful drug 
requiring systemic availability must strike a tight balance between showing sufficient hydrolytic 
activity to permit its release from its host membrane to travel around the body, whilst not 
causing such damage as to trigger a response from the enzymes responsible for maintain ing 
homeostasis, potentially trapping and neutralising the compound. 
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3.4 Techniques for Studying Drug-Membrane Interactions 
Although it is relatively easy to analyse the bulk effects of drug induced membrane disruption 
upon lipid polymorphism, it is considerably more difficult to quantitatively apply this to 
unilamellar vesicles which more closely mimic the cell membrane.   
When characterizing the interactions of drugs with membranes, no single technique will be able 
to provide all the necessary information. Parameters that are of use in the determination of 
drug-membrane behaviour include drug location, orientation and conformation within a 
membrane, the phase behaviour and stability of that membrane on introduction of a drug 
molecule and the nature of any chemical modifications that the drug may inflict on the 
membrane or vice versa. All of the following techniques are described in detail in Wiese and 
Seydel77 together with  illustrative examples.   
 
3.4.1 Classical approaches to drug membrane interactions  
Standard laboratory spectroscopic techniques such as UV and FTIR spectroscopy can be 
employed with great effect in the study of drug membrane interactions. Often, polarized FTIR 
spectroscopy is used: by monitoring changes in the position, width and intensity of IR bands, it is 
possible to describe local changes in phospholipid organization and orientation on the 
introduction of a drug molecule.  The temperature dependence of the wavenumber of the CH 2 
symmetric stretching vibration within DPPC was characterized in this way in the presence of 
salicylic acid, leading to information on how drug interaction affected transition temperatures 
within the bilayer78.  The simple and relatively inexpensive technique of UV-Vis spectroscopy has 
proved to be an excellent way of estimating the degree of partitioning of a drug into a lipid 
membrane, in a manner analogous to standard log P measurements.  For example, the 
partitioning of the anticancer drug derivative 4-hydroxytamoxifen into DPPC bilayers has been 
successfully determined in this way79.  Circular dichroism can also be used to study changes in 
drug location and conformation.  Drugs with anthracycline rings, such as doxorubicin, 
daunorubicin and idarubicin exhibit a variety of π-π* and n-π* transitions which are sensitive to 
the nature of the environment within which they reside.  The electrostatic interactions of 
positively charged lipid head-groups on the depth of bilayer layer location of these drugs has 
been ascertained by CD spectroscopy, as well as the effect of cholesterol within the bilayer 80. 
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Fluorescence techniques can be employed to great effect to analyse the way that drugs interact 
with membranes.  The scope of what can be achieved with fluorescence is too broad to be 
covered in detail in this chapter; a short overview is presented. Fluorescence emission, 
fluorescence lifetime imaging spectroscopy (FLIM), fluorescence anisotropy, fluorescence 
resonance energy transfer (FRET), fluorescence correlation spectroscopy (FCS) and single 
molecule detection techniques are all discussed in detail with relevant references in Lakowicz81.  
Recent research includes, however, steady state fluorescence anisotropy measurements (used in 
parallel with x-ray diffraction and NMR, see later) to study the effects of the non-steroidal anti-
inflammatory drug (NSAID) diclofenac on model and erythrocyte membranes82.  It was found 
that interaction of diclofenac caused an increase in rigidity in the polar head-group region of the 
model membranes and an increase in the disorder of the acyl chains. The antioxidant effects of  
NSAIDs and their interactions with membranes have also been studied using a combination of 
steady state anisotropy and fluorescence intensity decay83.  Quantifiable interactions between 
the lipid membrane and drug molecules can be achieved using fluorescence intensity 
measurements of environment-sensitive lipid probes, for example fluorescein-labelled 
dipalmitoylphosphatidylethanolamine, (FPE)84.  
The fluorescein head-group is extremely sensitive to electrostatic changes at the lipid/water 
interface, and so the intercalation of charged drugs leads to changes in fluorescence intensity.  
However, this can only provide relative quantification unless the partition function and pK a of 
the drug is known precisely. Fluorescence techniques can also be applied to cel l culture assays; 
for example, fluorescently labelled phospholipids have been incorporated into cell culture 
assays, to identify CADs which are implicated in the lipid storage disorder, phospholipidosis 85.  
Often classical lab techniques, and particularly fluorescence are more beneficial in probing drug-
membrane interactions when used as part of a multi-technique study. For example, steady-state 
fluorescence anisotropy, was used in conjunction with quasi electric light scattering, attenuated 
total reflectance infra red (ATR-FTIR) spectroscopy and 31P NMR to measure the interactions of 
the antibiotic ciprofloxacin with model membranes composed of phosphatidylglycerol (PG) or 
phosphatidylcholine (PC) head-groups86.  This work demonstrated a strong preference for the 
antibiotic binding to the anionic PG lipids, which are major components of the bacterial cell 
membrane.  
The classical techniques for the quantitative analysis of condensed-phase structures are small 
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angle X-ray scattering (SAXS) and neutron scattering (see Koch et al. for a comprehensive 
review87).  SAXS in particular allows the direct observation of the stability of lyotropic lipid 
structures and provides quantitative information on the variation in structure that the addition 
of a drug molecule can exert upon a lipid sample. 
By its nature, any crystal or semi-crystalline material such as those under consideration consists 
of a periodic lattice, with unit cell dimensions of a similar order of magnitude to the wavelength 
(λ) of an X-ray.  As such, any X-ray incident to such a crystal will be diffracted, with the degree of 
diffraction dependent upon the separation of the constituent molecules and the arrangement 
they have adopted.  By analysis of the variations in diffraction over time, the effects of the drug 
partitioning upon the phase behaviour of the lipid sample can be accurately plotted.  Since the 
development of a position-sensitive linear X-ray detector in 1972 by Dupont et al.88, the 
measurement of such parameters can be made almost in real-time, permitting the kinetic 
analysis of phase transitions such as those described in Figure 6 is response to stimuli such as 
pressure, temperature or intercalation of exogenously applied compounds. 
Calorimetry studies, analysing small changes in the heat and/or heat capacity of a system after a 
minute perturbation, can provide a precise picture structural or morphological changes. Of 
interest for those wishing to study drug-membrane interactions is isothermal titration 
calorimetry (ITC)89, in which consecutive injections of a known solution (in this case the drug 
under consideration) are mixed with a known concentration of vesicles or micelles under 
isothermal conditions.  ‘Blank’ runs are also performed to give the enthalpies of dilution of each 
analyte, and these heats of dilution are subtracted to give the energy of interaction between the 
drug and membrane. 
Differential scanning calorimetry (DSC) is a technique often applied in conjunction with SAXS  to 
probe the thermodynamic phase transitions of a lipid or mixture of lipids in a sample.  This 
provides a plot of enthalpy versus temperature, effectively recording the isobaric heat capacity 
of the sample: any sharp changes of the plot indicate a phase transition of some kind.  In the 
case of lipids and liquid crystals in general, this could be indicative of a change in lipid 
polymorphism or a chain melting process.  In this way, the precise phase boundaries for a given 
lipid system can be identified, reversibly and non-destructively, and coupled with SAXS 
structural data a well-defined map of phase behaviour can be established.  A full overview of the 
calorimetry of lipid membranes can be found in a review by Heerklotz 90 and references cited 
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therein. 
Both solid- and solution-state NMR approaches also directly probe interactions between 
amphiphilic molecules dissolved in a bilayer and their surrounding lipids 91, albeit often at high 
doping concentrations due to the low sensitivity of NMR spectroscopy.  These techniques have 
been applied in the modelling of the transport of highly lipophilic ligands such as 
cannabinoids91,92, but also in the pursuit of a mechanistic explanation for a number of lipid-
storage disorders, most notably phospholipidosis. 
High resolution NMR provides detailed information on the dynamics and conformation of 
membranes and the effect which the addition of a drug has upon those membranes; conversely 
it is also possible to determine the effect of a membrane on the orientation and conformation of 
a drug molecule.  Many nuclei can be studied, particularly 1H, 2H, 13C, 15N, 19F and 31P, meaning 
that specific isotopic enrichment of probes can yield a range of data including position, 
orientation and dynamics of a drug within a membrane.  Changes in the field at which resonance 
occurs, the spin-spin coupling and the spin-lattice and spin-spin relaxation rates can all be 
affected when drug molecules and membranes interact.  A comprehensive overview of specific 
uses of NMR spectroscopy in drug-membrane interactions can be found in Seydel and Wiese and 
references cited therein77.  Of particular note is the use of 31P NMR to study lipid polymorphism; 
lamellar, hexagonal and isotropic phases all have distinctive NMR signals which are sensitive to 
perturbation by drug interactions. 
Recent experiments described above in section 3.353,54 have demonstrated that certain classes 
of drug molecules are able to hydrolyse biological membranes, with this phenomenon being 
linked to drug translocation and non-specific binding. High pressure liquid chromatography 
(HPLC) techniques93, normally using light-scattering detection, are able to give an accurate and 
reproducible breakdown of the components during such processes. 
HPLC separates the components of a mixture upon based the differences in their affinities 
toward a static, solid-phase bed, known as a column.  This bed is typically composed of 
functionalised silica, alumina or polymer granules or around 5μm diameter, exposing a very high 
surface area to the analytes but consequently generating a very high back-pressure in the 
eluting solvent.  Signals are generated via optical or radiochemical techniques and recorded with 
respect to retention time, the time that each individual component remained resident upon the 
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column.  This requires precise pump control, as flow rates must be maintained at a constant 
level of ~1 ml/min at a pressure often in excess of 150 bar for reproducible retention times to be 
practically achievable. 
Light scattering analysis is covered in detail in section 5.6.2, (page 122) and so will only be 
described briefly here.  However, the interested reader is directed to comprehensive review s on 
the topic for in-depth analysis94,95.  Evaporative light-scattering detection relies upon the 
evaporation of the eluent stream by a directed gas flow into a heated chamber, resulting in the 
nebulisation of single molecules of the analyte particles.  The gas then acts as a carrier, lifting 
the aerosol stream past a high-intensity bulb.  The analyte causes some scattering of this light, 
which is typically detected at 90° to the incident beam.  The technique is destructive as once 
nebulised, the analyte is unrecoverable; despite this, it provides absolute quantitation (when 
compared to a calibration curve) for any sample of lower volatility than the eluent, which is 
extremely valuable in lipid analyses due to their lack of accessible chromophores or 
fluorophores. 
For complex mixtures such as those obtained from ex vivo membrane lipid extracts, HPLC 
coupled with high resolution mass spectrometry (MS) is sufficient for at least semi -quantitative 
analysis, but provides by no means the ideal solution.  A major problem with this technique is 
ion-suppression: lipid molecules ionise poorly and those that do tend to compete with one 
another for the available charges, even at very low concentrations 96.  However, via the use of 
nanolitre-sources for electrospray ionisation, coupled with MS/MS equipment and a range of 
stable-isotope internal standards, reasonably reproducible relative quantitation can be 
achieved97,98.  For a recent, practical guide to the MS analysis of complex lipid mixtures, see 
Seppänen-Laakso and Orešič99. One further issue with the study of drug membrane interactions 
by this technique is it requires a direct chemical interaction between the drug and the 
membrane to be used.  
What none of these techniques address, however, are the differences in behaviour between 
lipids in condensed phases and those in giant unilamellar vesicles.  Condensed-phase systems 
have much higher lipid concentrations than the more diffuse vesicle systems, but typically 
exhibit much lower diffusion rates for aqueous species due to the restrictions on solvent flow 
outlined in section 3.1.3.  Similarly, condensed-phase systems are often much closer to their 
excess-water point, or the lipid:water ratio at which the system is fully hydrated.  This poses 
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issues for studies such as this, where the system is dependent upon both a ready stream of 
water molecules and an even and rapid distribution of buffer, drug and hydrolysis product 
molecules. 
The differences are also an issue which complicates analyses.  Although very simple, vesicle 
systems are preferable where possible as they are much closer to the lipid environment 
encountered by drugs in vivo.  However, both NMR and SAXS require at least moderate sample 
concentrations and destructive techniques such as HPLC-ELSD require several ~50µg samples for 
any kind of time-resolved analysis to be possible.  This is largely incompatible with the extremely 
low lipid concentrations and high excess water environments required for biologically relev ant 
membrane models to be created.   
 
3.4.2 Industrial and high-throughput approaches 
 Drug discovery programmes based upon high-throughput synthesis and screening require rapid 
identification of potential problems relating to administration and transport of a c andidate drug, 
before large sums are spent on the compound’s manual optimisation and testing.  As a result, 
efforts were made to develop a robust predictive model that was amenable to microtitre -plate 
based assays, allowing the testing of many compounds in parallel.  Initial assays included those 
based around a suspended monolayer of human colon carcinoma (Caco-2) cells, with the rate of 
transport from one side to the other measured by UV-vis. spectroscopy100.  Although this 
technique gives reasonable agreement with in vivo studies in many cases, it suffers from the 
same impediments as any other live-cell assays, being relatively slow and cumbersome, and 
dependent upon the state of the cells in any given assay.  Furthermore, when studying slowly 
absorbed drugs, the model often deviates from in vivo results by some two orders of 
magnitude101. 
The net result of these failings was the development of the parallel artificial membrane 
permeability assay (PAMPA)77, where a membrane of a selected lipid or mixture of lipids is 
suspended across the pores in a hydrophobic filter frit.  This frit is then placed in a microtitre 
plate between two aqueous solutions, one containing the analyte, the other the receiving 
solution.  A range of related assays have been developed using this approach – see the recent 
reviews by Sugano et al.102,103 for further information.  
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3.4.3 In vitro and in vivo techniques 
In vitro techniques have their limitations when it comes to the more systemic or longer-term 
effects of drugs upon biological membranes, however, and thus in vivo techniques are required.  
This is particularly true in the study of non-specific binding of drugs to membranes, as the 
degree of binding and sequestration varies significantly between organs, and even between 
areas in the same organ.  For example, the lungs contain a significant number of acidic tissues 
and thus can accumulate potentially toxic doses of CADs such as amiodarone very rapidly104. 
The two major techniques used to quantitatively analyse drug distribution and specificity are 
PET and autoradiography of tissue sections.  PET is a non-invasive in vivo technique, allowing 
repeated experiments on the same living human subject and using extremely low (nanomolar to 
picomolar) doses of candidate drug molecules.  It is based upon the intrinsic labelling of drug 
compounds, tracers or known receptor ligands with “neutron-poor” isotopes of atoms such as 
carbon (forming 11C), oxygen (15O), fluorine (18F) or nitrogen (13N).  A proton in these isotopes 
decays rapidly to form a neutron, a positron and a neutrino.  The positron and neutrino leave 
the nucleus at high velocity: the neutrino is immediately lost, but the positron decelerates via 
interactions with the normal surrounding matter over a length scale of ~3mm before 
annihilating with an electron in the vicinity.  This event produces two gamma-ray photon of 
511keV which are emitted at 180° to one another, and which may be detected co-incidentally, 
allowing the spatial and temporal localisation of the tracer compound in the patient or subject.  
For a history of PET development, please see Nutt105; for a recent review of this and the related 
technique of single photon emission computed tomography (SPECT), refer to Heiss and 
Herholz106106. 
The short half-lives of the isotopes used for labelling (e.g. ~20 minutes for 11C) presents 
significant challenges to the synthesis of a carbon-11 labelled drug molecule of interest as this 
means that compounds must be prepared on-site on an ad hoc basis, using a cyclotron and rapid 
labelling, purification and analytical techniques37 in close proximity to the clinical PET scanner.  
The high sensitivity and the three-dimensional, functional and kinetic data generated by the 
technique mean that growing numbers of companies are investing in the technology.   
Autoradiography is an in vitro technique which requires significantly less investment in terms of 
equipment, but can only usually be performed in humans on post mortem or biopsied tissues . 
Animals can however, be administered in vivo with a labelled drug or compound of interest and 
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sacrificed, then the tissue of interest removed, sectioned and quantitatively imaged using x-ray 
film, phosphor imaging plates or scintillation gas detectors.  This can provide the precise 
location and concentrations of the analyte within each two-dimensional slice, but requires 
significantly more animals per study in order to study the kinetic profile of a labelled compound 
and to eliminate inter-subject heterogeneities that can generate artefacts in the data.  More 
fundamentally, if using experimental animals, assumptions have to be made in the translatio n of 
the findings to humans.  The technique has been used to study the distribution of CADs in a 
number of animal models and make comment about their effects on the plasma 
membrane107,108. 
 
3.4.4 More recent approaches 
The obvious conclusion from the above is that no one technique covers all the bases: a range of 
approaches are necessary to characterise even the simplest of drug-membrane systems.  
Fortunately, techniques such as surface plasmon resonance and linear dichroism which extend 
beyond the classical ones described are being developed to look at drug-membrane interactions 
from a new perspective.  
Surface plasmon resonance (SPR) works by measuring the change in refractive index near a 
sensor surface, for example as a protein or drug molecule of interest binds to that surface.   SPR 
can provide a label-free, quantitative analysis of the bulk state of a membrane in a small 
monolayer or bilayer region of interest, and it has been demonstrated that drug-membrane 
binding constants across three orders of magnitude can be easily obtained and reproduced 109.  It 
is also amenable to moderate throughput, flow-based analysis with assay timescales of around 
10-15 minutes, and thus presents some significant advantages over more traditional techniques. 
Standard SPR techniques have been taken a step further by the recent development of 
microfluidic channel-based SPR imaging chips110 which allow simultaneous imaging in parallel 
microchannels.  Alternatives to current high throughput screening are being developed; in 
particular the combination of printing of lipids onto surfaces (as supported lipid bilayers) and 
microfluidics may prove to be advantageous.  A recent article111 describes measurement of the 
change of membrane structural changes on binding of a non-steroidal anti-inflammatory drug to 
a series of supported lipid bilayers printed on a glass substrate.  This type of miniaturisation and 
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parallel screening technique, coupled with advances in detection methods may provide a 
method for rapid, robust and economical high-throughput testing of interaction. 
An alternative to the highly labour-intensive NMR techniques for the analysis of conformation 
and orientation within a membrane, described above, has recently been presented by 
miniaturised linear dichroism cells.  This approach utilises the differing absorbances of plane -
polarised light by a chromophore depending upon its orientation, and as such can be used to 
give quantitative, or at least semi-quantitative, data on the angle a compound assumes relative 
to the interface of a membrane.  This membrane is flattened into a disk or cylinder shape by 
viscosity shear forces created by the rapid rotation of a vesicle suspension in a small quartz cell. 
Whilst this technique has been in use for some time, signal-to-noise has proved to be a major 
issue before the manufacture of miniaturised (~500µm) cells112,113.  Absolute quantisation can 
still be problematic with this technique unless the molecule in question is rigid and has a well -
defined long axis: however, it is amenable to high-throughput testing and can be used to study 
almost any compound with some form of chromophore and so has some significant advantages 
over isotope-enriched NMR studies which present the only real alternative. 
Recently a new label free method for the study of the association of drugs with membranes has 
been developed in the form of ultraviolet visible sum frequency generation (UV-Vis SFG)114: the 
association constants of drugs with  membranes measured with this technique are found to 
correlate well to known partition coefficients. The drive to develop label free techniques has 
also led to a high throughput screening method for the interaction of CADs with short chain 
acidic phospholipids using critical micelle concentrations determined by surface tensiometry. 
This technique has provided good correlations with previously determined phospholipidosis 
inducing potential of 53 drug compounds115.   
However, it is not just in the development of new techniques where there have been advances 
in the study of drug membrane interactions. Cyclic voltammetry and AC impedance studies on 
supported lipid bilayers have demonstrated a rapid degradation of the membrane upon the 
application of both CADs116 and, interestingly, simple amphiphilic organic acids117, in a manner 
that may be analogous to that reported above.  Although these techniques only report upon the 
bulk properties of the membrane and so cannot reveal the molecular details of the 
phenomenon, both studies reported rapid and catastrophic defect formation in the supported 
bilayers over timescales consistent with those reported in previous experiments 53. 
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3.5 Conclusions  
The interaction of drugs with membranes is an area of high importance for the pharmaceutical 
industry when considering the efficacy and safety of their products.  The cell membrane is often 
overlooked in drug development programmes as it is generally the receptors and enzymes 
contained within it that are the target of the drug molecule.  However, the membrane is not a 
passive or necessarily benign solvent and directly impacts on the protein molecules and 
complexes it contains. Furthermore, interactions between exogenous, amphiphilic compounds 
(including the majority of drug classes) and the membrane can directly affect its structural 
integrity, which can be critically damaging to the cell. While this may produce a desirable 
outcome, for example killing a tumour cell, it may also cause unwanted damage to cells leading 
to disease pathology. 
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4 Rationale behind PhD research 
The following thesis details attempts made between 2006-2010 to characterise and comprehend 
the mechanistic steps through which a range of CAD-like compounds catalyse the hydrolysis of 
the ester bonds between the glycerol and fatty acid moieties in phospholipid membranes.  
Although a significant body of work had previously been conducted into the causes and 
consequences of the hydrolysis (see section 3.3 and references therein and previous theses by 
Sebai118, Bate119 (unpublished work) and Ling120 (unpublished work)), none has yet conclusively 
determined the parameters which affect the rates of reaction, or the process(es) through which 
they do so.  It has previously been demonstrated that the rate is dependent upon the make -up 
of the membrane53,118, and that differing CAD structures resulted in dramatically differing rates 
of reaction; however, the reasons behind these effects were not understood, although a number 
of plausible hypotheses have been presented. 
The purpose of this study was to attempt to unravel, in a systematic fashion, the various factors 
influencing the reaction and to attempt to control and utilise it.  As noted in section 3.2 above, 
membrane transport poses a significant problem for medicinal chemists, as the factors which 
influence and control a compound’s bioavailability are not fully understood.  As a result, 
compounds which show extremely promising results in vitro often fail to do so in animal or 
human trials, leading to extremely high attrition rates for novel compounds between candidate 
stage and the clinic.  Although the model systems presented here are several orders of 
magnitude less complex than the diverse lipid structures encountered in biology, it was hoped 
that this study might provide the foundations for a more quantitative understanding of inter -
cellular and systemic transport of small organic molecules in the absence of specific receptors, 
pumps, or chaperone proteins to facilitate their movement. 
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4.1 Previous Findings 
4.1.1 Hydrolysis mechanism 
HPLC studies of drug-lipid interactions had demonstrated conclusively that hydrolysis of the 
lipids’ acyl groups was taking place orders of magnitude faster than was observed in control 
samples, in a fashion that was catalytic with respect to the drug molecules.  The reaction was 
observed in a range of compounds which bore resemblance to one another in only very broad-
brush terms (for a full list see Baciu et al.53; those in use in this study are discussed below in 
section 4.2, page 55): all were charged at physiological pH, almost all showed low aqueous 
solubility or at least a strong preference for organic solvents, expressed by their relatively high 
log P values and all contained significant planar aromatic regions or constrained ring structures.  
Beyond that, however, the compounds had little or nothing in common, narrowing the list of 
potential causes. 
Perhaps unsurprisingly, these statements apply to almost all successful small molecule drug 
compounds.  The vast majority conform to an empirical law known as the “Rule of Five” 121, first 
presented by Lipinski et al. in 1997.  This proposed that as a general rule, ideal solubility and 
membrane permeability behaviour was found in compounds with a formula weight below 
500g/mol, with a log P of 5 or lower, five or fewer hydrogen-bond donors and ten or fewer 
hydrogen bond acceptors.  Although experimentally determined and with little or no theoretical 
justification, this model has held significant sway over pharmaceutical research since its 
publication, gathering almost 2,000 citations to date.  It is generally true for most classes of 
small molecule drug (although it can be argued that it becomes a self -fulfilling prophecy once 
accepted as a filter for candidate compounds in industry), but the membrane-traversing reaction 
observed by Baciu et al.53 may present a plausible mechanism through which the parameters 
above exert their influence. 
The drugs tested in the original paper were all cationic in nature, carrying an amine which 
became protonated at physiological pH.  It was hypothesised that the reaction was due to these 
protons, coupled with the intrinsic hydrophobicity/amphiphilicity of the molecules:  the further  
the drugs migrated towards a membrane hydrophobic interface, the greater the penalty for 
carrying an unpaired charge, as described in section 3.2.1.  This meant that the protons were 
only weakly bound, acting in effect as free acids attached to a phase transfer agent.  This 
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allowed them to approach closely to the acid-sensitive glycerol esters which form the core of 
most lipid molecules (see Table 1), and cause their acid-catalysed hydrolysis, as shown below in 
Figure 12, below. 
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Figure 12: The proposed ester hydrolysis mechanism, with raclopride shown as the proton donor.  Note that the drug is 
unchanged by the process, and how the mono-acyl product of the reaction is in itself a potential substrate. 
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If the reaction is the root cause of the lipid hydrolysis, then by making small chemical, structural 
or electrostatic modifications to the catalytic agent it should be possible to adjust the rate at 
which this occurs.  It seems likely that such a process contributes on at least some level to the in 
vivo transport of drug molecules; this means that the rate and degree of a compound’s 
bioavailability can therefore be tuned depending upon its desired application.  This has been 
successfully accomplished in the past by the pharmaceutical industry, although through trial and 
error rather than design: the transport of salbutamol, the asthma drug, was minimised to avoid 
the unpleasant side-effects caused by its β2-adrenergic agonist action upon systemic receptors 
by vastly increasing its lipophilicity.  This led to the introduction of salmeterol, the same drug 
but with a long membrane anchor, greatly increasing its membrane binding and thus slowing its 
release and minimising its systemic (rather than topical) availability 122.  As such, understanding 
the mechanistic underpinnings of this process is potentially of major interest to the 
pharmaceutical industry, as a lack of control of systemic availability of a compound is amongst 
the most significant contributors to attrition rates in drug development programmes.  
 
4.1.2 Hofmeister effects upon drug-mediated hydrolysis 
The initial study published on the drug-mediated hydrolysis had demonstrated the effects of 
drug structure upon the rates of reaction.  However, subsequent research suggested that effects 
could also be observed through the choice of counter-ion in the system, if the drug were 
administered as a salt54.  At its most basic level, the Hofmeister effect35,36 describes the effect of 
an ion upon the structure of water around it.  Although not as immediately intuitive as the 
effect of direct structural modifications, it has long been know that salt choice can have major 
effects upon the stability of colloids and suspensions: indeed, it was the effect upon protein 
solutions that first led to its discovery, previously described in section 3.2.3, page 27.   
Studies investigating the effect of a range of counter-ions to the CAD haloperidol were 
conducted, with the system showing a strong preference for organic, carboxylate anions 54.  
Although this was of some interest, the data did not follow that found in previous studies53, 
even under identical experimental conditions.  Furthermore, the two anions which showed the 
highest rates of hydrolysis were formed from amongst the strongest acids used: formic acid and 
trifluoroacetic acid.  This raised the possibility that a small excess of free acid could have had a 
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significant effect upon the observed rates. 
 
4.1.3 Buffer choices 
The buffer used in these experiments was 10mM Tris HCl at pH 7.4, in common with the 
majority of previous studies, allowing direct comparison of the data.  However, there were two 
major problems with this idea.  Firstly, the pH of 100mM Tris freebase solution is approximately 
10.9.  This means that in order to reach pH 7.4, only ≈1 in 3,000 Tris molecules remained in a 
state where they could absorb any further protons generated by the system.  Secondly, 
calculations performed subsequent to publication revealed that the effective concentration of 
haloperidol in the system was approaching 20mM, or twice that of the buffer. This should have 
had no impact as the drug was administered in a net neutral salt form.  However, it seems likely 
that the hydrophobic drug (log P ≈4.2) will migrate to the membrane rapidly leaving its more 
hydrophilic counter-ion effectively free in solution.  This charge separation could potentially 
cause unpredictable localised charge gradients and counter-ion condensation effects as the 
system sought to equilibrate. This was compounded by the unknown effects of the generation of 
fatty acids by the hydrolysis reaction upon the both the local and global pH of the system.  The 
pKa of a fatty acid within a membrane has been previously shown to be approximately 7.8
60, 
implying that around half the fatty acid molecules will be ionised in this system at any given 
time.  After 5% of the original lipid has degraded, then the fatty acid concentration will reach 
the same as that of the drug, i.e. ≈20mM: if half of these molecules are ionised, then the 
number of extra free H+ ions in solution reaches the concentration of the buffer.  As such, the 
pH of the system as a whole has become the topic of much debate within the project team. 
Despite this, however, there are precedents: Li et al.123 demonstrated that salts of haloperidol 
remain as a close-ion pair for some time after dissolution, even when chloride ions predominate 
significantly.  This has potential ramifications for drug formulation and initial transport models, 
although the long residency times of a drug and high chloride concentrations in vivo meant that 
ion conversion would be inevitable.  As a result of these observations, buffer and salt effects 
were made a priority in the investigations detailed below. 
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4.1.4 Membrane composition 
Some preliminary studies had been undertaken to investigate the effect of altering membrane 
composition upon the observed rates of drug-mediated hydrolysis118.  DOPC, the standard lipid  
model in these studies due to its low spontaneous curvature and relative ubiquity, was 
substituted with DLPC (a shorter-chained, saturated lipid with significantly lower stored 
curvature elastic stress) or DOPE, (see Figure 5), whose primary amine head-group leads to it 
forming inverse hexagonal phase under physiological conditions, meaning that DOPC-DOPE 
mixtures have a very high curvature stress due to the clash between their preferred packing 
structures.  These results suggested that this stress was the dominating factor: DOPE was 
hydrolysed faster than DOPC which is turn reacted faster than DLPC.  However, this data series 
was noisy and difficult to interpret, and it was decided that a study in more depth, covering a 
broader range of lipids, was to be made a priority. 
 
4.1.5 Working hypotheses 
As a result of these previous findings, three working hypotheses were generated which were to 
be investigated during the course of this study.  Firstly, it was proposed that the rate of lipid 
hydrolysis is dependent upon physical state of membrane and physico-chemical parameters of 
drug.  This is important, as it implies that firstly, the rate of hydrolysis can be quantitatively 
predicted given sufficient knowledge of the structure of the drug or metabolite of interest and 
the state of the native lipid membrane.  It also suggests a physico-chemical basis for the 
different tissue specificity of different drugs: the lipid makeup of the lungs, for example, is very 
different to that of the liver and this suggests a mechanism through which that specificity mig ht 
be controlled. 
Secondly, it was theorised that systemic transport is dependent, at least in part, upon this 
hydrolysis.  As outlined previously, there is no overarching theory that explains how and why 
some drug molecules travel as they do, particularly those with very high partition functions or 
very low aqueous solubility.  Furthermore, considering the vast, intricate and elegant network of 
biological feed-back processes controlling the body’s basic biochemical function, it seems almost 
beyond credibility that something so apparently fundamental as this might have simply slipped 
notice.  Links have previously been drawn between this process and phospholipidosis 53: the 
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reaction does not necessarily have to have a beneficial influence upon in vivo drug transport, 
but it would seem unlikely that such a process garnered no physiological response whatsoever . 
Thirdly and finally, it was theorised that hydrophobic drugs exhibiting low rates of hydrolysis 
may be sequestered in membranes, dramatically increasing non-specific binding.  Of the three 
hypotheses, this was the one on the firmest ground: it is accepted that hydrophobic drugs are 
retained in the membrane and indeed, some drugs are designed and optimised to make use of 
this fact124.  What again was unclear was how such drugs could ever be persuaded to leave their 
host membrane: drugs which are sequestered in membrane or adipose tissue are effectively  
useless unless they contain the receptors of interest.  This hydrolysis mechanism fills a potential 
niche in this regard, supplying a mechanism by which even the most hydrophobic and least 
soluble drug might effectively be transported through the bloodstream. 
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4.2 Experimental Approach 
The study was broken down into two main areas of research.  The effects of the drug’s steric 
and electronic structure upon its ability to hydrolyse membranes was probed using a small 
series of analogues of the dopamine-D2 antagonist raclopride, a common and well-characterised 
PET radiotracer in medical imaging studies125.  This compound was chosen over a range of others 
due to its synthetic accessibility, presented by the amide bond at its core (see Figure 13, below), 
its favourable solubility values which simplified handling, as well as its high specificity for the D 2 
receptors located in the striatum of the brain and relatively low non-specific binding compared 
to other such probes126. 
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Figure 13: Parent drug compounds used in the study.  For PET studies, the atom labelled with a star is substituted for an 
positron-emitting equivalent.  All compounds are shown in the salt form used.  1) The dopamine-D2 antagonist 
raclopride tartrate; 2) the D2-antagonist haloperidol HCl; 3) the D2-antagonist spiperone HCl; 4) the serotonin-HT1A and 
dopamine D4 antagonist WAY 100635 maleate.   
The other aspect of the investigation focussed upon the effects of the physico-chemical 
parameters of the membrane affected the reaction.  Previous work had demonstrated that 
membrane composition had a significant impact upon rates, presumably by changing the 
effective log P of the drug molecules by altering the ability of the membrane to absorb small 
molecules.  However, there was no clear logic behind the effects: again, hypotheses abounded, 
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but little was known for certain. 
Other physico-chemical variables also required investigation.  At their most basic level, lipid 
molecules in a cell membrane are vastly outnumbered by the surrounding aqueous media and 
form what are, in effect, giant unilamellar vesicles of some 20-80μm diameter.  However, the 
constraints of SAXS, solid-state NMR and HPLC analysis require significant masses of 
concentrated sample, meaning that the majority of previous studies were performed in 
condensed phase.  This will inevitably have distorted results to some degree: the water channels 
in a multilamellar DOPC system are of the order of 3-5nm127, meaning reduced rates of diffusion 
of drug, buffer and hydrolysis product molecules relative to vesicular systems.  Similarly, the 
choice of buffer and salt could potentially play a significant role in the process, giving rise to 
experimental artefacts.  It was recently demonstrated that PIPES buffer (1,4-
piperazinediethanesulfonic acid) caused significant perturbation to membranes by acting as a 
co-surfactant, causing unusual morphological changes and impacting the reliability of research 
results128.  Previous experiments53,54 were performed using a range of organic buffer molecules, 
and these may have influenced the findings thereof. 
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5 Assay development* 
5.1 Initial assay conditions 
5.1.1 Lipid preparation 
In order for these tests to be possible, a thoroughly robust and reproducible assay was required, 
both for condensed and ideally vesicle-phase models.  The starting point for such work was the 
assay developed by Sebai118 which provided reasonably reproducible rates of hydrolysis of 
samples in the bulk mesophase and thus formed a good starting point.  A typical data plot 
derived using these conditions is shown below, in Figure 14. 
 
Figure 14: A typical data plot showing the hydrolysis of DOPC by haloperidol under the initial assay conditions, measured 
by normal-phase HPLC.  Reproduced from Sebai
118
. 
In brief, in each vial 20mg (25µmol) DOPC with 5 mol% drug were dissolved in a mixture of 1:1 
                                                          
* Error bars have been omitted from this section, as each experiment was an iterative one-off 
step in the developmental process and both experimental and analytical conditions varied 
significantly between runs.  Furthermore, each experiment required approximately a month of 
lab and equipment time, thus limiting the opportunity for repeats.  This meant that there was 
neither sufficient data nor any major benefit to be gained by the analysis of the error margins of 
each dataset, and all data points gathered are shown.  However, once analytical conditions had 
been finalised, relevant results were aggregated to provide a robust statistical analysis – for 
these data, please see section 5.5, page 90. 
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chloroform and methanol and the solvent removed under a nitrogen stream.  The vials were 
then dried in a vacuum oven at 40°C overnight, before being hydrated with 10mM Tris HCl at pH 
7.4 (Tris(hydroxymethyl)aminomethane hydrochloride), 3:1 buffer/lipid w/w.  The assay vials 
were then vortexed and centrifuged three times to ensure homogeneity, forming a white 
opaque suspension and incubated at 37°C throughout the course of the experiments.  The pH of 
the buffer and all others described in this text were measured using a Hanna Instruments 
(Leighton Buzzard, UK) pH210 Microprocessor digital pH meter.  Lipids were purchased from 
Avanti Lipids (AL, USA); all other compounds were purchased from Sigma-Aldrich (UK) unless 
otherwise specified and were of at least 95% purity.  All buffers were made using HPLC grade 
water (VWR, UK).  If SAXS measurements were to be taken in parallel with the HPLC analyses, 8 -
10μl of the suspension was dispensed into a 1.5mm diameter glass capillary tube (Capillary Tube 
Supplies Ltd., UK) and was spun to the bottom of the capillary via centrifuge.  The capillary was 
then flame sealed and capped with a silicon gum to prevent drying. 
6μl samples were taken every 3-4 days using a Gilson pipette and dispensed into a 1ml HPLC 
sample vial.  These vials were dried under vacuum in a desiccator connected to a Thermo Fisher 
Micromodulyo freeze-dryer to halt any further reaction, and were then redissolved into 1ml 
methanol for HPLC analysis. 
These conditions were taken as a starting point for the development of the assay used 
throughout this thesis, to allow direct comparison with historical data.  The optimisation process 
and its results are described in full below, in section 5.4 page 72. 
 
5.1.2 HPLC equipment and initial chromatography conditions 
Analyses were performed using an all-PEEK (polyetheretherketone), dual-pump system (Model 
626 LC, Waters).  Initially, measurements were conducted on a Kromasil 60-5 column (Hi-Chrom) 
and analysed via evaporative light scattering, using an ESA 301 detector.  The initial mobile 
phase gradient used ran from 101/21/2/0.1 hexane/isopropyl alcohol/acetic acid/triethylamine 
(solvent A) w/w to 155:17.5:2:0.1 isopropyl alcohol/water/acetic acid/triethylamine (so lvent B), 
degassed through a Degassex DG-401 unit (Phenomenex).  100μl of the ethanol solution was 
injected on each occasion using a Waters 771Plus autosampler module, giving strong ELSD 
signals with relatively low amplification, meaning a good signal-to-noise ratio.  Each HPLC run 
Page | 60  
 
ran a gradient from 100% A to 50:50 A and B over the course of 35 minutes.  Due to the normal-
phase conditions chosen, oleic acid eluted first and was difficult to resolve from the solvent 
front; DOPC eluted with a retention time of approximately 18 minutes and lyso -OPC eluted after 
approximately 21 minutes, shown below in Figure 15. 
 
Figure 15: A typical HPLC spectrum showing the hydrolysis of DOPC by haloperidol hydrochloride (HPD) under the legacy 
analytical conditions used as a starting point in the study.  Oleic acid (OA) is eluted first, in a peak which was often 
difficult to distinguish from the solvent front.  Lyso-lipid (LPC), the most polar of the species, was eluted last.  
Reproduced from Sebai
118
. 
These conditions had a number of drawbacks that required improvement or resolution before 
truly high-throughput or real-time studies could begin.  Firstly, the gradient required for 
efficient separation meant that each sample took 35 minutes to run, as can be seen above.  
Previous experiments had shown almost total disruption of lipid vesicles by CADs over this 
timescale53, which effectively precluded the possibility of real-time analysis.  Furthermore, the 
complex solvent mixtures required meant that reproducibility was problematic, as small errors 
in component make-up could lead to significant changes in the retention times of the analytes.   
As a result, a thorough optimisation programme was initiated early in the study to look at both 
column technologies and elution gradients – see section 5.2 for details. 
 
5.1.3 Small-angle X-ray scattering 
SAXS was conducted using custom-built equipment, based around a Bede (Durham, UK), 
Microsource X-ray generator with integrated optics, an Ealing (Ealing Electro Optics, UK), linear 
transition stage and a Photonic Science Ltd (Battle, UK), Gemstar intensified CCD X -ray 
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detector129.  X-ray data were typically acquired over a 60-second exposure and spacings were 
calibrated against a silver behenate standard130.  Diffraction patterns gained from the samples 
prepared above were analysed with the IDL-based AXcess software package that was developed 
by Andrew Heron at Imperial College53. 
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5.2 HPLC optimisation 
Whilst the approaches described in section 5.1.2 yielded data about the initial rates of reaction, 
they provided few indications as to the eventual fate of the lyso-lipids generated as a result of 
the hydrolysis due to its inability to quantify the fatty acid peak.  Normal phase HPLC, as 
described above, retains compounds for a time that is (broadly speaking) proportional to their 
polarity and number of hydrogen bond donors and acceptors93; fatty acids, particularly the 18:1 
oleic acid generated from the hydrolysis of DOPC, are almost entirely neutral, hydrophobic 
species and have very few interactions with the stationary phase.  As a result, the retention time 
of the fatty acid was below 2 minutes, which coupled with its relatively broad peak profile 
meant it vanished into the solvent front of the HPLC spectra. 
Another issue was that the run time was far too long to be used for any real -time analysis of 
samples: in the fluorescence micrographs taken in the initial study, massive morphological 
changes had occurred within 30 minutes of drug administration.  Using the initial solvent 
profiles, this would only have allowed one data point, at t=0, which would be meaningless.  As a 
result, early efforts were devoted to optimizing the HPLC parameters to improve both resolution 
and run time. 
While lipids are amenable to separation by HPLC and a number of well-characterised approaches 
exist for their isolation, most techniques depend upon a two stage process.  Initially, lipids are 
separated into head-group classes via normal-phase chromatography; each of these peaks is 
then recovered, dried and redissolved in an organic solvent for reverse-phase chromatography 
to isolate the individual acyl species93,131.  This was both too cumbersome a technique for the 
purposes required in this study, but was also inhibited by solubility issues: it was extremely 
challenging to identify a solvent or mixture of solvents that would simultaneously deliver good 
chromatographic separation, would dissolve the di-acyl, mono-acyl and fatty acid species and 
was compatible with the all-PEEK HPLC system outlined in section 5.1.  The PEEK used in the 
manufacture of the HPLC was an issue, although it conferred certain advantages with regards to 
lipid binding, as it effectively eliminated the steel surfaces to which the lipids would otherwise 
bind strongly and spontaneously, blocking the tubes and causing mechanical failure of the 
device.  However, PEEK is incompatible with tetrahydrofuran (THF), chloroform and 
dimethylsulphoxide (DMSO), which cause swelling and softening of the polymer which prevents 
the use of these otherwise extremely strong and versatile solvents.  This was a considerable 
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disadvantage in this case, as many alternatives were not suitable for one reason or another: for 
example, while methanol rapidly solubilised both mono-acyl and di-acyl phosphocholine, it is 
largely immiscible with oleic acid except at very low acid concentrations.  
 
5.2.1 Exploration of column and solvent options 
The HPLC optimisation process began with the testing of a variety of column techniques and 
solvents that were employed over approximately a six month period: both normal- (silica, diol, 
amine and nitrile) and reverse-phase (C8, C18, and phenyl) column packings were experimented 
with in consultation with experts at Waters and Varian (now a part of Agilent) , each through a 
variety of solvents.  The major difficulty that presented itself was the vastly different behaviour 
of the acyl species versus the fatty acid.  It was possible to resolve the two acyl lipids on most 
normal phase systems, with varying degrees of success and with differing retention times, but in 
each case the fatty acid was effectively lost in the solvent front.  In contrast, reverse-phase 
techniques gave excellent resolution of the fatty acid from the acyl lipids, but it was extremely 
difficult to resolve the acyl species reliably.  This process could have been sped significantly had 
the HPLC been fitted with automated method development software; unfortunately, the unit 
was too old to be compatible with such a package and so there was little option but to perform  
the process manually. 
Several weeks of development led to the adoption of a 150 x 4.6 mm nitrile column, generously 
donated by Varian, as the separation medium of choice, with a subsequent reduction in analysis 
time from 35 minutes to 23 minutes, shown below in Figure 16.  Although efforts were made to 
modify and simplify the solvent system to improve reproducibility, these led to failure and so 
the same complex solvent mixture was retained.  This technique presented a slightly better 
retention profile for fatty acid species, while still permitting precise resolution of the two acyl 
classes, although it was still slower than was perhaps ideal. 
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Figure 16: A example of an HPLC spectrum showing DOPC degradation using the nitrile column method described in 
5.2.1.  Note that timescale is significantly shorter than in Figure 15 and that artefact peaks due to mobile phase have 
been eliminated, at the cost of a quantifiable fatty acid peak.  Green trace shows solvent profile, as % strong solvent. 
 
5.2.2 Final HPLC conditions 
After further consultation with Varian, a novel column packing was developed from a Polymer 
Labs test compound originally designed for the low-pressure separation of protein species.  
Known as PLRP-AQ, it contained 12μm hydrophilic, hydroxylated polymer beads with 
hydrophobic pores of around 100Å and a pore volume of 45%.  This gave a mixed mode 
selectivity via both partition as in gel phase and more normal adsorption interactions, with a 
particular affinity for amphiphilic molecules.  Successfully trialled as a 45mm column, this was 
scaled up to a full 150 x 3.9mm size for further analyses and the technique formed the backbone 
of the study during its final 12 months.  This column was used with a water and 0.1% formic acid 
to methanol gradient as external factors made the sourcing of adequate volumes of acetonitrile, 
the favoured ‘strong’ solvent, both difficult and prohibitively expensive.  This approach reduced 
run times to 15 minutes, and importantly allowed on-line, real-time analysis: for the first time, 
crude samples of lipid and buffer could be injected directly onto the column without pre -
treatment.  The solvent profile consisted of a short run at 95% water to clear the buffer and any 
inorganic salts from the column which were otherwise found to co-elute with the lyso-lipids.  
This was followed by a rapid climb to 70% methanol, followed by a shallow gradient to 95% 
methanol.  Retention times and mass-to-peak-area data are discussed in detail below in section 
5.3. 
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Figure 17: An example of an HPLC spectrum showing the degradation of DOPC analysed using the experimental PLRP 
column described in section 5.2.2.  Although peaks were broadened due to large particle size and the use of methanol 
rather than acetonitrile as the strong solvent, retention times were reduced and the need for sample pre-treatment was 
eliminated.  Green trace shows elution profile in % methanol; retention times are discussed in section 5.3. 
This made vesicle-based assays a real possibility: one of the major stumbling blocks to their 
usage was the requirement for sample drying before analysis.  In a condensed-phase sample, 
only a small amount of buffer is present and so even under drying, it was unlikely to have a 
significant effect upon the sample.  However, in a vesicle-based assay there is a much greater 
volume of water to remove in order to quench the reaction – this led to extremely high buffer 
concentrations towards the end of this process, introducing unpredictable artefacts.  
Throughout this process, the detector remained the ESA 301 unit described in section 5.1.  As 
the study progressed, photomultiplier tube voltages, nebuliser and evaporation temperatures 
and injection volumes were modified, and the machine itself was serviced or repaired several 
times, altering the absolute signals generated.  Fortunately, it was relatively easy to normalise 
the peaks recorded by the unit, meaning that these changes had little or no impact upon the 
data recorded, aside from providing a significant improvement to sensitivity and peak shape.   
This can be observed in the tight spacing of the aggregated dataset, which can be seen in detail 
in section 5.5. 
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5.3 Detector Calibration 
Calibration was conducted using standard solutions of each lipid required at a concentration of 
0.3-1mM in methanol, and the volume (and hence number of moles) injected was plotted 
against the peak area recorded by the ELSD.  Initially, precise lipid masses were measured using 
a five-decimal-place balance (Sartorius), to allow directly quantitative determination of the 
relative masses of lipid and lyso-lipid present in a given sample.  However, the masses involved 
(1mM DOPC is equivalent to 0.786mg/ml) meant that small drifts in balance calibration or even 
air pressure could lead to large error propagation, meaning such calibrations had significant 
error bars.  Because the point of each analysis was to assess the degree of hydrolysis as a 
percentage rather than in absolute units, this proved to be unnecessary: the peak areas were 
normalised to generate gradient data, and the gradients of different lipids were compared to 
allow the quantitative calculation of the degree of hydrolysis of any given sample, assuming that 
the hydrolysis of lyso-PC was negligible relative to that of DOPC.  Although this may be thought 
of as quite a serious approximation, the linear nature of all the data plots generated suggest it is 
a valid one, as shown in the results of a typical assay containing DOPC with 5 mol% raclopride 
tartrate, shown below in Figure 18, below. 
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Figure 18: The results of a typical DOPC hydrolysis assay, n = 3.  The lipid was co-lyophilised with 5 mol% raclopride 
tartrate and incubated at 37°C.  Trend line is added to guide the eye. 
This technique generated some interesting results that were of significant interest to the study.  
Firstly, it was found that at low sample concentrations, the performance of the ELSD unit was 
non-linear, whereas at higher sample concentrations or greater injection volumes, the signal 
obtained was directly proportional to the number of moles injected, shown below in Figure 19.  
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Figure 19: The non-linearity in signal observed at low sample concentration.  Although small, this effect was consistent 
and repeatable.  Example shown is from a stock solution of ~0.5mM DMPC in methanol, photomultiplier tube set to 
700V.  Inset shows the detail at low sample volumes. 
This was of note as previous studies had observed a significant lag period of some 30-50 hours in 
between the administration of a hydrolytic drug compound and the first recorded lyso -PC signal 
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(unpublished data).  This was initially taken to stem from some form of internal re-organisation, 
as the drug bound to the membrane and undertook some form of conformational change or 
reached some critical concentration before the reaction began to occur at any significant rate, 
similar to that observed in the activity of PLA2 (see section 3.3.1).  This was supported in some 
measure by SAXS data published previously54 (discussed at greater length in section 5.5.2), 
which showed significant, time-dependent phase changes in the long-range organisation of 
DOPC lamellae which correlated strongly with observed rates of hydrolysis.  However, the detail 
obtained from these calibration experiments suggest a much simpler alternative: that the ‘lag’ 
phase was simply an artefact generated by the limited sensitivity of the light-scattering detector 
at low sample levels.  This could potentially have had a significant impact during the early stages 
of each experiment when lyso-PC signals were low, leading to the non-zero y-intercepts 
observed in the data plots presented below.  Later experiments revealed that the error lay as 
much with the autosampler as the detector: repeated injections of 5μl samples gave a range of 
peak areas, suggesting that the unit could not accurately dispense volumes below 10μl.  The 
other finding of the calibration experiments was the discovery that the signal observed was, 
within error, constant between all lipid molecules, dramatically simplifying analysis, shown 
below in Figure 20.   
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Figure 20: Normalised calibration data from the injection of standard lipid solutions, concentration 0.3-1mM.  Data were 
normalised around the smallest reliable injection volume, 10µl.  There was no discernable correlation between 
molecular weight or degree of unsaturation and detector response in the region of interest.  Linear regression analysis 
gave errors of ±0.489a.u. intensity (2 s.d.). 
 
Lipid species Retention time /min 
DOPC 10.9 (17.6) 
DLPC 7.5 (12.7) 
DMPC 8.8 
DPPC 10.2 
POPC 11.0 
DOPE 11.6 
  
Lyso-OPC 6.1 (9.6) 
Lyso-LPC (5.5) 
Lyso-MPC 5.2 
Lyso-PPC 6.0 
Lyso-OPE 6.5 
  
Cholesterol 11.1 
Table 2: The retention time of each lipid species studied in this investigation, via the HPLC method described in section 
5.2.2.  Where two values are given (e.g.  for DOPC): the first is the retention time via the optimised  protocol; the value 
in brackets describes the result of the extended gradient described in section 6.2. 
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The retention times for each of the lipid species studies are listed above in Table 2.  The 
standard conditions described above worked well for the majority of PC and PE lipid studies, but 
it can be seen that the co-elution was observed between DLPC and several lyso-lipid peaks.  As a 
result, an extended version of this system with a shallower gradient step was established to run 
over 20 minutes: the retention times under these conditions are shown in brackets.  
Fatty acid peaks were not quantified under these conditions.  Most fatty acids are effectively 
immiscible with water and methanol: although they came off the column with a retention time 
of around 12-13 minutes, they did so in a broad and noisy band with a very low mean intensity, 
to the point where they made little or no contribution to the signals of other species.  This 
meant that, as described above, all the following data is presented on the assumption that 
raclopride’s hydrolytic activity towards di-acyl lipids is significantly greater than that towards 
lyso-lipids.  However, the linear growth of the lyso-lipid signals in all studies suggests that this is 
a valid assumption, although one that may not be true for all CAD-like compounds. 
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5.4 Buffers, salts and ionic strength 
5.4.1 Experimental issues and potential artefacts 
Upon revisiting the data derived from the original assay, several unusual phenomena were observed.  
Firstly, rates of hydrolysis were extremely slow, reaching only around 10-15% hydrolysis after some 
three weeks of incubation.  This compared very poorly with the extremely rapid morphological 
changes observed in GUVs via fluorescence microscopy (see Figure 10, above).  There was some 
concern that this was a result of either the choice of buffer, 10mM Tris HCl (Tris HCl), pH 7.4 at 37°C 
(equating to pH≈7.7 at room temperature132), or of the restrictions imposed upon the reaction 
kinetics by the multiple bilayers of the lamellar structure adopted by the lipid under these 
conditions, as described above.  It was also observed that rates of reaction were not constant: that 
the rate followed an accelerating curve over time, suggesting some kind of autocatalytic mechanism 
might be at play. 
 
5.4.2 Incubation conditions 
Early experiments showed biphasic results: over relatively short time periods, (<240 hours), the 
hydrolytic behaviour of the drug was linear and extremely repeatable. Above these timescales, 
the assays showed significantly different behaviour, demonstrating exponential growth of the 
lyso-PC mol fraction but with significant variability between runs (see Figure 21 for examples).  
These assays were stored at 37°C, as described in section 5.1.1, in plastic test-tube racks in an 
incubating oven.  No assay data were used from samples >700hrs old, as after this point 
significant chain-fission products were observed in the DOPC chromatograms, making results 
unreliable. 
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Figure 21: The apparently exponential rates of raclopride-mediated hydrolysis observed in early assays.  In these 
examples, raclopride tartrate was added at 5 mol% relative to lipid and hydrated 3:1 w/w with 10mM Tris HCl.  Assays 
were run with identical batches of lipid and drug, but on different dates. 
In between samples, it was observed that a significant percentage of the buffer solution i n each 
vial had evaporated from the lipid at the vial’s base and condensed around its neck, due to the 
thermal gradient caused by the contact of the vial base to the aluminium shelves of the 
incubator.  This led to experimental issues, as the samples had to be re-centrifuged and 
vortexed to ensure homogeneity before sampling.  This meant that the samples were 
experiencing different conditions over the course of the assay, rendering such results unreliable.  
Furthermore, although the water from each sample was evaporating away from the lipid, it is 
very unlikely that the buffer molecules themselves were doing so.  This will inevitably have led 
to high concentrations of buffer in the semi-dehydrated lipid, with unpredictable results. 
In order to counter this effect, the vials for subsequent assays were stored in aluminium heating 
blocks which provided close contact to the glass vials throughout their length.  This change had 
an immediate effect, as can be observed from Figure 22.   
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Figure 22: Data from the next three assays showing the hydrolysis of DOPC by 5 mol% raclopride performed under 
condition identical to those in Figure 21, but incubated in aluminium blocks.  Original data is overlaid for illustrative 
purposes.  
This was an unexpected result, in many ways.  While some effect upon rate was expected, Le 
Châtelier’s principle would suggest that dehydrating such a system would slow the rate of a 
hydrolysis reaction, not increase it.  It is quite possible, however, that the DOPC remained above 
its excess water point at all times before the introduction of the heating blocks: DOPC is fully 
hydrated at any point above 45 weight% water (corresponding to a water:lipid ratio of around 
35:1)133, meaning that the increase in rate could possibly be attributed to the relative increase in 
buffer concentration.  In either case, these preliminary experiments raised a number of 
questions which required resolving before the assay could be relied upon to any significant 
degree. 
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5.4.3 Excess water level 
Even after the introduction of the heating blocks, the lipid mixture rapidly took on a viscous, 
translucent appearance as the reaction progressed in an assay vial, more like a putty or a viscous gel 
than the expected white, opaque fluid.  It was proposed that this, too, was due to a shortage of 
excess free water: the volumes of water involved were sufficiently low that over time, even a slightly 
imperfect vial seal could lead to significant dehydration and hydrolysis, by its nature, consumes a 
molecule of water for each reaction step.  With a significant percentage of the available water held 
in the lipid head-groups’ hydration shells, it was possible that the reaction was being limited by its 
availability, or lack thereof.  Furthermore, this viscosity made accurate testing challenging, as 
extracting sufficient lipid to provide a clear signal became an issue. 
In order to eliminate this possibility, an assay was run with both raclopride and spiperone 
(another of the well-characterised compounds134 used during the original discovery) as detailed 
above.  However, the volume of 10mM Tris HCl buffer was varied in each vial, between 3:1 and 
100:1 w/w relative to lipid, as shown in Table 3.  This would not only highlight any rate-limiting 
effects due to low hydration, but would also provide an excess of buffer relative to drug and/or 
fatty acid in more dilute samples without directly increasing its concentration.  A control vial 
was also prepared, identical to those with the highest excess water levels but containing no 
drug, as it was suggested that the equivalent doped sample would react the fastest if hydration 
was indeed the limiting factor.  Five samples were taken from each vial over the course of 28 
days and freeze-dried immediately to prevent further reaction, before being analysed as above 
in section 5.1. 
Mass DOPC 
/mg DOPC /umol Drug name 
Lipid:drug 
ratio Mass drug /mg 
Buffer:lipid 
w/w Vol Buffer /μl % water 
20 25.44 Raclopride tartrate 20 0.51 3 60 75.00 
20 25.44 Raclopride tartrate 20 0.51 10 200 90.91 
20 25.44 Raclopride tartrate 20 0.51 25 500 96.15 
20 25.44 Raclopride tartrate 20 0.51 50 1000 98.04 
20 25.44 Raclopride tartrate 20 0.51 100 2000 99.01 
20 25.44 Spiperone 20 0.50 3 60 75.00 
20 25.44 Spiperone 20 0.50 10 200 90.91 
20 25.44 Spiperone 20 0.50 25 500 96.15 
20 25.44 Spiperone 20 0.50 50 1000 98.04 
20 25.44 Spiperone 20 0.50 100 2000 99.01 
Table 3: The experimental design of the initial experiment to determine the effect of excess water upon rates of 
hydrolysis. 
No hydrolysis was observed in any of the spiperone-doped samples: tubular crystals were 
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observed in all within seven days of initiation.  As these were not observed in the raclopride 
samples, it was taken that these crystals were formed of precipitated spiperone, which would 
prevent any reaction from occurring.  This may have been due to the drug being administered as 
a free-base, rather than as a more soluble salt form.  More interestingly though, hydrolysis was 
only observed in the first two raclopride samples, with the 3:1 w/w mixture reacting significantly 
faster than the 10:1 w/w vial.  Furthermore, the approximately threefold increase in dilution led 
to a similar decrease in rate.  This unexpected result led to the experiment being repeated, with 
DOPC-buffer mixtures between 2:1 and 10:1 w/w, all doped with raclopride tartrate at 5 mol% 
relative to the lipid.  The results of this experiment are shown below, in Figure 23. 
 
Figure 23:The hydrolysis observed in otherwise-identical DOPC samples doped with 5 mol% raclopride tartrate.  Ratios 
correspond to the amount of 10mM Tris HCl added relative to lipid, w/w. 
When the gradients of these data are converted into units of mol hr-1 molRAC
-1 (where molRAC is 
equal to the number of moles of raclopride present) and plotted against buffer:lipid ratio, the 
following plot emerges (Figure 24). 
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Figure 24: The dependence of the rate of raclopride-mediated DOPC hydrolysis as a function of buffer:lipid ratio.  Buffer 
was 10mM Tris HCl.  Equation of trend line is y = -0.041x + 0.59.  Assuming the trend remains linear until the lipid 
reaches its excess water point at 45 weight%
133
, this predicts a maximum rate of 0.556 mol hr
-1
molRAC
-1
.  Beyond this 
point, it seems unwise to speculate. 
The linear decrease in rate with dilution could really only be due to one of five things:  
 the dilution of the relatively hydrophilic raclopride, (log Doct 1.33 at pH 7.4
135) leaving 
less in the membrane to react 
 that despite its theoretically neutral form, the raclopride salt was overwhelming the 
buffer at low ratios, creating more extreme pH conditions than were realised 
 the buffer molecules were migrating to the interface and in some way inhibiting the 
reaction 
 the effect of the excess water upon the average DOPC aggregate size 
 the ratio between the number of tartrate to chloride anions in the system led to unusual 
surface effects at the membrane interface. 
Although not immediately intuitive, previous work had shown some dependence of the sample 
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viscosity136 and rate of hydrolysis54 upon the choice of counter-ion within the system.  As 
explained in section 4.1.3, at a 3:1 w/w ratio of 10mM buffer to lipid and 5 mol% raclopride 
tartrate with respect to lipid, there are approximately twice as many tartrate ions as there are 
chlorides in solution.  As the buffer volume increases, so too does the number of chlorides, 
meaning that at ratios greater than 6:1, chlorides outnumber tartrates.  As chloride is a 
reasonably chaotropic anion relative to the strongly kosmotropic tartrate, it was hypothesised 
that due to the Hofmeister effect (see section 4.1.2), the movement of this ratio might play a 
significant role in the conditions at the membrane interface. 
 
5.4.4 Buffer concentration 
In order to probe these effects, the experiments shown in Figure 23 were repeated with a more 
concentrated buffer so as to eliminate any such Hofmeister effects  (see section 4.1.2).  This 
would also have the effect of preventing any changes in pH in the system caused by the addition 
of drug, and could potentially also give some insights into any effects caused by the buffer 
molecules themselves.  As such, the entire experiment was repeated using 100mM Tris HCl as 
buffer.  It was rapidly observed that the viscosity and opalescence described above in the 10mM 
buffered systems was in some way linked to the buffer strength, as the 100mM sample s were 
significantly whiter and more fluid than previously.  However, none of the samples showed any 
measureable hydrolysis at all over a period of 650 hours and the experiment was abandoned. 
This was, in many regards, also unexpected.  A higher ionic strength within the buffer should, in 
theory, make the solution less welcoming to hydrophobic species and thus drive a greater 
percentage of the drug into the membrane, increasing the observed log D.  Similarly, it seems 
unlikely that this change caused the precipitation of the highly water-soluble drug.  This result 
implied, then, that the effect was either due to the buffer molecules themselves having an 
inhibitory action, that the counter-ion was involved in some way or that the reaction depended 
upon the drug in some way overwhelming the buffer and creating more extreme pH conditions 
than were expected, despite its theoretically net neutral form.  The final option was thought to 
be most likely, supported by the observation that none of the results plots generated showed a 
line through the origin, suggesting a lag-phase or a period of internal reorganisation before the 
reaction took hold.  However, this was easily explained with low injection calibration of the ELSD 
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detector, which revealed a non-linearity of signal at low mass levels (see section 5.3), suggesting 
that these results were simply an artefact of the detector. 
In order to confirm these findings, the effect of concentration was probed further, using Tris HCl 
at 100, 50, 25 and 12.5mM, formed by dilution from 100mM stock using HPLC grade water.  All 
were added at 3:1 w/w, as in previous studies, as it was felt that this gave a quantifiable rate of 
reaction but simultaneously offered some protection against the samples totally dehydrating 
during incubation. 
The results of this assay are shown below, in Figure 25: what they reveal is that a decrease in 
buffer concentration led to an increase in rate of reaction in a smooth fashion.  There was no 
obvious ‘critical concentration’, above which all hydrolysis ceased, simply that as buffer 
concentration increased the rate slowed until it was no longer detectable using the methods 
available.  This finding eliminated the physical effect of the water upon the lipid aggregate size 
from the investigation, as these effects were observed at a constant percentage of excess water, 
meaning that the lipids in each vial had, at least on average, an equal exposure to the bulk 
medium. 
 
Figure 25: The effects of increasing Tris HCl buffer concentration upon rate of DOPC hydrolysis by raclopride tartrate 
(n=2). 
However, it was still not possible to tell from these data which component of the system was 
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having the effect: the Tris molecules or the chloride counter-ions.  The latter posed a serious 
impediment to the idea that this process may be important in vivo: the typical chloride content 
of a physiological fluid such as blood serum is around 100-110mM137 over a volume of many 
litres, something that no amount of drug formulation could compete with.  However, the idea 
that Tris had an inhibitory effect was also problematic, as the vast majority of previous studies 
had been undertaken using this buffer or one of its derivatives. If this were in some way 
sequestering drug molecules or otherwise preventing CAD-lipid contact, many previous results 
would be rendered unreliable and our understanding of the process as a whole would require a 
thorough review.  As a result, identifying if one or more of these factors was responsible for the 
observed phenomena became an urgent priority.   
 
5.4.5 Choice of counter-ion  
Initially, the effect of the counter-ion upon the system was investigated.  Firstly, experiments 
were run using the sodium salt forms of all the anions studied in place of raclopride: formate, 
TFA, tartrate and chloride (shown below in Figure 26).  None of these assays showed any 
hydrolytic activity over three weeks’ incubation, strongly suggesting that the counter -ion in the 
bulk medium made little or no difference to the rates of reaction.  However, sodium ions are not 
membrane-permeable without assistance (see section 3.2, page 25 for a full discussion), unlike 
the amphiphilic CAD molecules which preferentially partition into the lipid bilayer.  As a result, 
the interface itself was not charged under these conditions, meaning that this model could not 
account for the effects of the condensation of the anions onto the membrane surface.  
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Figure 26: The anions studied to isolate the effects of the Hofmeister series
35
 upon the rates of CAD-catalysed DOPC 
hydrolysis. 
To investigate any counter-ion effects further, 4 solutions containing 100ml 100mM Tris free-
base (pH 10.8-10.9) were made up using HPLC-grade water.  These were buffered to pH 7.7 at 
room temperature (equivalent to pH 7.4 at 37°C132), with a range of organic acids: trifluoroacetic 
and methanesulphonic acids were added directly; maleic and L-tartaric acids were first dissolved 
in water to form a 2M solution, then added to the Tris.  All pH values obtained were in the range 
7.6-7.7 at room temperature (approx. 24°C). 
The first experiment performed was a repeat of the excess buffer assay shown in Figure 23: 
identical in every way, except for the substitution of Tris tartrate in place of Tris HCl.  This 
experiment was designed to isolate any Hofmeister effects which may have influenced the 
system, by eliminating (as far as was possible) any chloride ions within the system, meaning that 
ion exchange by the raclopride molecules with the bulk solution would have no effect.   As a 
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result, if chloride ions were inhibiting the reaction, the observed rates of hydrolysis for each of 
the vials in this assay would be equal. 
 
Figure 27: The hydrolysis observed in otherwise-identical DOPC samples doped with 5 mol% raclopride tartrate.  Ratios 
correspond to the volume of 10mM Tris tartrate added relative to lipid, w/w.  Control sample contains no drug, but is 
otherwise identical.  Samples containing ratios 2:1, 7:1, 10:1 dehydrated due to faulty vial seals and so are not shown. 
This revealed rates that were, within error, identical to those uncovered in section 5.4.3: as the 
volume of buffer in the system increased, the reaction slowed dramatically.  This meant that 
chloride ions were not responsible for the observed results, and that Hofmeister effects could 
be assumed negligible.  This directly contradicted the earlier, published findings reported to 
affect the rate of haloperidol-induced hydrolysis54 and so the experiment was repeated using 5 
mol% haloperidol hydrochloride rather than raclopride tartrate.  In this and subsequent 
haloperidol experiments, no hydrolysis was observed at all despite the appearance of a peak 
corresponding to haloperidol in the HPLC traces derived from the samples, meaning that the 
drug had not precipitated out in the way that spiperone was observed to do in section 5.4.3.  
These results will be discussed below in section 5.5.1. 
In order to confirm the findings of Figure 27, similar experiments were performed with 10mM 
Tris maleate, Tris TFA, Tris mesylate and unbuffered pure water at water-lipid ratios of 3:1, 6:1 
and 9:1 in order to give a spread of results.  These results (not shown) looked very similar to 
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those shown above, to within ±1% hydrolysis, with the exception of the maleate data which 
showed almost no degradation at all over some three weeks of incubation.   Similarly, when a 
range of Tris tartrate concentrations were used, similar to those in Figure 25, the results were 
effectively indistinguishable from those found using Tris HCl. 
One thing that rapidly became obvious about the mixtures was that the viscosity and 
opalescence observed in the samples (described in section 5.4.3) was significantly more 
apparent in the pure water samples than in the buffered ones.  This observation is of interest , as 
it was thought up until this point that the viscosity was due to a shortage of excess water due 
some form of ion-binding or formation of extended hydration shells by the Tris molecules.  
Instead, these results suggest that the effect is caused by a swelling of the channels between 
membranes due to electrostatic repulsion of the anionic fatty acids and/or cationic drugs, which 
will have a significantly greater influence in an unbuffered system with a consequently greater 
Debye length.  Recent studies have suggested that in weakly buffered systems such as the one 
under investigation, anionic vesicle diffusion rates are significantly slower than calculations 
predict due to the contribution of longer-range hydrostatic effects upon the vesicles effective 
cross-sectional area138. 
Interestingly, this behaviour could be mimicked by co-lyophilising with 5 mol% 
dimethylditetradecylammonium bromide (DMDTAB) (see Figure 28, below), before hydrating as 
normal with Tris HCl.  This compound provides a permanent cation, thus no potential to carry a 
proton and no hydrolysis.  However, it has an extremely high log P (calculated at 5.96 at pH 
7.434)and thus is almost totally membrane bound, mimicking the electrostatic effects of having 
high levels of cationic drug within the bilayer.  A system containing DMDTAB showed no 
membrane hydrolysis over the course of more than three weeks, but assumed the viscous and 
opalescent form described above within seconds of hydration.  The phase adopted by the 
sample was probed by SAXS (described fully in section 5.1.3) but no diffraction could be 
observed, suggesting an amorphous state rather than the expected lamellar phase.  
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Figure 28: The structure of the bilayer-forming cationic amphiphile, dimethylditetradecylammonium bromide. 
That the results for pure water mirrored those of the buffered systems is of little surprise , as the 
pH of water should be ≈7 as opposed to 7.4 in the controlled systems, and as the drug is added 
as a net neutral salt no changes to it should take place.  It does raise some interesting questions 
about the strength of Tris buffers at these pH values, though: if the pH is affected by the 
ionisation of a percentage of the fatty acid molecules generated during the hydrolysis reaction 
(discussed in section 4.1.3), then the fact that results in pure water mirror those in buffered 
media suggests either that pH plays no role in determining the rate (which seems unlikely given 
the proposed mechanism), or that the buffer is rapidly becoming overwhelmed.   As a result, a 
range of preliminary investigations were undertaken into the effects of a range of other buffers, 
described below in section 5.4.6. 
The inactivity of the Tris maleate assays remains unexplained, for now: it may have been due to 
simple experimental error, as the maleate assay diluted 3:1 buffer-lipid dehydrated very rapidly 
due to a faulty vial seal.  However, this was not the case for either of the other two vials and the 
source of their inactivity remains unclear. 
 
5.4.6 Salt concentration and ionic strength 
It had by this point been conclusively demonstrated that the kinetics and rate of the reaction in 
the condensed phase did not depend on the Hofmeister effect, nor the presence or otherwise of 
Tris molecules.  However, this did not explain why no reaction was observed in 100mM Tris 
hydrochloride when lower concentrations of the compound gave such repeatable results.  It was 
posited that the effect may have been due to the ionic strength of the solution: that increased 
screening of charge and of the dielectric constant gradient, (the difference in the capacitance of 
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the water versus the hydrophobic regions, a measure of the changes in polarity between the 
two regions), between the bulk medium and lipid interface may in some way inhibit the 
availability of protons to initiate the otherwise-catalytic reaction.  This too could pose a 
significant barrier to the applicability of the research to biological systems, which often have a 
sodium chloride concentration of >150mM and thus a much higher ionic strength that those 
previously studied. 
In order to isolate any effects of ionic strength upon the system, a number of assay vials were 
made up containing 3:1 ratios of 10mM Tris hydrochloride to DOPC (w/w) with 5 mol% 
raclopride tartrate and varying concentrations of NaCl as shown below in Table 4.  The NaCl was 
added before lyophilisation, so made no difference to total buffer volume or concentration.  
Every other variable was constant between each vial and the mixtures were incubated at 37°C, 
as standard.  The results are shown below in Figure 29. 
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Table 4: The composition of assay vials to isolate the influence of ionic strength upon the rate of reaction. 
Mass DOPC /mg Drug name NaCl conc /mM Vol Buffer /μl 
20 
Raclopride 
tartrate 
0 60 
20 
Raclopride 
tartrate 
10 60 
20 
Raclopride 
tartrate 
20 60 
20 
Raclopride 
tartrate 
30 60 
20 
Raclopride 
tartrate 
40 60 
20 
Raclopride 
tartrate 
50 60 
20 
Raclopride 
tartrate 
60 60 
20 
Raclopride 
tartrate 
70 60 
20 
Raclopride 
tartrate 
80 60 
20 
Raclopride 
tartrate 
90 60 
20 
Raclopride 
tartrate 
100 60 
 
 
Figure 29: The influence of NaCl concentration upon the rate of DOPC hydrolysis caused by 5 mol% raclopride tartrate, 
plotted as a function of time.  Buffer was 10mM Tris HCl.  Key refers to the NaCl concentration in each vial in mM. 
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Although on first glance this set of results appears very similar to earlier charts, upon closer 
inspection the situation is not so clear-cut.  A plot of [NaCl] vs. rate of reaction is shown below 
in Figure 30, showing that there is little if any relationship between the two variables, although 
there may be some correlation at low concentrations.  Furthermore, the rates observed in 
Figure 30 are comparable with those found in other experiments conducted in 3:1 buffer:lipid 
mixtures in the absence of any such salt, (cf. Figure 24, page 77), suggesting that the ionic 
strength of the bulk medium does not play any significant role in determining the rate of drug-
induced hydrolysis. 
 
 
Figure 30: The influence of NaCl concentration upon the rate of DOPC hydrolysis caused by 5 mol% raclopride tartrate, 
plotted as a function of NaCl concentration.  These rates are comparable, within error, to those found at 3:1 buffer:lipid 
in previous experiments in the absence of any salt. 
This discovery provided a significant boost, as it removed one of the major potential stumbling 
blocks that prevented the application of the discovery onto a physiological environment.  In 
order to develop this further, a number of alternative buffer systems were investigated in an 
attempt to move closer to a physiologically relevant system. 
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5.4.7 Choice of buffer molecule 
In section 4.1.3 it was shown that Tris buffers at pH 7.4, although simple, useful systems for 
buffering media that may be exposed to basic compounds, are of limited use when acidic 
molecules are introduced.  Originally it was chosen as the drugs of interest were typically basic 
in nature, but since raclopride is added as a net neutral salt and the course of the reaction 
produces significant concentrations of fatty acid molecules, research into the suitability of other 
options was required.  Furthermore, it inhibited the rate of reaction as its concentration 
increased, as demonstrated in section 5.4.4. 
The inverse relationship between Tris concentration and rate of lipid hydrolysis suggested that 
the buffer itself may somehow be poisoning the reaction.  It became a priority to identify 
whether this was an artefact of the condensed phase assay, was due to the choice of buffer or 
whether the reaction simply could not progress in strongly buffered systems.  If the latter was 
the case, then it became extremely unlikely that the reaction could provide the proposed 
‘missing’ mechanism of drug transport discussed in section 3.3. 
In order to probe the matter, two other buffers were selected from the ‘Good list’132 to 
investigate whether this was a buffer-specific effect or more of a general issue.  Phosphate-
buffered saline (PBS) and N-(2-hydroxyethyl)piperazine-N′-2-ethanesulfonic acid (HEPES) were 
dissolved in HPLC-grade water to give 10mM concentrations.  The PBS was pre-calibrated to give 
a pH of 7.4 @ 25˚C, (confirmed by independent measurement as previously), whereas the HEPES 
was purchased as a free acid, pH 5.23 @ 21.7˚C.  This was basified with NaOH to a pH of 7.63 @ 
21.9˚C, giving a pH of 7.4 @ 37˚C. 
The relative rates of hydrolysis caused by raclopride tartrate in DOPC hydrated with the three 
buffers Tris HCl, HEPES sodium and PBS was then probed directly.  The PBS assays appeared to 
remain very fluid and opaque relative to the Tris and HEPES, which became viscous and 
opalescent as described previously.  The results of the assay are shown below in Figure 31, 
below. 
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Figure 31: the effect of a range of 10mM buffers upon the rate of raclopride-catalysed DOPC hydrolysis. 
Significant care must be taken when analysing these results: a number of the mixtures assayed 
showed no degradation at all, including some where identical mixtures showed significant 
hydrolysis, suggesting an experimental error in preparation.  Omitting those results, it appears 
as though Tris does not inhibit the reaction significantly at 10mM concentrations relative to 
either of the two other buffers tested, nor relative to unbuffered pure water as tested in section 
5.4.5.  By contrast, the vials containing HEPES showed significantly slower rates of hydrolysis, 
although they were still detectable and quantifiable.  This may have been an artefact of the 
experiment, although recent research has demonstrated that the closely related buffer 1,4-
piperazinediethanesulfonic acid (PIPES) can cause significant fluidisation and perturbation to a 
membrane by intercalation throughout the interface due to its amphiphilic structure, in a 
manner analogous to the CADs under study128.  However, this was not pursued further: the data 
were sufficiently strong to suggest that even if rates were lower, the reaction occurred in 
HEPES-buffered systems at a rate that was both observable and, more importantly, quantifiable . 
In any case, it was felt that PBS provided a more physiologically relevant system of study and 
one which eliminated a number of the buffering issues raised previously .  As a result, all assays 
conducted after this point were performed in a PBS buffer, unless otherwise specified.  
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5.5 Assay reproducibility  
In order to probe the reliability of the condensed-phase results, data from 22 assays not known 
to be erroneous due to experimental error drawn from across the course of the investigation 
were collated and combined.  It was expected that there would be some variability within the 
data, as assays had been taken using several batches of both DOPC and raclopride tartrate from 
a number of different suppliers and analysed using several different HPLC approaches.  Beyond 
that, the ELSD detector upon which all the analytical HPLC data depended had failed several 
times leading to significant repairs and refurbishment, and it was expected that this would have 
had an effect upon the detection threshold of the data gathered, despite attempts to normalise 
it as far as possible.   
Despite these confounding factors, results from 22 assays performed over the three years of 
raclopride testing showed a strong correlation suggesting a high degree of reproducibility , as 
detailed in Figure 32.  It can be seen that comparison between assays leads to some spread in 
the data, due to experimental error, evaporation of stock solutions, pipetting errors etc. and 
that spread was more significant after long incubation periods as small differences in 
preparation were magnified over time. 
  
Page | 91  
 
 
Figure 32: Cumulative data from 22 separate experiments investigating raclopride tartrate mediated DOPC hydrolysis, 
hydrated at a ratio of 3:1 10mM buffer:lipid w/w.  Data includes points using differing buffers, salt concentrations, 
batches of reagent and HPLC conditions.  Line of best fit is equal to a rate of 0.241 mol hr
-1
 molRAC
-1
, p <1 x 10
-4
, r
2
 = 
0.602.   
The spread of results shown in these data are significant and greater, in some cases, than the 
magnitude of the trends observed in some experiments.  In order to obtain useful error bars, a 
quantitative assessment was required of the variability between vials in the same assay.  This 
was assessed through the preparation of nine identical assay vials, each containing DOPC doped 
with 5 mol% raclopride tartrate and hydrated in 10mM PBS solution as previously.  These vials 
were sampled over the course of some 600 hours, and the results compared (Figure 33, below).  
These revealed very tight grouping of data, lending a high degree of confidence to 
measurements produced via this technique.  The error-bars thus derived were used in all 
subsequent assays to give an indication of precision, as the experiments were so long in 
duration that few repeats of each were possible. 
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Figure 33: The mean hydrolysis values derived from 9 identical samples of DOPC with 5 mol% raclopride tartrate 
incubated with 10mM PBS.  The trend-line is equal to a rate of 0.114 mol hr
-1
 molRAC
-1
; error bars show the actual spread 
of results.  These error bars are used throughout the remainder of this report. 
 
5.5.1 Effects of raclopride concentration 
At this point in the investigation, all experiments had been conducted with 5 mol% raclopri de 
tartrate relative to DOPC, to allow direct comparison with earlier studies.  However, it was not 
known whether this was the optimum concentration for the drug: its relatively low log D means 
that a significant amount of drug, approximately 1/8th of that added, was partitioned in the bulk 
buffer and the effects of any aggregation such as those observed with spiperone in section 5.4.3 
were unknown.  Experiments were underway to investigate the phase behaviour of DOPC / lyso-
OPC / oleic acid systems both with and without raclopride by other investigators, but this was a 
time-consuming process and it was felt that a relatively rapid HPLC assay might provide at least 
a guide to assay design until the phase diagrams had been completed. 
It was also important to develop the basis for a calibration set for optical experiments such as 
those conducted on drug-lipid vesicle systems at the Diamond synchrotron (described in section 
5.6.2), which provided information complementary to that derived by HPLC.  Although it was 
accepted that rates in condensed-phase systems such as the one described were orders of 
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magnitude slower than those observed in giant vesicles53, it was hoped that the data from multi-
lamellar systems would act as a trend guide whilst a quantitative vesicle-based assay could be 
designed. 
As a result, an experiment was initiated to analyse the dose-response curve of raclopride in 
DOPC.  DOPC samples were doped with 0.1, 1, 10 and 20 mol% raclopride tartrate, as well as 
samples doped at 5 mol% to act as an internal standard.  It was felt that concentrations higher 
than 20 mol% would be likely to induce significant morphological disruption to the host 
membranes; concentrations below 0.1 mol% could not be accurately measured with the 
available apparatus.  These assays were hydrated with 10mM PBS, as above, and incubated at 
37°C for some three weeks.  The results are shown below, in Figure 34. 
 
Figure 34: The dose-response data of raclopride tartrate in DOPC (n=2, all data points shown).  Key refers to the 
concentration of raclopride tartrate present, in mol% relative to DOPC. 
These data reveal a complex relationship between the drug concentration of the system and the 
observed rates of hydrolysis.  Low concentrations of raclopride induced little or no hydrolysis 
beyond that observed in control experiments: while it has been observed that the performance 
of the ELS detector in use was non-linear at very low signals (see section 5.3), this does not 
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explain the total lack of observed lyso-lipid in these assays.  While there remains the potential 
for the findings to be a result of simple experimental error, there is also the plausible possibility 
that some critical concentration of drug molecules is required in the membrane before  
hydrolysis can take place.  Such a concept has precedent: for example, the small amphiphilic 
molecule curcumin has been observed to have two distinct binding modes when exposed to a 
DOPC membrane, corresponding to a saturable, low-energy mode at the membrane surface 
followed by a higher-energy binding which the authors attributed to sequestration of the 
molecule deep within the hydrophobic interior of the membrane139, and similar behaviour has 
been observed in a range of CADs140.  It may be that in these cases, ionic interactions between 
the dopant and the head-group provide a more favourable binding site or a kinetic barrier to 
prevent the partitioning of the amphiphile beyond the phosphate head-groups on the exterior 
of the membrane and into its oily core: this is likely to have a perturbing effect upon the 
membrane, which may offer a tool to study the process.  Some of the experiments intended to 
probe this effect are detailed below in sections 5.5.2 and 5.6. 
5.5.2 Results with other drugs 
Despite thorough characterisation of the system with raclopride tartrate, limited success was 
met when attempting to analyse the interactions of other drugs with DOPC using the methods 
outlined above.  Previous experiments by the group had observed rapid and dramatic effects 
with drugs including WAY-100635 maleate, spiperone HCl, haloperidol HCl and even raclopride’s 
closely-related analogue eticlopride HCl under near-identical conditions, but no detectable 
hydrolysis was observed by any of these compounds during the course of this study.  In the case 
of spiperone, crystals were observed forming in the base of each of the assay vials, sugges ting 
that the hydrophobic drug molecules had crystallised out of solution, preventing any reaction 
occurring.  However, in the case of haloperidol, a peak was observed on the HPLC traces taken 
suggesting that, in this case at least, the drug had been retained in the membrane.  Some 
hydrolysis was observed by organic salts of haloperidol, in a repeat of the experiments leading 
to the publication of the 2008 Industrial & Engineering Chemistry Research paper54.  However, 
the data was difficult to reproduce accurately due to the drug’s low solubility, high toxicity in 
lipid systems141 and the potential for the introduction of artefacts as explained in section 4.1.2, 
and it was abandoned in favour of raclopride. 
Haloperidol-doped DOPC samples analysed by SAXS showed a significant and reproducible 
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destabilisation and swelling of the lamellar sheets’ d-spacing which, over time, collapsed back to 
form a still-swollen but significantly better-defined (and therefore more ordered) Lα phase (see 
Figure 35, below)54. 
 
Figure 35: Small-angle X-ray scattering (SAXS) images showing the swelling of an Lα DOPC system through the addition of 
5 mol% haloperidol: (a) DOPC in excess water (61.36 (± 0.57 Å), (b) five days after the addition of haloperidol (107.70 (± 
3.21 Å), and (c) eight days (89.46 (± 1.07 Å).  Reproduced from Casey et al. 2008
54
. 
This swelling, which is not observed in the fluid lamellar phase formed by the control sample (d-
spacing of 61.3 Å, similar to that in Figure 35a) is the result of repulsion between charged bilayer 
interfaces142. This indicates that the drug intercalated into the membrane, forcing apart its 
constituent lamellar sheets.  However, the low resolution of the peaks in image in Figure 35b 
implies that this was not an even process: not all membrane layers contained the same 
concentration of haloperidol cations, leading to a range of swelling behaviour and a  disruption 
of the system’s long-range order. 
This extremely swollen system was not stable for long periods, and the system relaxed to a still -
significantly enlarged but much better-resolved system, shown in Figure 35c.  This may have 
been the result of an equilibration, as the haloperidol cations spread equally throughout the 
lamellae to form an equally-spaced system, or may have been due to a neutralisation of the 
charge on the haloperidol molecules, as they donated their protons in exchange for a more 
favourable interaction with the hydrophobic interior of the membrane as described above.  The 
lack of any detectable hydrolysis provides circumstantial evidence for the latter, as neutral 
molecules sequestered within the oily core of a membrane can play no part in the acid 
hydrolysis of its acyl bonds at the bulk water interface.  However, vesicle -based fluorescence 
results seem to support the former hypothesis and are discussed below in section 5.6.1.  
Interestingly, these effects were not observed in samples doped with raclopride tartrate, 
despite the latter’s hydrolytic activity.  This may imply that the more hydrophilic raclopride is 
A B C 
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only ever a transient visitor to the membrane interface, or alternatively that the internal 
hydrogen bonding present within raclopride135 permits the existence of the net neutral 
zwitterion species even at the membrane interface, effectively preventing any such charge -
charge repulsion between sheets. 
In an attempt to identify a minimum pharmacophore capable of causing the hydrolytic effect, 
perhexiline maleate was added to a series of DOPC systems.  Perhexiline is a simple, 
hydrophobic structure (calculated log D7.4 3.93
34) formed of two cyclohexyl and one piperidine 
moieties connected by an ethyl linker (shown in Figure 36), featuring no other structural groups.  
As a result, it was hoped that any hydrolytic activity observed in perhexiline-doped systems 
could be unequivocally assigned to the basic nitrogen in the molecule, if only through a lack of 
other possible options.  Beyond that, perhexiline-induced phospholipidosis has been observed 
to cause significant membrane lesions in both the liver143 and the brain144: in this way, the drug 
offered the chance to conclusively link the two phenomena. 
N
H
N
N
OH
O
Perhexiline
Imipramine
Ibuprofen
 
Figure 36: The structures of the anti-anginal drug perhexiline, the 5-HT inhibitor imipramine and the non-steroidal anti-
inflammatory drug ibuprofen. 
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Similarly, testing was carried out on imipramine HCl, a simple tricyclic antidepressant with a high 
affinity for serotonin (5-HT) receptors.  It, too, has strong links to phospholipidosis39, as well as a 
well-characterised influence on membrane fluidity and leakage in both model systems and 
erythrocyte membranes145.  Despite repeated testing, however, no hydrolysis beyond that of 
control was observed by either drug and the experiments were abandoned. 
One drug that did show consistent and reproducible hydrolytic action raised more potential 
questions than it answered.  Ibuprofen, (2-(4-(2-methylpropyl)phenyl)propanoic acid), showed a 
detectable and linear rate of hydrolysis at 5 mol% concentration, as shown below in Figure 37. 
 
Figure 37: The rate of ibuprofen-mediated DOPC hydrolysis, compared to that of raclopride tartrate (from Figure 33).  
Although slow, the lyso-lipid signal was reproducible and significant relative to that observed in control samples.  Rate is 
equal to 0.0597 /mol hr
-1
 molRAC
-1
, approximately half that observed for raclopride tartrate.  All Ibuprofen data points 
shown. 
Ibuprofen is a small, organic acid with a pKa of 4.45, meaning it is almost entirely ionised at pH 
7.4146.  It has a reasonable aqueous solubility in this form, but retains a significant solubility in 
organic media, particularly in lipid membranes giving a log DDOPC, 7.4 of 1.89, or half a log unit 
greater than raclopride147.  However, all other compounds observed to catalyse the ester 
hydrolysis of lipids have been cationic in nature; ibuprofen is an anion.  This means that in its 
preferred, ionised form it does not carry an acidic proton: paradoxically, it is only as a neutral 
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species that it can possibly show any activity if the hypothesis behind the reaction mechanism is 
correct. 
Ibuprofen has, interestingly, been previously observed to catalyse defect formation and 
eventual destruction of supported membranes, via cyclic voltammetry studies 117 as well as the 
destruction of lecithin liposomes to form lipid tubules and small micellar bodies in a manner 
exactly analogous to that described by Baciu et al., albeit over a slower timescale148.  Although 
these previous studies assume the effect is purely detergent-based (which seems absurd, 
considering the effect is time-dependent), a mechanism is proposed which adds some support 
to the idea of ibuprofen-induced hydrolysis.  Avdeef et al. suggest a “pH piston”, in which the 
depth of the binding between the ibuprofen molecule and the host membrane is determined 
solely by its ionisation state147, shown schematically below in Figure 38.  This model is supported 
by 1H NMR data, which shows two different interactions between ibuprofen and unsaturated 
lipid species, separated by a distance greater than the length of an ibuprofen molecule149. 
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Figure 38: The “pH piston” model proposed by Avdeef et al.
147
, showing the approximate equilibrium positions of the 
ibuprofen molecule in its a) neutral and b) ionised state in a DOPC membrane.  Support is presented in the form of 
1
H 
NMR data which show significant shifts in both the protons of the quaternary amine and of the methylene groups in the 
membrane’s hydrophobic core
149
. 
This leads to a biphasic binding curve, directly analogous to that described for curcumin and 
others above.  In the initial, low energy binding phase, ibuprofen was found to actually stabilise 
the membrane, reducing the incidence of defects and decreasing current flow in cyclic 
voltammetry studies117. It was proposed that this is due to an increase in membrane stiffness, 
and may give a clue as to the lack of hydrolysis observed in low concentration raclopride 
systems such as the ones described in section 5.5.1.  By contrast, in its neutral form the 
equilibrium position is proposed to be determined by π-π overlap between the drug’s phenyl 
ring, as observed in raclopride and a number of small drug molecules during ab initio 
A B 
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computational studies by Rosso et al.150, and is stabilised by a hydrogen bond between the 
carboxylic acid of ibuprofen and an acyl carbonyl from one of the surrounding lipids.  These 
interactions present a plausible route by which ibuprofen might catalyse the hydrolysis of such 
lipids: if the acidic hydrogen is thought of as in equilibrium between binding to the drug and an 
adjacent lipid acyl bond, ester hydrolysis will inevitably occur given a sufficient supply of 
available water molecules.  As water molecules are predicted to be found in large numbers at 
the level of a membrane’s glycerol moieties by molecular dynamics simulations 151, this seems a 
likely outcome of the above model. 
This does not necessarily apply to cationic compounds such as raclopride, however.  In the case 
of raclopride, the electrically neutral form adjacent to the glycerol moieties is the i nactive 
version, and the head-group co-ordinated ionic form is active.  One may speculate about the 
role of the internal salt form described by Tsai et al.135 in the role of proton donor to the neutral 
species, which might conveniently explain the lack of activity observed in even such close 
analogues as eticlopride, whose pKa is only ≈8 and thus too weak to be significant at 
physiological pH152.  At this stage in the investigation, little more could be said about the model 
although some speculative proposals were discussed.  However, later research shed more light 
upon the ionisation state of raclopride in the membrane and its influence upon the molecule’s 
depth of residency. 
 
  
Page | 101  
 
5.6 Vesicle-based assays  
The failure of the condensed-phase assay to reliably observe hydrolytic effects in so many 
systems either previously demonstrated or strongly suspected to be active led to attempts to 
develop a unilamellar vesicle-based technique, such as that described by Baciu et al.53  Although 
that fluorescence microscopy-based experiment revealed a wealth of data, it was not easily 
adapted to provide quantitative data regarding the chemistry and rate of reaction in the system 
and so was of limited value in characterising the process under investigation.  As such, 
techniques capable of directly measuring (rather than simply visualising) the process were 
required for further progress to be made. 
Another reason for the development of a vesicle-based assay lay in the surface activity of all 
such membrane-bound drugs.  Almost all CADs exhibit millimolar critical micelle concentrations 
(CMC) and begin to exhibit surfactant effects well below this concentration33.  Raclopride is not 
reported to form micelles in aqueous solution due to its zwitterionic nature152, but this does not 
preclude any surfactant effects as the drug will not necessarily remain in this state in a 
hydrophobic environment such as a membrane interior135.  Many studies have previously 
reported major structural and mechanical changes to lipid aggregate structures after the 
administration of a range of amphiphilic and hydrophobic drugs16,51,153,154, but where these have 
been explained they have been attributed to simple detergent or intercalation effects, rather 
than a chemical alteration as observed here.  Decoupling any such surfactant effects upon the 
membrane topography from those caused by the products of the hydrolytic reaction would 
provide an important foundation for the application of the reaction in systemic transport. 
Finally, the attempted development of vesicle models was driven by kinetic considerations.  
Condensed-phase models such as those outlined above are a long way removed from the 
micron-scale, broadly unilamellar structures making up cell membranes.  Furthermore the 
formation of multi-lamellar vesicles isolates a relatively large proportion of the lipid system from 
the bulk solution, with potential impacts upon the local pH and the distribution of drugs or 
reaction products within the system.  As a result, it is very difficult and probably unwise to draw 
strong conclusions about the absolute rate of these hydrolytic processes in vivo from the 
condensed-phase results described above. 
All vesicles were prepared using a LIPEX gas-driven extruder (Northern Lipids, Canada).  
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Lyophilised lipid powders or mixtures of lipid and probe were hydrated with the relevant buffer 
to form 1mM suspensions, which were then extruded 10 times through 2 stacked 200nm 
polycarbonate membranes (Nucleopore) using compressed nitrogen at approximately 8bar.  
Lipid suspension recovery was essentially quantitative via this process.  These suspensions were 
transferred to one or more polystyrene or special optical glass microcuvettes (VWR, UK), as 
PMMA cuvettes were known to induce artefacts in the ADIFAB assays described below.  Vesicle 
size and polydispersity was checked using dynamic light scattering using a Malvern Instruments 
High Performance Particle Sizer at 37°C.  The vesicle populations produced were reasonably 
consistent, with average diameter 175.4 ± 10.9nm (n=8).  All studies were conducted using pure 
DOPC as the host membrane, unless otherwise specified. 
These studies progressed broadly in parallel with the HPLC method development outlined above 
in section 5.2 and are reported here in chronological order.  This had the effect that the vesicle-
based HPLC experiments detailed in section 5.6.3 only became available after the 
experimentation into the optical methods detailed below. 
 
5.6.1 Fluorescence studies 
Initial experiments focussed upon optical methods, due to the extremely high sensitivity of 
fluorescence techniques and the availability of a range of well-characterised probes and 
protocols for the analysis of everything from fluidity and domain formation155 to vesicle 
leakage156.  Furthermore, fluorescence monitoring is an extremely rapid process, allowing 
sample rates of hundreds or thousands of Hertz if required, meaning that time resolved data 
could, in theory, be gathered with exquisite resolution using off-the-shelf apparatus. 
All fluorescent measurements were taken using a Cary Eclipse Fluorimeter (Varian Inc., now part 
of Agilent, UK).  Vesicle suspensions were analysed in either disposable polystyrene or special 
optical glass microcuvettes (VWR) in a four-position cuvette holder attached to a temperature 
controlled water bath.  Temperature was monitored through a thermocouple located in the 
sample holder itself and all measurements were performed at 37°C. 
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5.6.1.1 FPE 
An initial approach was to analyse the rate and degree of 
membrane binding of different compounds to unilamellar 
vesicles of DOPC, in an attempt to correlate literature 
partition coefficients, (normally taken in 1-octanol), with 
the binding to and hydrolysis of DOPC systems.  This was of 
particular importance, as many sources highlight the 
difference in affinities of drugs, particularly amphiphilic 
drugs, for membranes as opposed to standard models147 
and without an understanding of these differences, any 
relationship drawn would inevitably contain artefacts and a 
high degree of noise.  However, the fact that hydrolysis was 
expected to occur in these systems added a significant 
degree of complexity, as the effective partition function of 
a compound for a membrane is extremely sensitive to its 
composition157, stored curvature stress158,159 and 
electrostatic charge160, all of which were expected to 
change dynamically as the reaction progressed. 
In order to monitor this process, a fluorescein-labelled 
dioleoyl-sn-glycero-3-phosphatidylethanolamine (FPE) 
probe developed by O’Shea et al.161 was used, shown left in 
Figure 39.  This membrane-bound probe sits at the surface 
of the membrane, its fluorescence dependent upon the 
degree of delocalisation within the fluorescein moiety, 
which is in turn dependent upon the ionisation state of the 
molecule.  At the surface of a membrane, this is dictated by 
the surface potential (ψ), which is a function of the surface 
charge at the membrane and the bulk electrolyte 
concentration84.  As a result, FPE is an extremely sensitive 
probe into the charge density at the surface of a 
membrane, allowing (with sufficient knowledge of the 
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Figure 39: the structure of fluorescein-
labelled dioleoyl-sn-glycero-3-
phosphoethanolamine, (FPE). 
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partition behaviour of the compound of interest) quantitative and time-resolved analysis of 
binding behaviour.  While the absolute partitioning behaviour was not known for the systems in 
question, due to the issues outlined above, it was hoped that through the use of well-
characterised and hydrolytically inactive cationic standards with extremely high log P values 
such as DMDTAB, the data gathered could be used to generate at least a qualitative data trend 
that would be complementary to that available via SAXS measurement, as described in section 
5.5.2. 
As FPE exhibits what is effectively a zero flip-flop rate162, it was possible to add the lipid either 
before extrusion in order to generate at roughly uniform coverage of the probe over both 
leaflets of the vesicle, or alternatively to add it exogenously after extrusion of the DOPC.  This 
led to the probe being present only in the external leaflet, allowing, in principle, analysis of the 
rate of permeation of a drug across the membrane.  In all experiments, the 1mM DOPC vesicle 
suspensions were doped at 0.1 mol% with FPE dye, and 1ml of the suspension was analysed as 
described above.  λEXmax was found at 499nm, λEMMmax was found to be 529nm, ± 2nm.  Dopant 
solutions were made up to 10mM concentration in water, where possible; otherwise in 
methanol or DMSO.  This meant that a 1μl injection of dopant solution equated to a 1mol% 
addition relative to the lipid concentration.  After each injection, the mixture was agitated via 
the aspiration and release of 300μl of the suspension.  Data collection was continuous, except 
during these injections, giving what was in effect a micro-scale stopped-flow experiment. 
Control samples were run to check for contributions to fluorescence from all buffers, solvents, 
drugs and lipids, but all showed negligible effects at the wavelengths of interest.  This was 
important as raclopride, in particular, has some intrinsic fluorescence (λ EXmax ≈ 350nm) and so 
the potential existed for energy transfer effects to generate artefacts in the system if the 
emission spectra overlapped with the probe. 
Photobleaching of the probe was analysed by allowing two positive control samples, (those 
containing DMDTAB) to equilibrate under the excitation beam for extended periods.  DMDTAB 
was also used as the calibration control for the testing: the molecule has a very low intrinsic 
curvature, forming bilayers under almost all conditions and lying in a stable Lβ phase at room 
temperature163.  This means that it has a minimal effect upon the morphology of the vesicles, 
unlike the membrane-softening detergent effects of lyso-lipids and many CADs.  That, coupled 
with its extremely high partition function, (the molecule is effectively insoluble in water) and its 
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permanent cation meant that it could be assumed at all DMDTAB was rapidly absorbed by the 
lipid vesicles and thus that the signal obtained through this process was the maximum possible 
for that doping regime.  Typical raw data is shown below in Figure 40 for injections up to 
20mol% DMDTAB: the experiment was repeated five times under varying conditions , revealing 
similar trend-wise data in each. 
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Figure 40: A typical FPE fluorescence curve, obtained through the titration of DMDTAB solution into a population of FPE-
doped vesicles.  Injections in this experiment were continued until the concentration of DMDTAB reached 0.2mM, or 
20mol% relative to the lipid.  After this point, fluorescence was monitored for 20 minutes to observe equilibrium kinetics 
and rates of photobleaching.  (a) Raw data plot of intensity vs. time.  Inset is the region highlighted in red, showing 
significant increases in intensity for some minutes after injection. (b) The same data, plotted to show the increase in 
fluorescence intensity vs. added DMDTAB (photobleaching data removed for clarity). 
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The above plot reveals two interesting details about the kinetics of the probe.  Firstly, the 
fluorescence intensity of the FPE continued to rise: experiments showed that intensity was not 
saturated by even 50mol% DMDTAB, well above the compound’s CMC value , although increases 
were greatest during initial, small additions of cationic species.  This suggests that either the 
vesicles’ affinity for DMDTAB was effectively unsaturable, which seems unlikely considering its 
permanent cation and the curve shown above in Figure 40b, or alternatively that even in PBS the 
additional charge in the system was screened insufficiently well  to prevent DMDTAB aggregates 
from influencing probe molecules in adjacent membranes.  Neither was an ideal scenario for the 
purposes of these experiments, as they made direct quantification of the amount of dopant 
within a membrane problematic.  However, the effects of photobleaching were reasonably low 
in the system under study, approximately 1 a.u./minute of continuous illumination, meaning 
that for the initial injections which were of the greatest interest, the effects could largely be 
ignored. 
The second, more subtle point of interest in the above scan is highlighted in the inset on Figure 
40a.  This shows that the increase in fluorescence intensity was not over immediately: although 
there was an instantaneous jump in the fluorescence signal after DMDTAB injection and mixing, 
there was a slower component to the increase which took some 5 minutes to reach equilibrium.  
This introduced a number of issues, both as to the quantification of dopant in the membrane (as 
the slow-rising signal often made a contribution towards intensity that was similar to that 
observed from the instantaneous mixing) and the increased illumination which exacerbated 
losses to photobleaching, but also regarding the physical mechanism underpinning its effect s.  
Various models were proposed (outlined in Figure 41, below): slow diffusion of DMDTAB into 
the membrane as the electrostatic repulsion between the cations equilibrated with the 
hydrophobic attraction between the amphiphiles was supported by the apparent increase in 
effect with increasing dopant concentration (a), while another model suggested that the method 
of DMDTAB administration led to a high localised concentration of the compound, saturating 
FPE molecules (b).  This led to the initial rise, which then increased slowly as the DMDTAB 
equilibrated amongst other vesicles as they collided, exposing more probe molecules to their 
charged environment.  This explained the data well and was supported by some other 
experiments (discussed in section 5.6.4.1, below), but assumed the reasonably rapid transfer of 
DMDTAB molecules from one bilayer to another, requiring their energetic (and thus unlikely) 
rotation through 180°.
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Figure 41: The two proposed models which describe the kinetics of FPE response to DMDTAB.  In (a), the DMDTAB 
molecules (blue ellipsoids) are distributed evenly throughout the vesicle population and initially bind rapidly causing 
even, low fluorescence.  However, as they bind, the surface charge build-up repels other molecules, slowing 
equilibration.  In (b), DMDTAB-vesicle binding is very rapid, causing a high local concentration (and thus fluorescence) to 
develop and saturating the local FPE molecules.  Over time, these dopant molecules equilibrate throughout the system, 
increasing overall fluorescence. 
Experiments were attempted with FPE to measure the binding of a number of CAD-like 
molecules to vesicle populations.  Although outright quantitation was problematic, it was hoped 
that at the very least the experiments would provide a qualitative framework of trend data that 
could be used to compare CADs and their analogues to known standards.  As a result, 
experiments were conducted using haloperidol (in methanol), raclopride and two analogues of 
raclopride (all in buffer) which will be discussed in section 7.3. 
FPE exposed to haloperidol behaved, on first glance, in a manner analogous to the DMDTAB 
experiments described above: the probe increased significantly in intensity with each injection 
A 
B 
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of haloperidol solution, converging towards a maximum value after about twice the 
concentration of DMDTAB required, as shown below in Figure 42.  However, there are a number 
of important differences between the haloperidol data and that in Figure 40. 
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Figure 42: The fluorescence curves found in FPE experiments with haloperidol HCl: (a) the raw data, showing 
fluorescence signal vs. time; (b) the data when plotted against haloperidol concentration (long tail-off data from >20 
mins removed for clarity). 
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Upon closer examination, it can be observed that the “equilibration” period of a slow rise in 
intensity of some 5 minutes after each DMDTAB injection is replaced here by a sharp and 
immediate drop-off, far in excess of the 1 a.u./min photobleaching observed in Figure 40a.  
Initially, this was assigned to the previously-observed hydrolytic action of the drug carrying itself 
away for the bound FPE, or neutralising its membrane charge through the introduction of 
anionic fatty acid species thus dimming the probe’s output.  However, neither condensed - or 
vesicle-phase experiments in this study revealed any reproducible haloperidol-mediated 
hydrolysis.  Instead, then, it must be linked to movement of the compound away from the 
interface, either towards the membrane interior or, as seems more likely, precipitating out as 
was previously observed with the closely structurally related spiperone in section 5.4.3 (page 
75).  This could, in turn, provide an explanation for the SAXS results previously reported 54 (see 
Figure 35, page 95), where haloperidol induced significant swelling and disorder of its host 
membrane, which slowly relaxed back to something approaching its native state over the course 
of some eight days.  The more rapid efflux of haloperidol from the membrane in this experiment 
suggests a substantial difference in kinetics between the two phases, which may explain some of 
the disparity in timescales between previously reported data and that above. 
This was reinforced by the results gleaned from experiments with raclopride, or rather the lack 
of similar response triggered by the drug’s addition.  The addition of raclopride or any closely 
structurally-related analogue of the drug actually led to a small decrease in intensity (shown 
below in Figure 43), as if the drug was present as a neutral species or even an anion.   Control 
experiments with methanol had previously ruled out haloperidol’s carrier solvent as the source 
of the effect, and repeat experiments produced near-identical results. 
This  seems unlikely upon first examination, considering the pKa values of the functional groups 
present (the phenol and amine have pKa values of 6.11 and 9.52, respectively
152, giving 
raclopride a pKi of 7.82 and suggesting a predominantly cationic form at physiological pH).  
However, it is unlikely that the formation of a charged species is as favourable in hydrophobic 
media as in bulk water, meaning that one or other net neutral species, either the zwitterion or 
the unionised form, may be predicted to be preferred in the membrane interior.   
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Figure 43: The influence of raclopride tartrate upon the fluorescence of FPE when added exogenously to labelled DOPC 
vesicles. 
It seems improbable that a compound which had been demonstrated to hydrolyse the acyl 
groups at a lipid interface so effectively could impart its effects without binding to the 
membrane, and yet the strongly positive data from the haloperidol and DMDTAB trials were not 
replicated by raclopride.  The results mean that there was no increase of cationic charge at the 
interface: this does not implicitly mean that the raclopride was not bound, but does mean that 
any so present was not protonated, existing as a net neutral species.  Furthermore, this neutral 
species cannot have  significantly altered the surface charge density of the interface84: while 
stable internal salt species have been identified by molecular dynamic simulations 135, it seems 
doubtful that zwitterionic species such as they could exist next to the fluorophore without 
inducing a change in its electronic environment. 
However, this presents a conundrum: for raclopride to hydrolyse a membrane efficiently, it must 
have access to a steady stream of protons.  This evidence suggests that raclopride, unlike 
haloperidol, is only transiently charged within the membrane – that it is only capable of 
retaining protons for fleeting moments, and that the rate of hydrolysis is then dependent upon 
the probability of reaction between this briefly available proton and a neighbouring lipid 
molecule.  The small but measurable decrease in fluorescence over the course of the scans may 
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then be a product of photobleaching coupled with a contribution from anions created by a small 
number of liberated fatty acids. 
The strong response of FPE to haloperidol means, by contrast, that the vast majority of the drug 
is protonated at the interface and that this may explain its apparent lack of reactivity.  By 
strongly retaining its extra proton, it effectively neutralises its own activity.  The effective pKa 
must be dependent upon the depth of residency of the CAD in the bilayer: theoretical 
calculations suggest a drop of up to 4.5 log units of basicity as a compound is dragged through a 
membrane27.  This might also suggest a mechanism of sorts for some of the behaviour observed 
during the method development phase: a large volume of excess water will inevitably lead to 
smaller, vesicular aggregates comprising few lamellae, meaning higher curvature and deeper 
penetration of water into the membrane.  Larger, flatter aggregates will instead have curvature 
and thus head-group exposure determined by thermal fluctuations of an otherwise largely flat 
system.  This will lead to lower water penetration and therefore a more hydrophobic interface, 
lowering the probability of a CAD retaining its proton when resident.  
 
5.6.1.2 PENN-1 FRET probe 
PENN-1 is a lipid-based probe developed by Wichmann et al. in 2006 to report upon rates of 
lipid hydrolysis by enzymes such as PLA2164.  It consists of a phosphatidylethanolamine head-
group that is modified to present an unhydrolysable ether linkage in place of the ester moiety at 
the sn-1 position so as to prevent its recognition as a substrate by Phospholipase A 1, while each 
of the fatty acid chains carries a fluorescent probe to act as a FRET pair.  The probes chosen 
were 7-nitrobenzo-2-oxa-1,3-diazole amine (NBD) in the sn-1 position, at the end of a C12 alkyl 
linker, and the 2-hydroxy derivative of 9-diethylamino-5H-benzo[a]phenoxazin-5-one (Nile red) 
in the sn-2 position.  The dyes have extremely high spectral overlap and both probes are net 
neutral at physiological pH and so extremely lipophilic: although some disruption to the packing 
of the host membrane’s hydrophobic region was inevitable, it was at least minimised by the 
insertion of the largely planar, aromatic fluorophores. 
The dye presented an optical and directly quantifiable probe into the kinetics of the hydrolysis 
of the phospholipid ester bonds: by comparing the emission of the green, quenched NBD signal 
relative to the red emission of the FRET pair, the degree of hydrolysis of the probe could be 
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accurately measured in real-time and non-destructively.  The probe was generously donated by 
Carsten Schultz of the European Molecular Biology Laboratory in Heidelberg, and was stored in 
CHCl3 at -20°C until use.  Initially added in a method similar to that outlined above for FPE at 
0.1mol% relative to 1mM DOPC vesicles in pure water, it was observed that the much weaker 
FRET signal was very difficult to distinguish from noise except at very high photomultiplier tube 
(PMT) voltages; no improvement in signal-to-noise was observed through further dilution.  
However, by moving to a 1mol% ratio of PENN-1 to DOPC, λEXmax were found at 520nm (Nile red) 
and, more weakly, at 440nm (NBD) ± 5nm, due to high noise.  λEMMmax was easier to locate at 
approximately 610nm, with no fluorescence signal observed below 550nm implying a near-total 
transfer of energy between the green NBD dye and the larger Nile red, shown below in Figure 
44.  Control experiments run in chloroform confirmed that the NBD dye was present and visible 
as when analysed as a monomer, λEXmax ≈ 440nm, λEMMmax ≈ 520nm, although even under these 
conditions the intensity of the Nile red fluorophores’ absorption and emission seemed much 
greater than that of NBD. 
 
 
Figure 44: The FRET fluorescence spectra of PENN-1
164
, present at 1% in 1mM 100nm DOPC vesicles in water. 
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In previous studies conducted at Heidelberg using this and related dyes, the probe had either 
been dosed in relatively high concentrations into monolayers of cells or alternatively had been 
the only phospholipid present in a dilute solution of Triton-X, meaning that the signal relative to 
light scattering by the vesicles was relatively high164,165.  Furthermore, an unknown mechanism 
had led to the probe accumulating exclusively into intracellular membranes: no fluorescence 
was observed in these studies in the plasma membrane.  It was felt that neither of these 
protocols was ideal: PLA2 is sufficiently ubiquitous and cell membranes are so complex that 
drawing any meaningful conclusions from cellular studies would have posed significant 
difficulties, whereas the alternative assay described led to an artificially high enzyme-substrate 
ratio in a highly strained system, which meant that measurements taken on such a system could 
not be easily compared to those in a more biologically relevant environment.  
Previous studies using PENN-1 had been undertaken at Imperial College, based around 
fluorescence-monitoring of HPLC fractions using a Waters 474 in-line fluorescence detector 
coupled to the apparatus and set-up described in section 5.1.2 (L. Setchell, unpublished 
research).  However, due to either the kinetics of the condensed-phase system or the very 
differing affinities of the probe and its degradation products for the columns in use relative to 
the native lipids, these had failed to reveal any conclusive data.  As a result, vials were prepared 
in a manner similar to that described above: DOPC and 1 mol% PENN-1 were co-lyophilised from 
chloroform, then hydrated in water to give a 1mM suspension and extruded as described above.  
Raclopride tartrate, haloperidol free-base and ibuprofen free-base were dissolved in DMSO to 
form 10mM solutions.  1ml of lipid vesicle suspension was dispensed into a micro-cuvette along 
with 5μl drug solution or DMSO control, and the cuvette sealed with Parafilm.  The cuvettes 
were analysed at 37°C, initially sampling very rapidly in order to capture any unusual effects of 
the drugs partitioning into the membrane. 
This technique revealed no response in the 520/610nm emission ratio mediated by any of these 
compounds over the first 120 minutes of scanning: although absolute intensity at 610nm was 
lower in the DMSO control than in the other samples, this was not met by a concomitant 
increase in 544nm emission and so was almost certainly due to simple experimental error.  In 
order to assess whether the reaction was occurring very slowly or was experiencing a latency 
phase such as that shown in PLA2 experiments
59, measurements were continued for some six 
hours.  In this phase, measurements were taken once every ten minutes in order to minimise 
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photobleaching effects.  Again, however, no change in the 520/610nm ratio was observed for 
any of the compounds tested in this or repeat experiments, and the combination of low signal-
to-noise coupled with the extreme scarcity of the probe meant that this avenue of 
experimentation was abandoned. 
With hindsight, the probe was significantly better adapted to measuring the activity of PLA2 than 
it was our system: PLA2 is a cytosolic, globular protein and so does not depend significantly upon 
the hydrophobic region of the lipids for substrate recognition166.  By contrast, both the empirical 
data outlined above and  the computational results shown by Rosso et al.150 suggest a strong 
dependence of the rate and degree of hydrolysis upon interactions between the drug molecule 
and the fatty acid tail of the lipid substrate.  The use of PENN-1 as a probe therefore relied upon 
finding interactions between the CADs and one or other of the  large fluorophores which 
mimicked those of the drugs’ interactions with oleoyl chains, and these were not detected.  
 
5.6.1.3 ADIFAB 
Acrylodan-labelled intestinal fatty acid binding protein (ADIFAB) is, as its name suggests, a 
protein isolated from rat intestine covalently modified so that an acrylodan moiety is bound to 
its Lys27 residue167.  This amino acid changes conformation and environment when the protein 
binds to a fatty acid, in turn altering the those of the fluorophore and shifting its λEMMmax from 
435nm (unbound) to 487nm (bound) when exciting at the probe’s λEXmax of 386nm (all values ± 
2nm).  Monitoring at these wavelengths leads to some overlap of emission, and so for effective 
analysis of the state of the probe, the ratio between fluorescence at 432 and 505nm was 
measured.  The dissociation constant of the probe for oleic acid, as in this study, has been 
measured at  0.28μM (pKd = 6.55), meaning that the relationship between the fluorescence 
ratios and the free fatty acid in the system can be found via Equation 8, where Q = 
Ifree(432nm)/Ibound(432nm), Ro = the ratio of intensities at 505nm/432nm in the absence of fatty 
acid and Rmax = the ratios when the probe is saturated
167. 
[FFA] ≈ Kd x Q  
Equation 8 
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The probe offered the potential of an extremely sensitive tool to analyse the rates of hydrolysis 
in a rapid and non-destructive manner that did not intrinsically affect the membrane, as the 
protein is globular in nature and so is not, in theory, membrane bound.  It has also  been 
thoroughly characterised, permitting a directly quantitative analysis of the free fatty acid 
concentration in solution. 
However, this in turn poses issues: because the probe is only sensitive to free fatty acids, those 
retained within the membrane are effectively invisible to the protein and the acids’ high 
partition functions (oleic acid has a log P >5) meant that a significant degree of hydrolysis was 
required before meaningful signals could be determined.  Furthermore, this partition function 
was expected to vary dynamically during any given experiment as a function of composition, 
surface charges and curvature, making precise quantification difficult.  Finally, in order to 
minimise any effects due to variations in vesicle size and morphology, it was desirable to use a 
uniform population of extruded, unilamellar vesicles for testing.  This meant that ADIFAB had to 
be added exogenously after extrusion and yet research has demonstrated that fatty acids 
equilibrate across a membrane very rapidly61.  It was therefore possible that observed fatty acid 
concentrations could be significantly below those actually generated as a result of their 
sequestration both in the membrane and in the vesicles’ internal volume, from which the 
protein was effectively excluded. 
Preliminary experiments were undertaken to evaluate the potential of the probe.  DOPC vesicles 
were prepared at 100μM concentration in the supplied ADIFAB buffer, containing 20mM HEPES, 
140mM NaCl, 5mM KCl and 1mM Na2HPO4 according to the protocols described above.  100μM 
ADIFAB (FFA Sciences LLC, USA) was added in its 50mM Tris HCl storage buffer to give a total 
protein concentration of 0.2μM and dispensed into disposable polystyrene microcuvettes.  The 
temperature inside the fluorimeter was controlled as previously and set to 37°C throughout  and 
blank scans were run to correct for the scattering of blank cuvettes containing only HEPES 
buffer.  Standards were run containing HEPES and ADIFAB solutions without lipid to investigate 
the effects of DMSO and photobleaching upon the probe, as well as with 10μM oleic acid in 1μl 
DMSO to provide a positive control sample.  Data was recorded from each sample every 20 
seconds for 1 hour, during which time photobleaching was negligible  after an initial 
equilibration period.  These results showed an R0 value of 0.365 ± 0.016, identical to that of 
RDMSO, while Rmax was recorded as 3.67 ± 0.63, although this is reduced to 3.40 ± 0.22 if the 
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equilibration period is omitted (see Figure 45). 
 
Figure 45: ADIFAB control and photobleaching data, recorded every 20 seconds over 60 minutes.  The values are 
corrected for scattered light from blank scans of buffer alone: small errors in these values propagate to give the large 
distortions visible in the fatty acid-containing scan above.  Red box highlights apparent equilibration period. 
Calibration scans were run in both the presence and absence of 100μM 100nm DOPC vesicles  
(see below), to give a feel for both the sensitivity of the probe and also the extent of hydrolysis 
that would be required before a signal could be detected.  The apparent twenty-minute 
equilibration period at high signal gave some cause for concern, as it suggested that the probe 
may not be ideal for the measurement of dynamic systems such as the one in question: 
however, Figure 46b suggested it was only an issue at very high signal, and it was hoped that the 
gradual nature of the fatty acid build-up would minimise any impact. 
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Figure 46: Oleic acid calibration scans in (a) the absence and (b) the presence of 100μM 100nm DOPC vesicles. 
These calibrations were run using identical stock solutions of buffer, protein and fatty acid and 
all fatty acid solutions were made by serial dilution of the 10μM stock  so that only 1μl of DMSO 
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was ever injected.  The difference in R[DMSO] values shown above (R[DMSO] = 0.33 ± 0.010 in Figure 
46a; 0.44 ± 0.011 in Figure 46b) imply that the system is extremely sensitive to the final protein 
concentration, and therefore required the addition of a significant concentration of fatty acid in 
order to provide a saturated signal for normalisation at the end of each run.  Using the 
published Kd value
167 and assuming approximately 0.2μM ADIFAB, approximately a 0.5μM 
concentration of free acid was required to ensure saturation which could have posed difficulties 
considering the compound’s low aqueous solubility and high partition function.  As a result, th e 
empirical approximation for Rmax and Q in oleic acid binding published by Richieri et al.
168 was 
used in preliminary experiments, as it relied solely upon easily measured R and R 0 values 
(Equation 9). 
[FFA] = Kd x 19.5 x  
Equation 9 
 
Despite these limitations, it is clear from the data in Figure 46 that ADIFAB had the potential to 
detect hydrolysis levels of below 1% in vesicle suspensions and so was potentially a powerful 
and high-throughput probe into the activity of hydrolytic compounds in the membrane.  
An experiment similar to that in Figure 46b was prepared, dosing the 100μM 100nm DOPC 
vesicles with 0.1-10μM raclopride tartrate dissolved in DMSO, again by serial dilution so that in 
each case 1μl DMSO was added to 1ml DOPC suspension.  These were analysed on the 
fluorimeter overnight: rapidly for the first 15 minutes to capture any kinetic effects of binding, 
then once every ten minutes for the next 12 hours.  The results were unexpected, as can be 
seen below in Figure 47.  Illustrated in this example is the system that was doped with 0.1μM 
raclopride, corresponding to 0.1mol%.  However, similar behaviour was observed in all four 
cuvettes including, unexpectedly, the DMSO control. 
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Figure 47: The absolute fluorescence intensity and corrected 505/432nm peak ratios for 100μM 100nm DOPC vesicles 
doped with 0.1μM raclopride tartrate in 1μl DMSO.  Axes are offset for clarity. 
These findings were extremely interesting: bulk-phase assays had found what appeared to be a 
lag phase suggesting some kind of internal reorganisation of the drug-lipid aggregate before 
hydrolysis took place, and upon first glance this appeared to be the fluorescence manifestation 
of that phenomenon.  However, this could not possibly be the case in the DMSO control vial.  A 
number of repeat experiments were performed to confirm that this was a real result and not 
that, for example, the DMSO blank had become contaminated.  Similarly, control runs were 
performed to check for any fluorescent interactions between the probe and the drug, or 
anything unusual happening to the cuvette over time.  Repeats were also performed in PBS, 
which importantly gave a similar ionic strength to the HEPES solution supplied with the 
protein168 in case the HEPES was interfering through some mechanism.  Each found the same 
behaviour: after some six hours, the fluorescence intensity began to rise dramatically at both 
432 and 505nm, and yet the ratio between the two peaks was always identical within error. 
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Figure 48: The gradual evaporation of the ADIFAB-labelled vesicle suspension produced a highly curved interface, which 
led to a significant increase of the quantum yield of the probe suggesting a degree of surface activity. 
Eventually, the effect was isolated to the slow evaporation of the buffer from the heated 
cuvettes.  The shape of the microcuvettes meant that after a period, a highly curved interface 
developed.  As evaporation continued, this curvature decreased until eventually a flat interface 
was restored (shown schematically above in Figure 48) and that despite the protein’s apparently 
cytosolic nature169, this was reflected in the fluorescence of the probe.  Repeat reactions with 
fully sealed cuvettes showed negligible evaporation over the course of 12 hours and similarly 
flat fluorescence emission spectra.  Although there was a very small rise in R during these 
experiments, it was also observed in control samples and so was probably due to protein 
unfolding over the time-course of the experiment.  The experiments were repeated under a 
variety of conditions and with other CAD compounds, but no change in R was observed and the 
reactions were abandoned. 
 
5.6.2 Dynamic light scattering  
5.6.2.1 Lab-based laser scattering 
It was hoped that at least a qualitative analysis of the morphological effects of the drugs upon 
the vesicle systems could be assessed by dynamic light scattering, using the Malvern 
Instruments High Performance Light Scattering unit described in section 5.6.  Dynamic light 
scattering works by comparing the Rayleigh scattering of coherent light by small particles in a 
suspension, up to about half the wavelength of the incident light, at different periods over time.  
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The change in scattering over time is dependent upon the Brownian motion of the particles 
suspended in the sample.  This is a function of the concentration and hydrodynamic radius of 
the suspension and the time interval between sampling, as well as the viscosity of the 
suspending medium.  Large particles, or those suspended in a viscous environment are only able 
to travel short distances in between samples, leading to small steps between scattered 
intensities and rounded, smooth graphs; smaller aggregates can travel much further in the same 
time period, presenting jagged, saw-tooth data-plots as shown schematically in Figure 49b and 
c, below. 
The difference in signal collected over time by a detector situated at an angle to the incident 
beam (see Figure 49a).  Data is collected and deconvoluted from the resulting patterns of 
constructive and destructive interference, although quite sophisticated techniques are required 
to achieve high resolution data except from very dilute samples due to multiple scattering 
effects, as scattered light is deflected in new directions on its path through a densely-packed 
suspension.  For a full review on the technique and the associated data handling protocols, 
please see Berne and Pecora (2000)170: experimentally, almost the entire process was 
automated by the supplied Malvern HPPS software and little user input was required. 
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Figure 49: a) Dynamic light scattering records the fluctuations in scattered light from an incident laser beam.  The speed 
and scale of the fluctuations are dependent upon the size of the particles, their concentration (through constructive and 
destructive interference) and the viscosity of the suspending medium.   Large particles, or those in viscous suspensions, 
move very slowly making the fluctuations in their scatter large and ponderous (b) relative to the rapid, saw-tooth scatter 
exhibited by suspensions of smaller aggregates or colloids (c), shown here in schematic form. 
While this technique could not provide a quantitative view of the state of hydrolysis within the 
membrane, it could provide data about the average structure of the vesicles within the sample 
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cuvette.  Although such averaged data is inevitably of relatively low resolution, when coupled to 
the complementary data that was to be derived from the on-line vesicle-based HPLC methods 
under development, it was hoped that a much fuller picture would emerge. 
The technique could also potentially explain the longer-term future of the daughter lipid 
structures created by the hydrolysis of the parent, diacyl species.  If the vesicles behaved in a 
manner similar to the condensed-phase samples observed in earlier experiments53, it was 
predicted that the sample would degrade from a largely monodisperse suspension of unilamellar 
vesicles into a large number of small micelles enriched in lyso-lipid and a much larger, effectively 
insoluble aggregate enriched in fatty acids in the inverse hexagonal phase.  These structures 
would eventually degrade further, to form highly water-soluble glycerolphosphatidylcholine 
species and fatty acids that would be almost completely immiscible with water.  However, the 
actual rate of this process remained largely unknown, and it was uncertain whether or not the 
DLS machine available would have the necessary resolution to observe the process, or whether 
the original, sharp and monodisperse signal would simply spread out into a broad, low -intensity 
and data-poor blur (see Figure 50). 
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Figure 50: The two likely outcomes of the observation of the effects of hydrolysis via DLS.  A monodisperse suspension 
of small vesicles produces a narrow, sharp function (top); a polydisperse mixture produces a broad, flat response of 
limited quantitative value. 
In order to investigate these possibilities, preliminary studies were undertaken using the 
available in-house DLS.  10mM DOPC vesicles were made in pure water by extrusion using 
100nm filters, to give vesicles of average diameter 112.0nm, FWHM 36.7nm, PDI 0.012.  These 
were dispensed into four microcuvettes and two doped with 5mol% raclopride tartrate (added 
in 10μl water), one haloperidol free-base (in DMSO) and one with 10μl DMSO as a control.  In 
each case the mixtures were agitated by aspiration and dispensing a portion of the suspension 
using an Eppendorf pipette, then were sealed and inserted into the DLS, the sample chamber of 
which had been pre-heated to 37°C.  Sizing information was recorded in three scans of thirty 
seconds each, recorded on ten occasions over two hours. 
None of the samples showed any significant deviations from initial parameters described above 
in terms of sizing or scattering intensity over this period.  To check for any sign of activity, each 
cuvette was incubated overnight at 37°C and rescanned three times for thirty seconds each: 
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again, none showed any changes beyond experimental noise.  It appeared that the haloperidol 
precipitated from the suspension during its overnight incubation, which may not be surprising 
considering the low aqueous solubility of the free base.  However, no such precipitate was 
observed in the cuvettes containing raclopride. 
Although these results constituted a setback, it was quite possible that the reaction was 
occurring at a reasonable rate in these systems but that the results were not observable wit h 
the available apparatus: Rayleigh scatter scales with [particle diameter] 6, meaning that small, 5-
10nm micellar aggregates such as those expected scatter negligibly relative to the 200nm parent 
vesicles.  As a result, a much more flexible experiment was proposed, using custom-built 
equipment and analysed using in-house, bespoke software based around LabView code 
(National Instruments, USA) written by N. Brooks. 
 
5.6.2.2 Synchrotron light scattering studies at the Diamond Light Source (UK) 
Synchrotron radiation offers complementary information to that obtainable via DLS: Soft X-rays 
with a wavelength around 1 Ångstrom interact with features of a similar length scale and so are 
ideal for probing the wall structure of lipid bilayer vesicles (which generally have a bilayer 
thickness on the order of 50 Ångstroms). Scattering proceeds in the same manner as in the 
classical condensed-phase SAXS experiments described in section 3.4.1, but in this case the 
scattering is caused by the deflection of the incident beam through interaction with the 
phosphate groups at the interface between the hydrophilic and hydrophobic regions of the 
membrane. 
The scattering angles used in this type of experiment are small, typically from 0.01-1°, and the 
scattered intensity is very weak relative to the incident beam.  The scattered rays can shed light 
on the bilayer thickness, the average vesicle radius, the degree of polydispersity (defined by 
 ) and, for multilamellar systems, the repeat spacing (d-spacing) between each 
layer171.  A schematic of this is shown in Figure 51. 
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Figure 51: A schematic showing the scattered X-ray intensity as a function of q, and how this relates to the location of 
the head-groups within the bilayer.  Adapted from Brzustowicz and Brunger, 2005
171
.  
Experiments were performed on the I-22 beam-line at the Diamond Light Source at the Harwell 
Science and Innovation Campus near Didcot, Oxfordshire.  I-22 is a high intensity, small angle 
scattering beam-line with a tuneable X-ray energy from 3.7 keV (3.35Å) to 20 keV (0.6Å), and 
adjustable detector flight tube length from 1 – 9 metres.  X-rays are detected by a 2-dimensional 
RAPID high sensitivity multi wire gas detector. Vesicle suspensions were made up as previously 
described in section 5.6 using 200nm-pore membranes, to make a 10mM concentration.  
Experiments were initially attempted with 1mM suspensions as in previous experiments, but it 
was found that the signal was so weak at this concentration that extremely long exposures (>5 
minutes) were required to recover any useable images, preventing the capture of any kinetic 
data.  Suspensions were made up in saline solution and in PBS, as described previously; 
solutions of raclopride tartrate, spiperone HCl and WAY 100635 maleate were prepared to 
10mM concentrations in DMSO (see Figure 13, page 56 for structures). 
Experiments were performed in a stopped-flow fashion.  Three syringe pumps were prepared: 
Pump A contained a 50ml syringe of the relevant buffer solution, Pump B contained a 20ml 
syringe of vesicle suspension and Pump C contained 1ml of drug solut ion in DMSO, as shown 
below in Figure 52.  Each was connected to a three-way mixing tee (IDEX Health & Science, 
formerly Upchurch Scientific) which led to a 2 mm diameter polycarbonate X-ray capillary (Enki 
Microtubes, Italy) in the path of the X-ray beam.  The capillary tube was held in a temperature-
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controlled block which was attached to a circulating water bath, which allowed the temperature 
to be controlled and measured to within 0.1°C.  Pump control was achieved remotely using an 
in-house developed scripting program written using National Instruments ’ LabView by Dr Nick 
Brooks.  This software permitted sequential runs of experiments to be performed automatically, 
meaning that user input was required only to refill reagent reservoirs.  The capillary was initially 
flooded with 5 volumes of buffer, before being loaded with vesicle suspension and either 0.01, 
0.1, 1 or 10mol% drug.  Data collection began immediately, and 60 exposures of 25 seconds 
each were recorded, with a 5 second delay between each.  Control experiments were performed 
using pure DMSO instead of drug under identical conditions; positive controls were performed 
with bee-venom PLA2, using 5mM DOPC vesicles prepared in PLA2 buffer consisting of 50mM Tris 
HCl, 100mM NaCl and 1mM CaCl2.  The scattering images collected generally showed diffuse X-
ray scatter with one very broad peak. 
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Figure 52: The experimental set-up used during the vesicle scattering studies attempted at the Diamond synchrotron 
light source in Didcot, Oxfordshire, UK.  Syringe A contained 50ml aqueous buffer, B contained 20ml vesicle suspension 
in the same buffer and C contained 1ml drug solution in DMSO. 
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Figure 53: An image captured during a typical synchrotron radiation scattering experiment showing the raw data yielded 
by the apparatus described above (exposure time = 25 s).  60 of these were taken per experiment and combined to show 
the time-resolved behaviour of the vesicle populations. 
 
5.6.2.2.1 Synchrotron scattering theory and modelling 
Data analysis was performed in several iterative steps.  Initially, the raw data (see Figure 53) was 
processed to remove as much background scattering as possible using appropriate background 
images.  Each image was then radially integrated to provide a 1-D diffraction plot of intensity vs. 
q, where /λ (2θ is the scattering angle and λ is the wavelength of the incident 
beam)172.  The q scale was calibrated against a standard sample of wet rat-tail collagen with a 
well-defined layer spacing of 676Å173.  These 1-D plots were collated and plotted against time to 
form a ‘stackplot’ showing changes in the vesicles’ scattering over time.  This stackplot was 
fitted in the region 0.05<q<0.2 pixels to yield data on the average position of the positions of 
the lipid phosphate groups relative to the bilayer centre and the d-spacing of any multilamellar 
vesicles formed based upon the model of Brzustowicz and Brunger171  (described below, typical 
results shown in Figure 54). 
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Figure 54: (a) A typical 1-D I vs. q plot, after noise subtraction; (b) the same data, with beam flare excluded and showing 
the fit of the model described below (yellow line). 
The model outlined by Brzustowicz and Brunger171 assumes that no correlation between vesicles 
is observed in the sample, meaning that the 1-D X-ray intensity I(q) depends only upon the 
bilayer form factor, F(q), the Fourier transform of the electron density of the bilayer ρ(r) which is 
shown schematically above in Figure 51.  In this model, the bilayer is divided into three regions 
(k), where at the lipid head-groups k = 1 and 3 and at the centre of the hydrophobic core, k = 2.  
The electron density profile may then be modelled as a series of n Gaussian shells, each with 
amplitude ρk, centre position relative to the centre of the vesicle δk and uncertainty (essentially, 
the roughness of the function) ςk, leading to Equation 10, below. 
 
Equation 10 
If it is assumed that each vesicle in the population is spherical and thus radially symmetrical, the 
form factor F(q) can be found via a Fourier transform of Equation 10. 
 
Equation 11 
In order to find an expression for the measurable quantity F(q)2, the polydispersity was taken 
into account, again using the Brzustowicz model using a Gaussian fit to describe a population of 
A B 
Page | 133  
 
vesicles with average radius R0.  If  
 
Equation 12 
where εk = displacement from the vesicle radius, then Equation 13 results. 
 
Equation 13 
However, the model outlined in Equation 13 applies only to systems containing only unilamellar 
vesicles; experience suggested that a significant number of multi-lamellar vesicles would also 
exist in the suspension, especially after the administration of the DMSO solution.  This could 
potentially lead to significant diffraction, as the intensity of scatter from multi-lamellar bilayers 
is significantly greater than that from single-walled vesicles.  As a result, a further Gaussian term 
was added to allow for these data, shown below in Equation 14. 
 
Equation 14  
 
5.6.2.2.2 Synchrotron scattering results 
Although several thousand images were recorded under a range of conditions, it was difficult to 
extract meaningful conclusions.  In part, this was due to the diffuse nature of the target 
material: even at 10mM concentrations, the signal-to-noise ratio of the collected data was poor, 
complicating analysis.  As a result, the most reliable information came from the d-spacing data 
generated by the multi-lamellar vesicles that were inevitably present in the suspensions – an 
unfortunate finding, considering the purpose of the exercise and the kinetic considerations 
outlined in section 5.6.  Other errors were introduced by the inter-dependence between the 
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parameters making up the model: in theory, it was possible to find values corresponding to the 
vesicle average size in a manner analogous to the DLS values above, but in practise the function 
often generated nonsense values and so the numbers generated were disregarded.  However, all 
experiments returned an initial d-spacing of around 56Å suggesting good reproducibility and 
showed rapid increases in this distance with 10% DMSO solutions, as might be expected.  A 
smaller initial increase in d-spacing of 1-2Å, (exemplar data shown below in Figure 55) was 
observed in all systems, presumably due to the relaxation of the vesicles as the flow speed 
through the fluidic system dropped, leading to a concomitant drop in shear forces.   This may not 
reflect an actual change in d-spacing, but instead be a result of the change in morphology as the 
vesicles returned to a spherical shape, due to the inter-dependences described above. 
 
Figure 55: Exemplar data gathered during X-ray scattering experiments on 200nm DOPC vesicles containing varying 
proportions of, in this case, spiperone HCl added in DMSO.  Note the initial rise in d-spacing as the vesicles ‘relaxed’ as 
the flow was stopped. 
The PLA2 data which provided the positive control data for the experiment revealed the 
expected dose-dependent increase in bilayer thickness and d-spacing over the time-course of 
the experiments, (as shown below in Figure 56), triggered by the accumulation of negative 
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charge in the membrane due to fatty acid.  During this period, the water channel thickness 
(found as the difference in location between the two maxima, representing the phosphate 
moieties at the lipid-water interfaces) remained effectively constant in all fits, at a steady 4Å, 
comparing well with literature values of around 3-5Å127.  This implies that the expansion was 
due to hydrolysis occurring, as no DMSO or other co-surfactants were present and the protein is 
only transiently bound to the membrane, minimising its contribution. 
 
Figure 56: d-spacing data recorded for 5mM DOPC vesicle systems containing differing concentrations of PLA2 enzyme.  
One unit of enzyme will hydrolyse 1.0 μmole of L-α-phosphatidylcholine to L-α-lysophosphatidylcholine and a fatty acid 
per min at pH 8.9 at 25 °C, although observed rates were significantly below these values in both these experiments and 
others conducted by other researchers. 
Unfortunately, no other results showed a change in vesicle morphology over the course of the 
experiments.  Data similar to the above were recorded for WAY 100635 maleate, spiperone HCl 
and raclopride tartrate (all in DMSO), but none revealed anything significant beyond the DMSO 
spectra recorded that could not be attributed to experimental artefacts.  Membrane swelling 
was observed in most samples after doping, with two to three times the change in d-spacing 
observed in saline systems than in PBS-buffered samples observed even in DMSO control 
experiments (for exemplar data, see Figure 57, below). 
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Figure 57: The increase in d-spacing exhibited by 200nm DOPC vesicles upon addition of 10% DMSO to the buffer.  
Although both systems experience some swelling after injection, the vesicles in the unbuffered solution exhibited 
greater than twice that shown by the buffered system. 
This is of passing interest, as the Debye lengths in both cases were effectively identical and all 
drugs were added as neutral salts in DMSO.  This suggests that the phosphate ions had a role to 
play in controlling dopant distribution within the system, although the mechanism for this is 
unknown.  Again though, due to the interdependence between the variables of the model as 
outlined above, it was difficult to attribute this to any one effect.  Microscopy studies 
demonstrated that the administration of DMSO caused significant vesicle rupture in the 
immediate vicinity of the injection (experiments described in section 5.6.4.1), and it may be that 
the observed data simply reflects the formation of many more multi-lamellar bodies in saline 
than in PBS, although this remains speculation. 
Little more of value was identifiable from the experiments: significant data was lost in the 
experiments due to beam flare, which obliterated the linear region of signal which might have 
provided much more precise vesicle size information.  Major issues were also experienced with 
beam damage to the polycarbonate capillaries – this led to distortions in the gathered data, 
producing whiskered tails of beam-flare which led to the loss of many data points.   
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The reasons for the failure of such different drugs with partition values spread across three 
orders of magnitude to show any significant effects upon the membranes remains unknown.  All 
have previously been demonstrated to hydrolyse membranes rapidly; although some non-
specific binding to the fluidic system was inevitable, this was as likely to be an issue for the 
much more plentiful lipids as it was for the drugs and so any such effects should have av eraged 
out. 
 
Figure 58: The increase in d-spacing caused by the addition of 10mol% of several CADs to the vesicle suspensions.  It can 
clearly be observed that most if not all the contribution after the vesicles’ initial relaxation is caused by the carrier 
solvent. 
What was genuinely surprising is that the introduction of charged species had little or no more 
effect than the membrane-softening DMSO (see above): the Debye length within both systems 
was of the order of 7Å174, meaning that electrostatic effects were expected in a way analogous 
to the SAXS images shown in Figure 35 (page 95).  Those experiments also served to define a 
typical d-spacing for a DOPC lamellar stack of around 61.4Å54, similar to those values shown in 
Figure 58.  Those results were observed in a condensed-phase system with a high degree of 
long-range order – it is possible that in a more chaotic system dominated by single unilamellar 
vesicles such effects should average out, but one might still expect the uneven distribution of 
the exogenously-applied drug across the membrane leaflets to have some effect. 
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5.6.3 HPLC assay 
By this point, the direct-injection HPLC assay had become available, making vesicle-based 
chromatographic experiments available for the first time (see section 5.2.2).  This had the 
potential to add significantly to our understanding of the kinetics of the system: data points 
could be gathered with a temporal resolution of 15 minutes without sample preparation, 
allowing reasonably closely-spaced analyses to be conducted even on samples reacting as fast as 
that in Figure 10. 
Initially, an isocratic technique with a high percentage of organic solvents was developed which 
yielded good quality results.  Unfortunately, this led to the co-elution of the inorganic salts and 
buffers in the samples with many of the lyso-lipid signals of interest, meaning that the more 
complex gradient was required.  A number of alternative techniques and tweaks to the method 
were also suggested (personal communication with James Stratta, Varian) including column 
heating or doping the eluent with trifluoroethanol: unfortunately, the combined restrictions of 
an all-PEEK system and financial constraints made such optimisations impractical.   However, the 
gradient method described above gave sufficient resolution for the purposes of this study and 
with a high degree of reproducibility, becoming the workhorse technique for many important 
experiments. 
Vesicle suspensions were prepared for HPLC testing in the same way as described previously: 
lyophilised lipids were hydrated with water or buffer to form an opaque and milky 1mM 
mixture, which was vortexed and extruded ten times through 200nm-pore polycarbonate 
membranes to form a largely homogenous suspension of unilamellar vesicles, average diameter 
≈180nm as described above.  1ml of this suspension was dispensed into a glass HPLC vial and 
doped with a drug or control substance dissolved in water or DMSO, depending upon the 
compound.  The drugs were added in 1μl solvent (0.1% of total medium) to minimise any 
dilution or solvent effects, ( final concentrations were 10-7, 10-6, 10-5 or 10-4M, corresponding to 
0.01, 0.1, 1 or 10 mol% relative to the lipids) and the suspensions agitated to promote 
homogenous mixing.  This was one significant departure from the assay conditions in the 
condensed-phase experiments: in this case, drugs were added exogenously to complete 
lamellae; previously, drugs had been co-lyophilised with the lipids, meaning that their 
incorporation into the bilayers was instantaneous and even across the system.  The autosampler 
module of the HPLC had a temperature controlled sample chamber, meaning that all 
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experiments could otherwise be run under identical conditions to those in condensed phase 
described above.  This chamber and the vesicle suspensions were pre-heated to 37°C before the 
drug solutions were added so that temperature was constant throughout the analyses. 
This sweep of concentrations was designed to bridge the gaps between the relatively high dose 
regimes created in the condensed phase assays and the very low, nanomolar doses experienced 
by such lipid structures under physiological and pharmacological conditions.  Hydrolytic effects 
had been observed very rapidly in previous vesicle studies: it was hoped that these experiments 
would demonstrate the contribution of the reaction to in vivo transport and bioavailability 
under low-dosage conditions as well as providing a calibration set for the Diamond studies†. 
Preliminary experiments were conducted using WAY 100636 maleate (in DMSO solution) in 
DOPC vesicles in an unbuffered saline solution, as adding the compound under these conditions 
had caused some form of response in the raw synchrotron data described above.  However, 
when analysed by HPLC they showed zero hydrolysis over the course of 12 hours at all 
concentrations.  However, this was not unexpected: in contrast to previous work118 at no point 
in this study were any hydrolysis effects observed which could be ascribed to WAY activity.  As a 
result, the experiments were repeated using DOPC vesicles in a pure water medium, using 
raclopride tartrate dissolved in water to create the full range of drug concentrations outlined 
above. 
These four vials were analysed for twelve hours after the point of drug injection, meaning that 
each vial was sampled once per hour.  Again, over this period no lyso-OPC signal was observed 
at any point, suggesting that either no reaction was occurring or that it was far too slow for the 
products to be quantifiable, in contrast to previous studies53.  However, a white precipitate was 
observed in the vial doped with 10 -4M (10 mol%) raclopride.  This had been observed previously 
in some of the light-scattering and fluorescence studies outlined above but dismissed as an 
artefact caused by lipid aggregation on, for example, a small flaw in the surface of micro -
cuvettes.  However, it was observed in this study in what appeared to be a dose-dependent 
manner: over the next 48 hours of incubation, all four vials began to show the formation of a 
precipitate far in excess of the volumes of raclopride tartrate added, although no lyso -OPC 
                                                          
†
 These studies were undertaken during the development and refinement of the software platforms required 
to analyse the data from the Diamond synchrotron experiments: as a result, the failure of those experiments 
to show any activity was not at this point known. 
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peaks were observed at any point. 
This was the cause of some excitement – if some unknown mechanism was causing the 
precipitation of the lyso-lipid or some drug-lipid complex, the lack of measured lyso-PC could be 
neatly explained and the result could potentially provide direct evidence that the drug was 
being expelled from the bilayer as part of the process.  This seemed odd, however: lyso-OPC is a 
reasonably soluble compound in water as is raclopride and although the inverse is true for oleic 
acid, it is a liquid at 37°C, forming an oily layer on the surface of bulk water rather than a 
crystalline aggregate.  Furthermore, there was no obvious driving force for precipitation: lyso -
OPC is soluble up to its CMC of 5μM175 and even if the highly lipophilic fatty acid could be 
persuaded to leave the remaining membrane, any mixture of DOPC, oleic acid and L -OPC not 
heavily enriched in the acid will form an easily-dispersed liquid crystal phase (R. Macey, 
unpublished work). 
This experiment was repeated a number of times, varying the type of drug and the lipid 
concentration, but to no avail.  On no occasion was any lyso-OPC peak observed, but in many 
the white aggregate or precipitate formed.  Positive control experiments were conducted using 
bee venom PLA2 enzyme, similar to those conducted at Diamond (in conjunction with Claire 
Stanley).  Experiments were conducted using 5 and 10 units/ml PLA2 with 100nm DOPC vesicles 
in PLA2 buffer as described previously at 25°C.  These experiments were conducted using dilute 
100μM DOPC suspensions in order to tie in with other experiments in progress and thus 
required high signal amplification for meaningful data to be extracted.  However, they showed a 
rapid increase in the lyso-lipid signal as the DOPC peak decreased in area, reaching an 
equilibrium at approximately 25% DOPC-75% L-OPC within 60 minutes (for exemplar data, see 
Figure 59).   
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Figure 59: A typical data plot showing the rate of hydrolysis caused by the addition of 10u/ml bee-venom PLA2 to a 
suspension of 100µM DOPC vesicles.  Data fits well to a logarithmic plot,( , R
2
 = 0.94), as 
demonstrated by Richieri and Burack
176
. 
This was an important result, in many regards: it proved that the vesic le-based HPLC system 
really could function as an on-line, preparation-free experiment, delivering quantitative, 
relatively highly temporally resolved data in an automated fashion.  However, the ease with 
which the activity of PLA2 could be monitored with the HPLC assay meant that whatever was 
causing the precipitate in drug-doped samples was very unlikely to be hydrolytic in nature, as 
lyso-OPC signals were observed below 1 mol%, corresponding to a 1μM concentration.  A 
number of attempts were made to characterise the precipitate: a 20mM suspension was sent 
for solid-state 31P NMR and samples were analysed via polarising microscopy.  However, all 
results were inconclusive, showing nothing more than multilamellar bodies and attempts to 
consistently reproduce the aggregates under clean, controlled conditions met with failure.  As a 
result, the effect was attributed to simple aggregation of unilamellar vesicles into multilamellar  
stacks which sank due to their relatively high density.   
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5.6.4 Possible reasons for experimental failures 
There are a number of possible reasons for the failures, not least that the reaction may simply 
be extremely slow, meaning that the rates of hydrolysis exhibited in condensed-phase systems 
are in fact representative of those in any system.  However, both previous experimental findings 
and the rapid partitioning behaviour observed with the FPE probe relative to similar condensed -
phase SAXS experiments suggest that this is not the case.  Earlier experiments showed 
significant and rapid membrane degradation by compounds which have shown no activity at all 
under any of the conditions described above, bulk-phase or in vesicles, despite the broadly 
identical experimental conditions.  It seems unlikely that this is due to batch variability between 
lipid or drug stocks, especially as the results above have been collected over a four year period; 
similarly, it is improbable that all the previously reported results (or all those above) are the 
products of experimental artefacts induced by carelessness or contamination, as both sets 
exhibit such consistent behaviour. 
One possible suspect behind the failure of the vesicle studies is that of drug administration, or 
more accurately of the homogeneity of drug concentration across the vesicle population.  In 
condensed-phase samples, the drug is co-lyophilised with the lipid, leading to an even spread of 
the compound throughout each leaflet of the lamellae and in roughly equal concentration 
throughout.  Such an administration technique is not possible in vesicle experiments: the data 
gathered during a previously reported study53 showed that dramatic morphological changes 
could be induced by lipid hydrolysis over a timescale shorter than that required to extrude a 
homogenous population of unilamellar vesicles, and giant vesic les grown in the presence of CAD 
compounds were much smaller than expected and filled with small daughter micelles and mixed 
vesicular bodies (see Figure 10b).  Because of this, drugs were added exogenously to pre-formed 
vesicles, and it was hoped that a combination of electrostatic repulsion and entropy-driven 
migration would rapidly lead to an averaged drug concentration across the entire vesicle 
population. 
If this were not the case, it may explain a proportion of the results outlined above.  CAD 
compounds, by their very nature, are surface active and show a marked preference for 
hydrophobic or interfacial environments.  Should a high local concentration form in a small 
population of the vesicles present, it is quite possible that they would cause either the vesicles’ 
rupture through detergent effects or could alternatively form meta-stable mixed micelles and 
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small vesicles, highly enriched in CAD.  If the former is the case, the ruptured fragments would 
begin to act as sites of nucleation about which other vesicles would coalesce, forming bulky, 
multilamellar aggregates; in the latter case, little hydrolysis would occur due to the low numbers 
of acyl species exposed to the drugs and it is very unlikely that a detectable level of l yso-lipid 
would be formed. 
 
5.6.4.1 Experimental evidence to support hypotheses 
Although hypothetical explanations, both are backed to some degree by experimental findings.  
A number of proof-of-concept microscopy experiments were conducted in collaboration with 
Claire Stanley and Dr Nick Brooks in an attempt to recreate the results of the experiments in 
Figure 10 in the much more complex environment of a living cell or population of cells.   
The bio-mechanical microscope (BMM) system was a custom-built design built by Dr Nick 
Brooks, based around a Nikon TE2000-E inverted microscope utilising Hoffman modulation 
optics177 to enhance the contrast between a P-815 mouse tumour cell immobilised upon a 
micro-pipette and the bulk 50mM HEPES buffer.  CAD solutions were introduced to this buffer at 
physiological concentrations (10-5 – 10-15M) in either DMSO or water depending upon the 
solubility of the drug in question.  The system was maintained at a temperature of 37°C using a 
circulating water bath (Grant LTD6G, -20 to 100 oC), connected to the sample holder using 
flexible plastic tubing and controlled using a PT 100 thermocouple (TC Ltd, Uxbridge UK). 
These experiments were very complex and the data derived was difficult to quantify and so they 
were discontinued, but not before two significant phenomena were observed.  Firstly, in 
successful experiments membrane budding was observed, with membrane fragments of the P-
815 mouse tumour cell becoming sequestered in the micro-pipette used to prevent the cell 
drifting out of the plane of the microscope, as shown below in Figure 60, below. 
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Figure 60: Membrane budding observed in a P-815 mouse tumour cell after administration of 2μl spiperone HCl solution 
into the HEPES buffer solution, creating a global drug concentration of 6 x 10
-13
 M.  (a) shows the cell at t = 0, (b) shows 
the same cell at t = 90 minutes.  Fragments similar to those observed in image (b) above were found throughout the 
microscope slide after the experiment.  However, only those retained in the microscope’s narrow field of focus are 
visible. 
The second observation was that the drugs did not distribute equally throughout the buffer 
medium: cells close to the point of administration suffered a near-instantaneous collapse, 
puckering and shrinking very rapidly, followed by a slow recovery to a about two-thirds of their 
original diameter and the formation of large ‘blebs’ of cellular lipid material, empty of cytoplasm 
as shown below in Figure 61.  Those more than a millimetre or two from the site of drug 
injection showed no reaction at all – it was this effect that led to the abandonment of the 
experiments, as it was impossible to consistently induce the same level of effect in cells in order 
to reproduce the data.  This also meant that there was no effective technique for determining 
the absolute concentration of drug in any cell: although the global average concentration was 
known, the observed effects indicated strongly this was not representative of the cell 
population. 
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B 
Page | 145  
 
 
Figure 61: The ‘blebbing’ of cells following the administration of 10
-7
M haloperidol HCl in 2 µl DMSO to 200 µl cell 
suspension in HEPES buffer.  Cells >≈1mm from the site of injection were unaffected. 
These observations make sense in the light of the previously reported data and those presented 
above.  The initial, rapid binding to a nearby membrane followed by a slow equilibration phase 
may be reflected in the unusual fluorescence behaviour observed when haloperidol bound to 
FPE-doped membranes as described in section 5.6.1.1 and similarly the previous SAXS analyses 
described in section 5.5.2.  Similarly, this offers an explanation as to the effectiveness of the 
initial fluorescence experiment that was reported by the group53 (Figure 10): in this experiment, 
the lipids present were arrayed as a series of anchored vesicles on a flat platinum electrode, 
some centimetres from the site of drug administration.  This means that the drug solution would 
have had the opportunity to diffuse a lot further and distribute itself across a much wider region 
than would be the case in a free-floating suspension of vesicles or cells, where drug-membrane 
contact would be almost instantaneous (see Figure 62, below). 
Page | 146  
 
 
Figure 62: Schematic representations of the drug concentrations (shown as the shaded gradient) in microscopy 
experiments such as those in Figure 10(left) and in vesicle suspensions such as those described in this chapter (right).  In 
microscopy experiments, each vesicle is roughly equidistant from the site of injection and so receives an equal dose; in 
suspension, the high log P of the drug means it is rapidly absorbed within a few mm of administration and so many 
vesicles experience no exposure at all. 
The fact remains, however, that these fluorescence and SAXS effects were not observed in 
raclopride-doped systems, and yet raclopride is the only compound (aside from ibuprofen) to 
have shown consistent, reproducible rates of hydrolytic activity.  Indeed, raclopride caused no 
effects upon the fluorescence of FPE at all within error, once dilution effects had been 
eliminated; although raclopride-induced hydrolysis induced some small changes in d-spacing and 
packing in condensed-phase systems (discussed in more detail in section 5.5.2), these were in no 
way as significant or as rapid as those induced by haloperidol.  As it is vanishingly unlikely that 
raclopride can induce the hydrolysis of a glycerol ester bond in a membrane without in some 
way penetrating the interface of that system, its ability to do so with little or no detectable 
footprint is confusing, especially when combined with partitioning data (see section 7.3, page 
193).  The experimental evidence above demonstrates conclusively that it is doing so as a 
neutral species, either as a genuinely unionised molecule due to the reduced ability of the 
compound to retain its charge in the membrane, or as some form of internal salt or zwitterion.  
Potential explanations for this will be discussed in section 7.3. 
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6 Effects of membrane composition 
The failure of the vesicle assay to produce the high-throughput, real-time results hoped fore led 
to a change of approach as it meant that large-scale investigations of the effects of drug 
structure became impractical.  Instead, the investigation turned to focus upon the influence of 
the membrane composition (and thus stress, curvature etc.) exerted upon the reaction, and to 
unpick the mechanistic detail of the process.  Under the dynamic and rapidly-changing 
environments observed in previous experiments53, this would have been very challenging due to 
the high degree of flux within the membrane composition.  However, the slow-reacting and 
reproducible condensed-phase assay provided the ideal platform from which to probe these 
effects. 
 
Figure 63: The intercalation of drugs into a stressed bilayer can lead to a free energy gain.  In the examples above, a Type 
I monolayer is made to lie flat through the intercalation of a drug molecule (red) between its fatty acid tails; a Type II 
membrane is made to lie flat via intercalation between the head-groups, allowing increased space for chain splay. 
Previous studies had posited that the rate of hydrolysis was proportional to the curvature elastic 
stress within the membrane53: that the drug compounds would have an increased affinity for 
highly stressed membranes, deriving a free-energy gain as they intercalated between the 
component molecules and thus allowing more room for chain-splay or screen head-group 
repulsions (see Figure 63).  Such a concept has precedent: it was shown by Attard et al. in 2000 
that membrane biosynthesis is at least in part regulated through such processes 12, and a range 
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of enzyme activity has since been observed to be dependent on such forces 178,179.  It has also 
been investigated theoretically, with studies demonstrating the interplay between vesicle 
morphology and the local versus global concentration of co-surfactants or other amphiphilic 
inclusions180, with results matching those predicted by experiment181.  However, research has 
always pursued the impact of the binding of exogenously applied amphiphiles o n the shape of 
the host membrane, rather than the other way round as is of interest here and to the best of 
our knowledge, this is the first study undertaken from such a direction. 
The model proposed by Attard and later researchers suggests that the partit ion function of a 
compound into a vesicle or bilayer is strongly dependent upon the local mechanical state of the 
membrane, which may in turn be affected by global factors such as the composition and mixing 
characteristics of its constituents.  As can be seen in Figure 63, these factors influence both the 
extent of the partitioning but also the depth at which the compound resides.  This, then,  implies 
that a modified version of the crude octanol-water log P assay used so extensively by the 
pharmaceutical industry may actually prove one of the more useful predictors into a candidate 
compound’s eventual bioavailability. 
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6.1 DOPC-DOPE mixtures 
In order to probe the effects of membrane composition a range of experiments were initiated  
that were designed to look at not just the ingredients of each system, but to isolate the assorted 
physico-chemical parameters which altered with composition and to identify which, if any, was 
responsible for the observed changes in rate.  The first experiment investigated the influence of 
DOPE within a DOPC membrane, which has been demonstrated to add significantly to the 
curvature stress of a membrane as it attempts to drive the bilayer towards the HII phase
182.  
Under excess water conditions DOPC and DOPE mix almost ideally, showing negligible de -mixing 
at any composition183, preventing any effects due to phase separation.  In this state, the system 
remains lamellar from 100% DOPC until around 75-80% DOPE184,185,  when the concentration of 
the strongly type II PE reaches a temperature-dependent critical point and drives the system 
into the inverse hexagonal phase as described in Figure 6, (page 23).  However, DOPE also 
introduces free amines into the membrane interface: hydrogen-bond donors which could have a 
confounding effect by dominating the binding between the drug and the lipid, which has been 
demonstrated computationally to depend in DOPC upon the π-π interactions between the drug 
and the lipids’ fatty acid tails150.   
Regardless of any intermediates, this phase change would exclude water from all but the narrow 
channels characterising the inverse hexagonal phase, thus slowing the diffusion of drug 
molecules into and lyso-lipids away from the interface.  It was therefore expected that as the 
system changed from the lamellar to the inverse hexagonal state at the phase boundary, a 
major change in the rate of hydrolysis would be observed.  There have been reports of unusual 
rhombohedral and phases observed near the phase transition boundary under certain 
conditions184: however, there remains some controversy regarding their existence in suspension 
as opposed to supported on solid surfaces. 
This Lα-HII phase boundary was to be found somewhere around 80mol% DOPE
185: although 
20mol% DOPC is reported to be sufficient for the system to retain a metastable lamellar 
structure186, it forms  intermediate structures tentatively identified as cubic before progressing 
to HII over a matter of hours.  The effect of raclopride upon these structures was unknown, and 
so SAXS studies were performed in parallel with the HPLC trials. 
In order to probe the contribution of these factors, an experiment broadly similar to those 
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outlined in section 5.1.1 was set up as shown in Table 5, below.  Due to experimental error, 
raclopride tartrate was added at approximately 6.66 mol% relative to lipid rather than the 5 
mol% that was standard: however, the inclusion of two vials containing only DOPC lipids 
provided an internal standard meaning that the data was not wasted. 
Vial DOPC /mol% DOPE /mol% DOPC /mg DOPE /mg Lipid:Rac ratio Mass Rac /mg 
A 100 0 30 0.00 15 1.27 
B 100 0 30 0.00 15 1.27 
C 80 20 24 5.68 15 1.27 
D 80 20 24 5.68 15 1.27 
E 60 40 18 11.36 15 1.27 
F 60 40 18 11.36 15 1.27 
G 40 60 12 17.04 15 1.27 
H 40 60 12 17.04 15 1.27 
I 20 80 6 22.72 15 1.27 
J 20 80 6 22.72 15 1.27 
K 0 100 0 28.39 15 1.27 
L 0 100 0 28.39 15 1.27 
Table 5: The experimental set-up for the experiment to probe the influence of DOPE upon the rates of raclopride 
mediated hydrolysis.  Due to experimental error, raclopride tartrate was added at a 15:1 lipid:drug ratio, equating to 
6.66mol%. 
After drying under vacuum overnight, the lipids were hydrated using 10mM PBS buffer and 
homogenised as normal.  Approximately 10μl of each suspension was dispensed into a 1.5mm 
diameter X-ray capillary tube and sealed as described in section 5.1.3: these capillaries were 
incubated under the same conditions as the bulk sample vials and so hopefully exhibited 
identical behaviour over time.  Samples were analysed repeatedly over a period of some 500 
hours from incubation – the results of the HPLC measurements are displayed below in Figure 64.  
Unsurprisingly, DOPE co-eluted with DOPC and lyso-OPE with lyso-OPC due to the reverse-phase 
chromatography conditions, meaning that hydrophobic effects dominated the separations 
observed (see Table 2, page 70).  This had the virtue of simplifying the analyses as calibration 
plots for the PC and PE lipids were essentially identical, albeit at the loss of direct information 
on any chemoselectivity in the reaction.  Data was collated as previously, and is displayed below 
in Figure 64. 
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Figure 64: The time-resolved degradation of mixtures of DOPC and DOPE by 6.66mol% raclopride tartrate. (a) the total 
rates of lyso-lipid formation as a function of time (n=2); (b) the absolute rates plotted as a function of membrane 
composition.  Error bars are 2 s.d., as data from Figure 33 is not valid in this experiment.  Phase behaviour is shown as a 
function of composition. 
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These data showed an unexpected trend: in contrast to previous experiments53,118, not only did 
DOPE appear to inhibit the reaction but it did so in a manner that varied linearly with 
concentration, whereas the phase of the system had little if any role.  The data gathered from 
the samples of 100% DOPE fitted the trend very closely, and even samples which exhibited 
phase changes over the course of the reaction period continued to show linear rates of 
generation of lyso-lipid.  The samples composed of 80% DOPE 20% DOPC (shown above in Figure 
64b as the transition zone) experienced a catastrophic phase change after approx. 250 hours 
after which they showed negligible diffraction, meaning no long-range order existed within the 
lipid aggregate.  The appearance of these samples also changed, forming a viscous, transparent 
gel.  Despite this, they showed an identical rate of generation of lyso-lipids before and after this 
transformation. 
In many regards, this is a confusing finding: the transition from Lα  HII phase creates large, 
hydrophobic voids in between the packed lipid cylinders, (as discussed in section 3.1.3, page 18), 
which leads to big free energy gains when the system absorbs molecules to fill them.  In the 
experiments detailed previously, (see Figure 34), at least some link was observed between the 
concentration of drug within the system and the observed rate of hydrolysis , whereas the 
evidence above gives it a much more limited role.  What it does clearly demonstrate, though, is 
that bulk phase properties have little influence upon rates in this system: the linearity of the 
plot in Figure 64 as it crossed at least one phase boundary means that the rates must be 
determined by drug-lipid intermolecular parameters, rather than through interplay between the 
drug and the membrane as a whole.  This could, however, be due to the formation of strong 
hydrogen bonds between the raclopride molecules and the primary amine head-group of the 
DOPE – this would sequester the drug molecules some distance from the interface (as shown for 
the case of acetic acid by Hitchcock et al.187), and could prevent their exposure to the changing 
environment in the membrane core. 
Another definite result is that the curvature elastic stress of a membrane is not a reliable 
predictor of the hydrolytic activity of a drug within it.  Due to its inter-molecular hydrogen 
bonds, DOPE has more than three times the negative spontaneous curvature of DOPC (-
0.351nm-1 versus -0.115nm-1)188 and a mixture of the two varies linearly with composition189: 
maintaining a bilayer structure containing any significant concentration of such components 
must come at a major energetic cost.  Although this network of inter-lipid hydrogen bonds may 
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be disrupted by the drugs’ presence, they are present in far too low a concentration to prevent 
significant lipid-lipid bonding occurring.  It would appear then that this stored mechanical 
energy has little or no role in the regulation of hydrolysis rates in this system, or at least that in 
the case of PC-PE mixtures any contribution is dominated instead by direct intermolecular 
forces. 
 
6.1.1 Other lipid head-groups 
The same experiment was conducted using a range of charged phospholipids with the same 
dioleoyl acyl chains.  Samples were prepared using mixtures of DOPC with 1,2-dioleoyl-sn-
glycero-3-phosphate (sodium salt) (DOPA), 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 
(sodium salt) (DOPG) and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt) (DOPS).  All 
of these lipids contain an effectively permanent anion, and so had the potential to significantly 
increase the partitioning of raclopride into the membrane both through simple electrostatic 
attraction but also through the potential formation of hydrogen bends between the drug and 
individual lipid molecules.  Unlike the net neutral PC and PE species, this  bond would be much 
more likely to form between the drug and the phosphate anion, locating the drug much closer to 
the sensitive acyl interface.  Previous experiments with DOPC-DOPG mixtures (D. Casey, 
unpublished research) suggested that although the charged lipid had a roughly identical rate of 
hydrolysis whatever its concentration, increasing its mole fraction led to a concomitant rise in 
the rate of DOPC hydrolysis which might be attributed to this effect.  However, this data was 
extremely noisy and unclear due to the problematic solubility of the DOPG under the HPLC 
conditions at the time, and so the experiment was repeated and broadened using the new 
column media and conditions described in section 5.2.2. 
Unfortunately, the new conditions provided no better resolution of the broad, diffuse charged 
lipid peaks despite chromatographic experiments with a range of reverse-phase solvents such as 
acetonitrile and iso-propyl alcohol.  As previously, the lipids were released by the column before 
the eluent phase was able to dissolve them fully, leading to broad, jagged peaks with very low 
resolution.  The restrictions imposed by an all-PEEK HPLC system meant that stronger solvents 
which may have alleviated this issue were not suitable and chromatographic quantification was 
abandoned. 
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Instead, analysis was attempted using 31P NMR via a 400MHz Bruker system.  Dried samples, 
approx. total mass 1-2mg, were redissolved in 0.75ml CDCl3 and analysed for periods of up to an 
hour each (>1200 scans).  However, resolution was too low for confident analysis even over 
these extended scanning periods, showing little or no detail above background.  As a result, the 
≈200 samples taken over the course of the experiment were stored under high vacuum until 
such a point as a suitably high throughput analytical technique becomes available.  
Despite the failure of the direct quantification, samples were still available for SAXS analysis and 
images were taken throughout the course of the experiment.  As in previous studies, these were 
prepared at the point of lipid hydration and, once sealed in their capillaries, were stored under 
conditions identical to the bulk suspensions.  As in the case of DOPC, all three charged lipid 
species are reported to form Lα phases at full hydration
190, thus any departure from this form 
must have been due to hydrolysis effects. 
 
40 
50 
60 
70 
80 
90 
100 
110 
0 100 200 300 400 500 600 
d
-s
p
ac
in
g 
/Å
 
Elapsed time /hr 
100% DOPC 
20% DOPA 
40% DOPA 
60% DOPA 
80% DOPA 
100% DOPA 
A 
Page | 155  
 
 
 
Figure 65: The SAXS data generated from mixtures of DOPC with charged lipids: (a) DOPA; (b) DOPS; (c) DOPG.  All data 
are plotted on identical axes for clarity.  Suspected phase coexistence was observed in the samples containing 40% DOPS 
60% DOPC, but diffraction was too diffuse for accurate identification.  DOPC data added for reference from calibrated 
phase diagram data (R. Macey, unpublished data), recorded in the absence of raclopride. 
40 
50 
60 
70 
80 
90 
100 
110 
0 100 200 300 400 500 600 
d
-s
p
ac
in
g 
/Å
 
Elapsed time /hr 
100% DOPC 
20% DOPS 
40% DOPS 
60% DOPS 
80% DOPS 
100% DOPS 
40 
50 
60 
70 
80 
90 
100 
110 
0 100 200 300 400 500 600 
d
-s
p
ac
in
g 
/Å
 
Elapsed time /hr 
100% DOPC 
20% DOPG 
40% DOPG 
60% DOPG 
80% DOPG 
100% DOPG 
C 
B 
Page | 156  
 
As a general rule, d-spacing increased in most systems by around 10Å, although this was not 
consistent throughout.  The DOPA data was particularly noisy, showing no discernable trends at 
all, and the data from the 60% DOPS 40% DOPC sample shows a consistent and regular 
downward trend in d-spacing, in contrast with all other plots in the table.  A suspected phase 
coexistence was observed in the samples containing 40% DOPS 60% DOPC, but diffraction was 
too diffuse for an precise identification. 
 
Figure 66: The X-ray scatter from a sample of 40% DOPS 60% DOPC with raclopride as a raw image (left) and as an I vs. q 
plot (right).  White arrows show features indicating possible phase coexistence. 
There is also generally a greater degree of swelling observed in the data above than in that from 
DOPC alone: however, this is not unexpected.  Even in PBS solution, the Debye length is ≈7Å174; 
vesicle scattering experiments (see section 5.6.2.2) showed an average bilayer thickness of 
≈53Å; for a charged system such as those above, a reasonable estimate of minimum water 
channel thickness would be around two Debye lengths, giving a total d-spacing of 68-70Å, in 
good agreement with the data recorded above.  Any effects of raclopride upon the membrane 
macro-structure are likely to be lost within this effect, as even at the lowest concentration of 
charged lipids studied there are four times the number of anionic species to drug molecules.  
As can be seen above, the X-ray scattering data in isolation is of limited value without coupling 
to precise composition data at each point.  While solid-state NMR offers a potential alternative 
probe into the phase behaviour of each system, solution-state experiments failed to provide the 
required rate data from the samples available and HPLC experiments were unable to shed light 
upon the issue.  Higher flux sources such as the Diamond synchrotron described in section 
5.6.2.2 may have improved our understanding of the systems, particularly the poorly-resolved 
or ambiguous images such as those outlined above. 
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6.2 Saturated lipids in the membrane 
In order to investigate further the parameters governing the rates of hydrolysis, a range of 
experiments were conducted in a similar vein to those outlined in Table 5, mixing DOPC with a 
series of saturated phosphocholine lipids.  1,2-Dilauroyl-sn-glycero-3-phosphocholine (DLPC), 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-palmitoyl-sn-glycerol-3-
phosphocholine (DPPC) were all mixed with DOPC and prepared as previously with 5mol% 
raclopride tartrate.  These molecules feature a head-group identical to that of DOPC, but with 
fully-saturated fatty acid tails of 12, 14 and 16 carbons each, respectively.  
This promised to isolate a number of variables in the space of one experiment.  The cis-
unsaturated bonds in the tails of DOPC reduce their effective length, making them almost 
exactly the all-trans length of those in DPPC.  By mixing DOPC with DLPC and DMPC, a degree of 
hydrophobic mismatch would be introduced with the potential to influence hydrolytic rates.  
However, the long, fully saturated chains are able to pack around one another very closely, 
giving the lipids relatively high chain-melting transition temperatures.  DLPC becomes fully liquid 
at around 8°C, and DMPC at 22-24°C, whereas pure DPPC melts slightly above 40°C191 and while 
their elastic bending constants are difficult to relate directly due to these differing melting 
temperatures, the elastic bending constants for the lipids increases with increasing chain 
length188.  In common with the other assays performed, these experiments were incubated at 
37°C, meaning that the DPPC was constantly below its transition temperature.   In order to 
investigate the phase behaviour of these DOPC-DPPC-raclopride mixtures, each was analysed by 
DSC using a PerkinElmer Instruments Diamond DSC, but no significant peaks were observed for 
any transitions above 0°C except in the case of pure DPPC where the chain melting transition 
was found at 42°C.   
These relatively high transition temperatures had a number of implications.  It has been 
demonstrated through ITC experiments that amphiphilic species such as lyso-lipids compounds 
experience a log P lower by an order of magnitude or more when host membranes are in the gel 
phase compared to the fluid lamellar, although this effect is not observed when the added 
species is extremely hydrophobic as in the case of, for example, fatty acids 192.  There is also, 
unexpectedly, evidence that shorter chained-lipids are better at sequestering small amphiphilic 
molecules than do longer lipids even when both are in the fluid phase157, although this 
experiment was performed at a constant temperature meaning that the shorter-chain lipid was 
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further above its melting temperature (and thus more disordered and fluid) than was the 
longer-chained species.  However, this effect was limited in intensity (the log P of 
chlorpromazine dropped from 3.91 in DLPC to 3.53 in DPPC at 50ºC) and so is unlikely to 
significantly influence the results of this investigation. 
It has been reported that the introduction of CAD-like compounds into a membrane can both 
decrease and broaden its phase transition temperature in a dose-dependent manner193.  
However, the effect was limited to a drop of only about 2°C at 5 mol% raclopride in the DSC 
experiments above, meaning that DPPC will still be above its phase boundary at the start of the 
experimental protocol.  It has also been demonstrated that the addition of fatty acids to such 
membranes will increase the transition temperature under all pH conditions below their pKa in 
the membrane (around 7.7194) by intercalating between lipid molecules, limiting inter-head-
group repulsion195.  This, in turn, will change the partition function and membrane topography 
experienced by any amphiphile such as raclopride, setting in motion what might be considered 
as a purely physico-chemical feedback loop. 
Even through this brief summary, it can be seen that the hydrolysis of lipid acyl bonds by a CAD -
like molecule will unfold in a dynamic and extremely complex environment, and one that is 
affected by many interdependent factors.  In this regard, it is in some ways reassuring that the 
evidence from section 6.1 demonstrates (at least in the case of the Lα  HII transition) that the 
effects of complex composition changes may still lead to relatively simple results . 
In order to accurately quantify the extent of hydrolysis in the DLPC-containing samples, the 
HPLC conditions described in section 5.2.2 (page 66) was required, as the DLPC peak co-eluted 
with that of the lyso-OPC under the standard protocol.  As a result, a longer, shallower gradient 
was identified running over some 20 minutes.  The retention times under these conditions are 
shown on page 70 in Table 2. 
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6.2.1 Results with DLPC, DMPC and DPPC 
The experiments were run exactly as in section 6.1, although with 5 mol% raclopride tartrate 
added as in all previous experiments.  HPLC and SAXS analyses were conducted over a 625 hour 
period from hydration and the chromatography results plotted against the calibration factors 
derived previously in section 5.3.  HPLC analyses were conducted on all samples; the large 
number of assay vials made SAXS under all conditions impractical, so instead images were taken 
using samples from 20, 60 and 100mol% saturated lipid mixtures.   Mechanical failure meant that 
SAXS facilities were not available until ≈200 hours after sample hydration and so early data was 
lost – however, four SAXS images of each capillary were recorded after this point.  In common 
with the above charged lipid experiments this data revealed little of value, though, revealing no 
clear trends.  HPLC were much more fruitful, though, and results are presented below in Figure 
67.   
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Figure 67: The influence of a range of fully saturated lipids upon the rate of total lyso-PC formation catalysed by 5 mol% 
raclopride tartrate, showing the effects of (a) DLPC, (b) DMPC, (c) DPPC, n = 2.  Data are plotted against cumulative DOPC 
data shown in Figure 33, (blue solid lines), which also indicate typical errors from data derived in Figure 33.  After ≈300 
hours, pure DMPC samples began to show wildly fluctuating data, suggesting some form of contamination or sampling 
error had occurred: as such, the erroneous data points are omitted. 
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In each of the above plots, the same trends appear:  hydrolysis in mixtures containing 20, 40 and 60mol% saturated lipid 
is, within error, identical to that observed in pure DOPC.  However, above this threshold, hydrolysis begins to occur very 
rapidly and in contrast to the DOPE experiment described previously, the increase is not linear with saturated lipid 
concentration (illustrated in  
Figure 68, below), instead presenting a sigmoidal relationship, p < 0.001. 
 
 
Figure 68: The relationship between saturated-chain lipid concentrations in the membrane and the rate of its hydrolysis 
by raclopride tartrate.  Remaining proportion of membrane was composed of DOPC.  Blue shaded area shows region of 
phase co-existence as identified by fluorescence studies
196
.  Indicative error bars are shown for 100% DOPC data, and are 
derived from Figure 33. 
This relationship means that the earlier hypothesis that rates are controlled by direct drug-lipid 
forces must be discounted: there appears to be a discontinuity shown here between those 
mixtures below 60% saturated lipid and those above that concentration.   The fact that this 
behaviour was repeated in all three experimental systems means that the effect is probably due 
to the imperfect mixing of high concentrations of saturated lipids with DOPC.  In contrast to the 
mixing of DOPC with DOPE, a temperature and composition-dependent phase coexistence 
region is observed between ordered domains enriched in saturated lipids and fluid disordered 
regions enriched in unsaturated molecules.  In the case of DOPC-DPPC mixtures at 37°C, the co-
existence region has been found by fluorescence methods196 and X-ray diffraction197 (see below) 
to form at shortly below 80% DPPC, tying in neatly with the experimental data presented above;  
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DLPC or DMPC systems do not show the same obvious discontinuities as they are both fluid at 
37°C, but it is not unreasonable to suggest that a similar mechanism may be at play . 
   
Figure 69: Phase diagrams published showing the de-mixing of DOPC and DPPC through fluorescence methods by Lentz 
et al.
196
 (left) and through SAXS analysis by Furuya and Mitsui
197
 (right, where S denotes a solid or gel phase and F 
denotes a fluid system).  Red lines are added to show the relevant temperature in the current study. 
As described in section 6.2, these ordered, viscous domains typically exhibit a much lower 
capacity to absorb amphiphilic species than an equivalent-sized fluid-disordered region192, 
although in the case of strongly hydrophobic, planar species such as cholesterol this trend is 
reversed198.  This is likely to be due to the close packing of the acyl chains in the gel phase, 
limiting the space that can be occupied by exogenous amphiphiles without causing energetically 
costly flaws in the membrane lattice.  This makes the above data all the more surprising: it 
appears that the formation of liquid-ordered domains in the membrane significantly increases 
the rate of hydrolysis.   
Although unexpected, parallels can be drawn with the activity of PLA2 in membranes of different 
phase behaviour, in a manner that may shed some light upon the situation.  It has been 
observed that the “lag-burst” kinetics of PLA2’s activity are very much a feature of the liquid-
disordered phase; by contrast, when PLA2 is added to lipids such as DPPC in the gel phase, rapid 
hydrolysis occurs almost immediately unless inhibited by the addition of delipidated serine 
albumin199.  This was explained by the activation of PLA2 by anionic domains: during the “lag” 
phase of PLA2 in a disordered membrane, all the anionic fatty acid generated is free to diffuse 
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laterally away from the enzyme, driven by a combination of Brownian motion and charge-charge 
repulsion.   By contrast, the diffusion rates in gel-phase lipids are some 70 times slower200, 
meaning that an activating local concentration of carboxylate groups can be developed much 
more rapidly.  Although not activated in the same way, CADs have previously been proven to 
have higher affinities and activities in anionic than neutral membranes (D. Casey, unpublished 
work): it does not seem unfeasible that a similar effect may be contributing under these 
circumstances, counter-acting the lower log P experienced by the drugs that was discussed 
previously.  On first glance, this would suggest that the reaction becomes self-promoting: that as 
the reaction progresses, the increase in anionic fatty acids within the host membrane would 
attract more and more drug, leading to exponentially increasing rates which are conspicuously 
absent in all the data presented.  However, this scenario is only important in cases where large 
excesses of cationic amphiphile are available: in the experimental models studied in this report, 
the high partition function of the drug means that it is effectively >90% membrane -bound under 
initial conditions, meaning that an homogenous distribution of anions across the membrane 
interface after this point can have a limited impact. 
 
6.2.2 POPC 
While the hydrolysis data presented above in Figure 67 indicates a trend of increase in rate with 
increasing acyl chain length, (presented more thoroughly in Figure 72, below), there is an 
obvious and significant discontinuity between the rates of formation of lyso-lipid species in 
mixtures dominated by unsaturated lipids relative to saturated species.  While this is probably 
phase-dependent, based upon the data above, it was important to eliminate any direct effects 
of the unsaturation of the acyl chains: to prove that there was no significant differences 
between the observed rates of reaction due to any affinity between, for example, the phenyl 
ring of raclopride with the 18:1 cis-double bond of the oleoyl chains, as predicted by Rosso et 
al150. 
To confirm this hypothesis, an experiment similar to those above was conducted using mixtures 
of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) with DOPC.  This lipid carries one 
saturated C16 chain and one mono-unsaturated C18 chain meaning it can act as a lateral 
surfactant, preventing the formation of domains such as those described above.  It mixes ideally 
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with DOPC at all ratios, forming a stable fluid lamellar structure at essentially all temperatures 
above its chain-melting point of -5°C201.  However, under these circumstances it was capable of 
isolating the contribution of the fatty acid tail group in determining the rate of the reaction: if 
the choice of acyl group was of significant import, one might expect to find an activity mid-way 
between that of DOPC and DPPC.  If, as theorised above, the fluidity of the membrane is the 
rate-determining factor, POPC would be expected to cause a much smaller difference to the 
measured rates of hydrolysis. 
The experiment was prepared in a similar way to those above: POPC and DOPC were mixed at 
ratios from 20:80 respectively through to 100% POPC and co-lyophilised with 5 mol% raclopride.  
These samples were hydrated with PBS and samples were taken over the course of some 600 
hours.  The data obtained is displayed below (Figure 70), alongside the averaged rate observed 
in pure DOPC experiments obtained from Figure 32 for reference.  Unfortunately, the similarity 
in chemical structure between the two potential lyso-lipids coupled with their propensity to 
isomerise into the sn-1 form55 meant that the reaction products co-eluted, destroying any 
information into the reaction’s chemoselectivity.  However, the data presents a strong 
indication that the process is effectively random, with both chains experiencing an equa l 
probability of being digested. 
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Figure 70: The rates of lyso-lipid formation in a range of mixtures of DOPC and POPC.  100% DOPC data is added for 
reference, derived from Figure 33.  This is also the source of the error bars, as previously. 
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Figure 71: The d-spacing exhibited by each of the samples as a function of time, plotted on the same axes as in Figure 65.  
All values are within experimental error limits of one another, with a slight upwards trend over the course of the 
measurements.  DOPC data are included from calibrated phase diagram studies (R Macey, unpublished data), and were 
recorded in the absence of raclopride. 
The absolute rates identified are within error of those from Figure 33 and extremely consistent 
within the experiment, giving a rate of 0.132 ± 0.0159 mol hr-1 molRAC
-1, if pure DOPC data is 
excluded.  It is also apparent from the SAXS data above that no substantial physical changes are 
taking place in the membrane structure during this period: the data is extremely close -grouped 
when compared to that in Figure 65 (data above is plotted on identical axes for ease of 
comparison).  This lies in stark contrast to the effects that more hydrophobic drugs like 
haloperidol wreak upon the structure of the host bilayers (see Figure 35, page 95), and raises a 
number of questions about how the effects of raclopride are mediated if there is little or no sign 
of membrane insertion by the drug, an idea supported by the fluorescence data in section 
5.6.1.1. 
This strongly indicates that there is a negligible contribution towards rates of reaction caused by 
direct drug-fatty tail interactions, suggesting that the observed trend in rates of reaction from 
DLPCDMPCDPPC is due more to microdomain formation and thus restricted lateral diffusion 
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timescales than it is to any kind of direct drug-lipid complex formation.  This is particularly 
evident when the rates of hydrolysis of the pure lipids studied are compared side-by-side, as 
shown below in Figure 72. 
  
Figure 72: The relative rates of hydrolysis of the pure lipid species analysed.  Error bars are calculated from the standard 
deviation of all POPC data points, assuming that all DOPC-POPC mixtures have identical rates of hydrolysis under 
identical conditions.  Error bars = 2 s.d. derived from Figure 33. 
Interestingly, these changes in lateral diffusion are not necessarily linked to changes i n sample 
surface viscosity: at 37°C, it has been demonstrated in electron spin resonance experiments that 
DOPC and POPC both have higher surface order parameters at 37°C than do DMPC or DLPC202.  
However, these data do correlate reasonably strongly with the bilayer elastic bending constants 
– accurate Gaussian curvature modulus values exist for very few lipids or lipid mixtures 203,  but 
although there are considerable variations in the absolute values recorded depending on the 
technique used for analysis, there is a consistent trend showing rigidity in the order DOPC ≈ 
POPC < DLPC < DMPC < DPPC188.  This makes physical sense if it is assumed, as a first 
approximation, that the rate-limiting step of the reaction is the slow migration of protons from 
the strongly basic drug molecules toward the weakly nucleophilic acyl bond.  This will be driven 
by the change in dielectric environment that the drug experiences as it approaches the 
hydrophobic interface, decreasing the favourability of the charged relative to the neutral 
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species.  However, in the same way as every other chemical reaction, the probability of this 
transfer occurring will be dependent upon both the contact time of the two reagents (in this 
case, the basic centre of raclopride and an adjacent lipid carbonyl bond) and the relative 
orientation of the two. 
For the proton to be transferred to the weakly nucleophilic carbonyl bond, it is likely to require 
extended exposure to both the hydrophobic region and the target acyl bond linkage.  In a gel-
phase bilayer, diffusional timescales are sufficiently slow that this may take place efficiently; b y 
contrast, CAD-like compounds experiencing a turbulent and undulating fluid interface have 
neither the same sustained contact with the acyl interface nor the stable hydrophobic 
environment, leading to a much lower probability of reaction. 
Another way in which this fluidity and thermally-induced turbulence may affect the rate is more 
indirect.  It seems likely that the probability of a CAD triggering hydrolysis will depend strongly 
upon its depth within the bilayer, which in turn depends upon its effective pKa.  This is 
influenced strongly by the depth of water penetration into the interface (shown schematically 
below in Figure 73), as charged species such as the protonated form of the drugs are only 
favourable in a hydrophilic environment.  However, it is a delicate balancing act: the acyl 
moieties of the phospholipid backbone are not strongly nucleophilic, meaning that rates of 
reaction will be very slow, yet in the hydrophobic environments that promote the drugs’ release 
of the captured protons, the lipids’ ester form is preferred.  That suggests the idea that t here 
may only be a narrow window of conditions under which the reaction may be observed at a 
meaningful rate under these very simple conditions, but also suggests potential approaches by 
which this may be probed.  For example, NMR experiments can readily identify the depth of 
water penetration into a membrane, whereas the addition or total removal of chelating metals 
which would interfere with the head-group environment may prove to form the basis of the 
differences between the results presented here and those previously reported53.  Alternatively, 
the depth of water penetration into a membrane can be directly visualised using membrane 
bound, environment-sensitive probes such as LAURDAN (6-acyl-2-dimethylamino-napthalene), 
which shift their emission spectra in response to the degree of water penetration into a 
membrane81. 
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Figure 73: The depth that an amphiphile resides in the membrane will depend upon its physico-chemical parameters but 
also those of its host membrane.  In the example above, a drug molecule (in red) is co-localised with the lipids’ acyl 
bonds when the membrane effectively excludes water; as the membrane becomes disordered, a greater volume of 
water penetrates beyond the head-groups, expanding the hydrophilic region.  As a result, it is hypothesised that the 
drug retreats deeper into the membrane, preventing hydrolysis. 
These results also demonstrate that the partition coefficient of a compound is not as vital to the 
rate of hydrolysis as was previously thought.  As previously discussed, Luxnat and Galla have 
found that at a given temperature, a short-chain lipid can solubilise a higher concentration of 
drug than a longer chain structure even when both are in the Lα phase, presumably because it is 
easier to intercalate between the molecules of the more weakly bound short tails 157.  This 
disparity is still greater when the long-chained lipid is in the gel phase, and yet in exactly this 
situation the above results show significantly faster hydrolysis in DPPC, the gel-phase aggregate, 
than in any of the fluid systems. 
It is difficult to compare the activity of DOPE using this trend due to its hydrogen-bonding 
capacity and its inverse hexagonal arrangement opening a range of potential confounding 
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factors.  The inverse hexagonal phase limits the applicability of membrane bilayer bending 
moduli, rendering such comparisons meaningless.  Furthermore, the lack of obvious 
discontinuity in rate at the phase boundary makes it appear likely that the contribution of the 
hydrogen-bond forming head-group dominates the drug-lipid interactions in this case.  If a 
drug’s tertiary nitrogen is in effect sharing its acidic proton with a second amine distant from 
the target acyl moieties, the probability of a hydrolytic reaction will become almost negligible.  
Biological membranes are almost exclusively fluid under normal conditions.  However, a range 
of CADs have been observed to cause rapid morphological and physico-chemical alterations in 
erythrocytes (for a full review, see Schreier 200016): although CADs are often associated with 
membrane fluidisation, at lower concentrations they can increase membrane stiffness, create 
meta-stable, crenelated domains or even trigger phase transitions.  There also exist natural 
regions of constrained lateral diffusion in the native cell membrane.  The original stable, micron-
sized “lipid rafts” hypothesised by Simons and Ikonen204 have been revised so that the 
sphingomyelin-rich domains are now thought to be around 20nm diameter and with a lifetime 
measured in tens of milliseconds205: however, this is quite a long time on the scale of chemical 
reactions, and these may yet have some relevance to drug transport models. 
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6.3 Influence of cholesterol 
Both erythrocyte membranes and lipid nanodomains in live cells are strongly enriched in 
cholesterol: the strong affinity between ceramide-based lipids and cholesterol was originally 
mooted as the basis for the lipid raft hypothesis204, and red blood cells are up to 45% 
cholesterol182, amongst the highest in human tissue.  Furthermore, the introduction of 
cholesterol into a phospholipid membrane has the effect of dramatically stiffening the 
membrane188 and thickening it via chain ordering206, which should promote the lipid hydrolysis 
reaction if the above hypothesis is correct. 
Unfortunately, it has also been demonstrated to prevent drugs from binding to lipid 
membranes, presumably via a competitive process due to its very low aqueous solubility 157,207.  
It induces significant changes in the head-group orientation of its host membranes, the 
“umbrella” effect (shown below in Figure 74), where the phosphate group of an adjacent 
phospholipid alters its conformation to minimise water contact with the cholesterol 
molecule208,209.  These strong interactions, honed through evolutionary processes, are 
significantly greater than those between CADs and similar lipids and so the drugs are displaced 
and may precipitate out. 
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Figure 74: The “umbrella model” of cholesterol integration (purple) into membranes.  Initially, the intercalation of 
cholesterol increases order within the membrane, but exposes the hydrophobic sterol molecules to water which 
penetrates beyond the lipid head-groups (top).  To ameliorate this hydrophobic stress, the lipid head-groups distort to 
shield the sterols, (lower), but have a finite capacity to do so, setting an effective maximum concentration of cholesterol 
in the membrane.  
The very fact that cholesterol and many phospholipids have such strong interactions effectively 
limits the solubility of the sterol in a membrane, however.  Above concentrations of 45-50 
mol%, the cholesterol begins to precipitate out of the bilayer210, as the sterol:phospholipid ratio 
exceeds 1:1 and there are no longer sufficient lipids to prevent its contact with water.  As a 
result, it was not possible to experiment with cholesterol concentrations greater than 50  mol% 
and even these showed the formation of precipitated cholesterol crystals. 
In order to probe and quantify these effects upon the rates of hydrolysis, DOPC was co -
lyophilised with cholesterol to form mixtures of 10-50 mol%.  These lipid films were hydrated 
and homogenised as normal and were analysed by HPLC over the course of some 600 hours.  
Samples were removed and dispensed into 1.5mm diameter capillaries for SAXS analysis, but 
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despite careful sealing all samples dehydrated very rapidly under incubation and so that aspect 
of the experiment was abandoned. 
As can be seen from Table 2 on page 70, the retention times of cholesterol and DOPC run very 
close to one another and prevented their independent resolution.  In order to calibrate the data, 
the contributions of cholesterol and DOPC to each peak were calculated with reference to 
standard solutions and the cholesterol signal was removed algorithmically.  However, the values 
thus derived were found under the assumption that the levels of lyso-PC formed were small, 
which may have induced errors during the later stages of the experiment.  The processed results 
are shown below in Figure 75. 
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Figure 75: The hydrolysis of DOPC in the presence of varying mole fractions of cholesterol: (a) the formation of lyso-OPC 
as a function of time; (b) the rate of formation as a function of cholesterol mole fraction.  This suggests a straight 
competitive displacement between raclopride and cholesterol.  100% DOPC data and error bars from Figure 33. 
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These results demonstrate either that raclopride and cholesterol are competing for the same 
binding sites at the lipid membrane, or that the conformational shifts induced in nearby lipids by 
the presence of cholesterol effectively destroys the preferred habitat of the drug within the 
membrane.  The former seems more likely, both by virtue of simplicity but also based upon the 
findings of NMR experiments probing the orientation of amphiphilic drugs at the membrane , 
which have shown them occupying positions at the interface identical to that shown 
schematically above in Figure 74211.  
This finding has some interesting implications for drug binding to biological membranes. Most 
obviously, it suggests that red blood cells (which have membranes comprising up to 45% 
cholesterol182) may not be effective transport media for drugs in vivo.  Proteins such as A-
glycoprotein and Serum Albumin collect and transport the vast majority of such lipophilic 
species in the blood and are widely studied as a result, as their actions can lead to a range of 
unpredictable outcomes for the in vivo efficacy of an otherwise promising candidate drug 
compound212.  However, a number of amphiphilic compounds including CADs like imipramine 
have been observed to induce membrane deformations in red blood cells and so it would seem 
likely that even under very high-cholesterol conditions, a proportion of the drug molecules are 
absorbed into the membrane. 
However, raclopride is not amongst those compounds inducing detectable erythrocyte 
deformation.  At approximately the concentration of cholesterol found in red blood cells, no 
hydrolysis was observed at all.  If it is assumed as a first approximation that cholesterol is not 
directly preventing the hydrolytic activity of raclopride, then it is acting only as a steric block.  If 
this is the case, reference to the dose-response data plotted in Figure 34 (page 93) suggests that 
little or any of the administered raclopride has been absorbed by the membrane.  While this 
effect may disappear when considering the extremely large number of erythrocytes available in 
vivo, it still provides food for thought, suggesting an exquisite relationship between CAD 
structure and their uptake by red blood cells. 
Of more direct interest is the observation that cholesterol levels vary significantly between even 
otherwise-healthy individuals, between 4-8mmol/l blood serum213, a not inconsiderable amount 
when considering the compound’s high log P.  This level varies rapidly and dynamically with 
diet214, meaning that uptake and transport of an amphiphilic or hydrophobic drug could 
potentially be significantly removed from baseline figures depending on a pa tient’s choice of 
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breakfast. 
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7 The future 
In order to achieve the goals set out in section 4, a broader range of drug analogues will require 
investigation, necessitating a number of different experimental methods depending on t he 
throughput required.  One of the over-riding conclusions of the whole project to date has been 
that no one technique covers all the bases: in order to generate useful models, a combination of 
high and low throughput approaches will be required, working in synch with one another across 
an integrated programme.  High throughput techniques such as plate-based fluorimetry, HPLC 
and surface plasmon resonance provide important, scatter-gun data – while they can only report 
upon the bulk, average properties of a population of cells or vesicles, they fulfil an important 
trailblazer role for the lower throughput, highly spatially and temporally resolved techniques 
which will pick out the finer points of the mechanistic detail. 
Lower throughput techniques have the potential to generate huge volumes of data about 
individual data points on the above results, covering the precise behaviour of each system in 
exquisite detail.  In order to probe the tissue specificity of the drug-lipid interactions as 
proposed in the working hypotheses (page 53), a combination of mass spectrometry (MS) driven 
lipidomics215 and spatially resolved techniques such as fluorescence microscopy  and MS imaging 
will be required.  MS imaging in particular shows great potential: by imaging ex vivo tissue 
before and after treatment with a compound, changes in the spatial distribution of specific lipid 
species can be monitored at a micron resolution via direct MALDI-MS of tissue slices216. 
The data presented above has all been fed into the computational modelling work-stream which 
runs in parallel with the non-specific binding initiative, and some of the early products of their  
labours have already been alluded to150.  Work is continuing on modelling both individual drug-
lipid binding interactions, which may be of extreme value if the results in section 6 (page 147 
onwards) are to be believed, and also into coarse-grain modelling of the membrane as a whole.  
Although this technique obviously lacks the resolution of the molecule-molecule interaction 
modelling, in some regards it provides a much more useful picture of the mechanical proces ses 
occurring at the lipid interface in terms of molecule depth, orientation and diffusion rates which 
have become increasingly important over the course of this investigation.  The eventual aim is to 
coalesce all the various, disparate data strands into one vast, coherent data-set, allowing the 
production of a computational model that will be able to predict the biological transport of any 
given molecule from structure alone.  That, however, remains a long way off. 
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Until then, the gold standard for measuring in vivo distribution remains PET: despite its 
extremely low throughput, it permits sequential imaging of the same animal model, thus 
eliminating inter-subject heterogeneity encountered in techniques which require post-mortem 
analysis such as autoradiography.  It also provides real-time, quantitative monitoring of plasma 
drug levels both in and outside the region of interest, meaning it can supply accurate figures not 
just for receptor localisation but also non-specific binding and total volume of distribution.  In 
order to maximise the use of PET techniques, collaboration is set to continue with the GSK 
Clinical Imaging Centre and their new small animal PET facility.  Large animal studies will 
become available in due course, regulatory affairs permitting,  which will greatly simplify the 
access and availability of this, most powerful of techniques. 
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7.1 Synthetic research towards future PET models of non-specific 
binding‡ 
In order to explore the influence of drug structure on the measured rates of hydrolysis, the 
syntheses of a small number of raclopride analogues was attempted.  A spread of these 
compounds could then be radiolabelled and used for PET analysis in vivo.  These were also to be 
analysed with the best available biophysical assays developed, to place them into some kind of 
rank order of hydrolytic activity in an attempt to correlate the in vitro measurements with those 
from the clinic.  This could potentially point towards the development of a predictive model for 
lipid transport, the ideal result of the NSB project as a whole. 
Raclopride, with its central amide bond (see Figure 13, page 56), offered great flexibility and 
relatively simple synthetic accessibility.  This allowed the development of  a small range of 
bimodal imaging agents prepared to allow the potential analysis of in and ex vivo models with 
the same probe: raclopride-like molecules were synthesised with an intrinsic fluorophore, 
permitting their direct imaging in cell culture and tissue section as well as via much lower-
throughput but potentially higher quality PET techniques. 
  
                                                          
‡
 Adapted in part from thesis submitted for Master of Research award, 2007. 
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7.2 Synthesis 
The compounds synthesised fell into two distinct families, as two different roles were required.  
Initially, an array of raclopride analogues was generated to form structures as closely related as 
was practical to the parent compound’s aromatic region.  Literature from the suppliers of 
raclopride along with experimental findings suggested that the benzylamide region of the 
compound was photosensitive, which appeared in keeping with its intrinsic fluorescence, 
absorbing strongly under UV light (λ ≈ 360nm).  As a result, attempts to synthesise analogues 
retaining all the chemical features of the 3,5-dichloro-2-hydroxy-6-methoxy-benzoic acid met 
with failure.  Rather than becoming heavily involved in specialist techniques and facilities to 
perform the chemistry in the dark, analogues were instead made using 2, 6-dimethoxy, 2-
hydroxy-6-methoxy or 2, 6-dihydroxybenzoic acid building blocks, as shown below in Figure 76.  
Analogues of each of these are labelled A, B and C throughout. 
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Figure 76: The photosensitivity of 3,5-dichloro-2-hydroxy-6-methoxy-benzoic acid products made them less than ideal 
for array-based synthesis.  As a result, less sensitive analogues were prepared based upon the benzoic acids shown 
above.  For the reaction mechanism of polystyrene-supported 2-isobutoxy-1-isobutoxycarbonyl-1,2-dihydroquinoline 
(PS-IIDQ), please see Figure 78. 
This made syntheses significantly easier, although yields were found in the order A > B > C due 
to the electron-donating effect of the substituent methoxy groups in A and B which helped 
increase the nucleophilicity of the benzoic acid.  While this approach greatly simplified the 
synthesis, it did so at the cost of the zwitterionic behaviour of the analogues at neutral pH which 
was maintained only by the two strongly electron-withdrawing chloride groups (in comparison 
to raclopride, eticlopride which only features one chloride group is always cationic at neutral 
pH152).  Predicted pKa values (using Chemicalize physico-chemical prediction software, 
ChemAxon UK) of the 2-hydroxy group change from 6.26 in raclopride to 7.97 in B1 while little 
change is observed in the pKa of the basic nitrogen, meaning the compound moves from being 
almost entirely zwitterionic at pH 7.4 to being almost entirely cationic.  
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These compounds featured only a low intrinsic fluorescence, however, which limited their use in 
tissue section or cell culture assays.  As a result, a second range of compounds was generated, 
replacing these aromatic regions with N-methyl anthranoyl (MANT) amides217, shown in Figure 
77.  These MANT species form the smallest available organic fluorophores, (λEXmax ≈ 350nm, 
λEMMmax ≈ 446nm), but give high, stable fluorescent yields as high as 0.95 in organic solvents and 
approximately 0.25 in aqueous media218.  As a result, these compounds were potentially the 
perfect choice to repeat and build upon the fluorescence microscopy performed in previous 
studies53, which had been based upon a commercially available 7-nitrobenz-2-oxa-1,3-diazole 
(NBD) labelled spiperone analogue. 
NH
O
NH
N
 
Figure 77: The N-methyl anthranoyl amide analogue of raclopride (D1), synthesised for its high fluorescent yield and 
relatively close structural resemblance.  The non-methylated analogue of this compound has been demonstrated to 
show some D2 antagonism, similar to that of raclopride
219
. 
 
7.2.1 Synthetic techniques, purification and characterisation 
Extremely high purity was required for all compounds to be tested: because the reaction under 
consideration is slow (at least in the condensed phase) and catalytic, a small percentage of high 
active contaminant could totally dwarf the contribution from the drug itself and lead to 
misleading results.  PET trials have even more stringent purity requirements – because the 
volumes of positron-emitting label are so small, in the pico-or atto-molar range, the unlabelled 
substrate must be extremely clean to prevent the labels being mopped up by trace 
contaminants.  This level of purity is very difficult to achieve manually without the sacrifice of 
significant percentages of otherwise-viable product, and so a range of UV and mass-triggered 
automated purification techniques were utilised. 
Mass-direct automated reverse phase preparative HPLC (MDAP) of methoxy/hydroxy species 
was conducted at GSK Stevenage on a Waters Sunfire C18 column, 150 x 30mm internal diameter 
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using a mobile phase gradient from water/0.1% vol. formic acid to acetonitrile/0.1% vol. formic 
acid over 15 minutes.  Quantification was via a Waters diode array (220-330nm, averaged) and 
peak identification by Waters electrospray MS (switching +/-).  As a result, most compounds 
were isolated in the formate salt form. 
MANT amide products were isolated using a Combiflash Companion preparative flash 
chromatography device (Teledyne Isco, USA), using the appropriate pre-packed C18 RediSep Rf 
column cartridges.  The mobile phase gradient ran from 18MΩ water/0.1% formic acid through 
to methanol, due to the low availability of acetonitrile during this period.  Detection was 
performed at 254 and 350nm, with collection triggered using 350nm absorbance so as to only 
capture MANT-containing species.  As previously, most compounds were isolated as formate 
salts. 
 
7.2.1.1 Methoxy/hydroxy species 
Synthesis of the non-labelled raclopride analogues was conducted using solid phase amide-
coupling reagents from the relevant benzoic acid and amine precursors.  Previous attempts had 
demonstrated the relative inactivity of the 2,6-methoxy- and 2,6-hydroxy-benzoic acids in amide 
synthesis leading to low yields with common reagents such as dicyclohexylcarbodiimide, and 
more direct syntheses involving the use of thionyl chloride had proved difficult to purify.  As a 
result, polymer-supported 2-isobutoxy-1-isobutoxycarbonyl-1,2-dihydroquinoline (PS-IIDQ) was 
chosen as a coupling reagent220. This powerful reagent gave rapid, clean formation of all the 2, 
6-methoxybenzoic acid derivatives synthesised under very mild conditions, with somewhat 
lower yields for the hydroxy analogues. Furthermore, the side-products of the reaction are all 
either volatile or are retained on the resin bead, as shown below in Figure 78, allowing 
purification in some cases by simply filtering the reaction mixture and evaporating the 
solvents221. 
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Figure 78: The reaction mechanism of polystyrene-supported 2-isobutoxy-1-isobutoxycarbonyl-1,2-dihydroquinoline (PS-
IIDQ).  All side-products are, under ideal circumstances, either volatile or retained upon the polystyrene bead allowing 
for extremely simple purifications. 
For illustrative purposes, this procedure will be described for the first compound to be 
successfully isolated, 2, 6-dimethoxy-N-(2-piperidin-1-yl-ethyl)-benzamide, (A1): other syntheses 
were identical in all respects except for the amine species involved. 
2,6-dimethoxy-N-(2-piperidin-1-yl-ethyl)-benzamide, (free base) A1, (shown below in section 
7.2.2).  60mg (0.33mmol) 2,6-dimethoxybenzoic acid was dissolved in 10ml tetrahydrofuran 
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(THF) with 45mg (0.33mmol) 2-piperidin-1-yl-ethylamine in a glass jar with a fermentation cap.  
0.4125g (1.6mmol/g, 2 equivalents) PS-IIDQ was added and the reaction mixture was shaken at 
300rpm overnight at room temperature. 
A white precipitate was observed in the flask after reaction: this dissolved when 
dichloromethane (DCM) was added to the vessel.  The mixture was filtered under gravity an d 
the solvent removed under reduced pressure to leave an off-white product.  10ml cold THF was 
added and the mixture shaken briefly to leave the white precipitate observed previously.  This 
was isolated by vacuum filtration and dried in a vacuum oven at 40°C overnight to give 54.1mg 
(0.185 mmol, 56.1% yield).  Subsequent 1H NMR analysis in CDCl3 showed the product to be 
>95% pure. 1H NMR [CDCl3]  = 1.28 (2H, m); 1.50 (3H, m); 2.42 (3H, m, broad); 2.54 (2H, t); 2.93 
(2H, t); 6.41 (2H, d); 7.06 (H, t) ppm. 
For those reactions showing lower yields, further purification steps were required.  Solid -phase 
scavenging, using polymer-supported isocyanate and trisamine resins, was disregarded as 
impractical in this case due to the potential for the scavenging agents to remove significant 
quantities of target compound at the same time as the impurities.  The level of purity required 
was such that at the milligram scales being worked upon, isolation by hand using normal -phase 
silica would lead to significant losses of yield.  As such, purification was undertaken on an 
automated reverse-phase column using mass-spectrometry and/or diode array peak 
identification on industrial facilities generously provided by GlaxoSmithKline plc, described fully 
below in section 7.2.1.  Typical purities were in the region of 95-100% and were confirmed by 1H 
NMR. 
Some side-product formation was observed using the PS-IIDQ technique.  1H NMR and mass 
spectrometry analyses identified the compounds as the urethane structure shown in Figure 79.  
It was the preferential formation of this species that prevent the isolation of any significant 
amount of compound A4 (see Table 6). 
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O
NO R''
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Figure 79: The urethane structure formed when the amine in the last step of the reaction mechanism shown in Figure 78 
attacks from the more hindered side. 
 
7.2.1.2 N-methyl anthranoyl species 
N-methyl anthranoyl analogues of raclopride (labelled D), (as well as their des-methyl 
counterparts to allow for potential PET imaging, labelled E), were prepared in a straightforward, 
one-step acylation reaction combining the N-methyl isatoic anhydride with the relevant amine 
under anhydrous reflux conditions.  High temperatures were not entirely necessary, as 
production of carbon dioxide was observed almost immediately after the combination of the 
reagents (see Figure 80), but it was found to improve yields after testing. 
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Figure 80: The reaction mechanism of N-methyl isatoic anhydride, combining here with 2-aminomethyl-1-
ethylpyrrolidine to form compound D1.  The reagents were combined in 10ml dry THF and boiled under anhydrous 
reflux conditions for 1 hour, forming good yields. 
In the absence of water, this reaction proceeded in good yield; water caused the hydrolysis of 
the anhydride forming 2-N-methyl benzoic acid, which fluoresced at a lower wavelength of 
around 400nm.  The reaction to form the des-methyl product was similar, but had a greater 
propensity to form side-products due to the formation of a free aniline during the process, 
which could then combine with another anhydride molecule in a potential chain reaction,  as 
shown in Figure 81. 
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Figure 81: The mechanism of side-product formation when using methyl isatoic anhydride as an acylating agent. 
N-(1-Ethyl-pyrrolidin-2-ylmethyl)-2-methylamino-benzamide, (formate salt) D1, and N-(1-Ethyl-
pyrrolidin-2-ylmethyl)-2-amino-benzamide, (formate salt) E1 
177mg (1mmol) N-methyl isatoic anhydride and 256mg (2mmol) 2-aminoethyl-1-ethyl 
pyrrolidine were dissolved in 10ml THF and heated to 60°C under a reflux condenser and a 
nitrogen atmosphere for one hour.  TLC analysis on silica plates (95% DCM, 5% MeOH) showed 2 
spots under UV  365nm: Rf ≈0.7 (purple, side-product
222) and Rf ≈0.1 (blue, product).  The 
desired product was isolated by Combiflash, as outlined above.  178.5mg (0.581mmol, 58.1%) 
was collected. 1H NMR showed >95% purity, [CDCl3] δ = 1.36 (3H, t); 1.91 (H, m); 2.04 (2H, m); 
2.21 (H, m); 2.71 (3H, s); 2.94 (2H, m); 3.31 (H, m); 3.68 (2H, m); 3.85 (2H, m); 6.66 (2H, m); 7.33 
(H, t); 7.47 (H, d); 8.38 (formate); 8.79 (H, amide) ppm. 
The des-methyl analogue, E1, was synthesised similarly, using 163mg (1mmol) isatoic anhydride 
in place of the N-substituted reagent.  After purification, 118mg (0.412mmol, 41.2% yield) was 
returned and was shown to be >95% pure by 1H NMR [CDCl3]  = 1.28 (3H, t); 1.81 (H, m); 1.98 
(2H, m); 2.17 (2H, m); 2.72 (2H, m); 3.18 (H, m); 3.45 (H, m); 3.64 (2H, m); 3.76 (H, dd); 6.70 (2H, 
dt); 7.24 (H, t); 7.63 (H, d); 8.80 (formate) ppm. 
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Purities were confirmed by analytical HPLC using an Agilent 1200 series C18 system analysed via 
diode array at 254, 360 and 446nm and by LCMS using a Waters 1525 system through a reverse 
phase Waters Atlantis DC18 30mm x 4.6mm column and a Waters LCT Premier quadrupole MS.  
In both cases, results showed a single peak. 
 
7.2.2 Results 
The results of the synthetic programme are shown below in Table 6.  Wherever possible, 
coherent families of compounds were created to allow direct comparisons across the data-set.  
However, not all compounds were tested, due to experimental issues at varying stages and 
shifting priorities: some of this synthetic work was undertaken early in the project, and as it was 
discovered that the previous theories regarding the factors controlling hydrolysis were 
incomplete, research moved towards a more mechanistic study leading to the results in sections 
5 and 6.  In some regards, these results are included for completeness, and to form the basis of 
future studies should this topic be investigated further. 
Almost all of the compounds below were purified by automated, reverse-phase chromatography 
techniques.  As such, those containing basic centres were isolated as formate salts; the formula 
weights below correspond only to the parent molecule in its free-base form. 
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Compound identifier Structure FW Mass available /mg Purity /% 
A1 
N
N
H
OO
O
 
292.38 24.7 >95 
B1 N
N
H
OO
OH  
278.35 41.6 >95 
C1 
N
N
H
OOH
OH  
264.33 75.4 >95 
D1 
N
H
O
N
NH
 
261.37 178.5 >95 
E1 N
H
O
N
NH
2  
247.34 65.3 >90 
A2 N
H
OO
O
N
 
292.38 54.1 >95 
B2 
N
H
OO
OH
N
 
278.35 88.0 >95 
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Compound identifier Structure FW Mass available /mg Purity /% 
C2 N
H
OOH
OH
N
 
264.33 80.3 >95 
D2 NH
O
NH
N
 
261.37 258.88 >95 
E2 N
H
O
NH
2
N
 
247.34 127.8 >95 
A3 N N
OO
O
N
+
O
O
 
371.40 19.5 >95 
A4 N
H
OO
O
N
 
258.28 <1 N/A 
B4 N
H
OO
OH
N
 
244.25 74.3 >95 
C4 N
H
OOH
OH
N
 
230.23 8.4 >95 
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Compound identifier Structure FW Mass available /mg Purity /% 
A5 
N
H
NOO
O
O
O
 
364.45 75.1 >95 
B5 
N
H
NOOH
O
O
O
 
350.42 63.6 >95 
C5 
N
H
NOOH
OH
O
O
 
336.39 7.7 >85 
D6 
N
H
O
NH
O
 
234.30 21.6 >95 
E6 N
H
O
NH
2
O
 
220.27 122.27 >95 
D7 
N
H
O
NH
N
 
221.30 233.86 >95 
E7 N
H
O
NH
2
N
 
207.28 194.55 >95 
Table 6: The results of the synthetic programme undertaken to probe the dependence of the hydrolytic activity observed 
upon the structural parameters of a number of raclopride analogues.  Not all compounds were tested, due to changing 
priorities and experimental issues. 
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A number of these compounds had prior art describing either their synthesis or, in some cases, 
their activity.  For example, B1 is a precursor in radiolabelling studies223, D3 was previously 
produced by TimTec Compound Libraries (USA), CAS number 348612-09-9.  As previously 
mentioned, E1 has been patented for its dopamine-D2 antagonist activity
219, while E2 and E3 
were identified as potential drug candidates in 1970 by Bonola and  Sianesi224 and Jacobs225, 
respectively.  E7 has been patented as a herbicide in France226.  The other compounds are novel, 
or at least unpublished as far as can be ascertained. 
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7.3 Physico-chemical data 
The physico-chemical parameters for a number of compounds intended for PET analysis were 
analysed at the GSK Clinical Imaging Centre (CIC) at Hammersmith Hospital by Chloe Child, using 
GSK’s standard high-throughput, HPLC-based profile.  The log D was determined, with reference 
to well-characterised standard compounds, at pH 2.2, 7.4 and 10.5 using the chromatographic 
hydrophobicity index (CHI)227, as was each compound’s affinity toward immobilised artificial 
membranes (IAM), human serum albumin (HSA) (which binds anionic, hydrophobic compounds 
such as fatty acids in the blood) and α1-acid glycoprotein (AGP), which acts as a hydrophobic 
cation transporter.  This process was carried out for compounds D1, 2, 6, and 7, which were 
finally selected to go forward for 11C labelling and PET distribution measurement in porcine 
models. 
All HPLC studies were conducted using the Agilent 1200 series models based at the CIC.  Log D 
was measured using a Luna 50 x 3mm C18 column (Phenomenex, USA), while IAM assays were 
conducted using a specialised column containing immobilised DLPC molecules bound to an 
amine-functionalised surface.  AGP measurements were taken using a 50 x 3.0 mm AGP column 
(Chrom Tech, USA), while HSA measurements were taken using s similar HSA-functionalised 
column.  Samples were eluted using a gradient of 50mM ammonium acetate (10mM phosphoric 
acid for pH2.2 studies) into acetonitrile (Log D and IAM) or propan-2-ol (AGP and HSA).  IAM, 
AGP and HSA assays were all run at pH 7.4. 
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Compound CHI Log D pH 2.2 CHI Log D pH 7.4 CHI Log D pH 10.5 Log K IAM 
Raclopride 1.01 2.26 1.47 2.07 
Haloperidol 1.05 2.18 3.21 2.84 
D1 -0.10 1.18 2.50 2.51 
D2 -0.18 1.30 2.61 2.50 
D6 1.23 2.14 2.03 1.49 
D7 -0.70 0.80 1.60 2.24 
Compound % AGP Log K AGP %HSA Log K HSA 
Raclopride 52.44  75.39  
Haloperidol 88.63  91.05  
D1 66.29 0.28 50.25 0.00 
D2 68.36 0.32 53.77 0.06 
D6 40.00 -0.18 57.09 0.11 
D7 58.27 0.13 45.53 -0.09 
Table 7: The results of the HPLC-based physical chemistry assays run at GSK’s Clinical Imaging Centre by Chloe Child.  Log 
D values were calculated from each compound’s chromatographic hydrophobicity index (CHI)
227
; immobilised artificial 
membrane affinity (IAM), α1-acid glycoprotein (AGP) and human serum albumin (HSA) binding were determined via 
specialist column coatings. 
The values derived from these processes illuminate a number of interesting points raised during 
the attempts to generate fluorescence assays detailed previously in section 5.6.1.  Each of the 
basic compounds, D1, 2 and 7, show significantly higher affinities for the amphiphilic membrane 
environment of the IAM assay than they do for the more purely hydrophobic one of the reverse -
phase, C18 CHI assay.  The binding values they display are closely related to those displayed by 
the fully neutral species at high pH: in the case of D7, even more so.  This suggests that the free 
energy that is released by an amine in one of these compounds when it binds a proton is 
exceeded by the cost of dragging that charge into the hydrophobic interior of a membrane: that 
these close structural analogues of raclopride dwell sufficiently deeply within the membrane 
that there are insufficient polar interactions to stabilise a long-term bond to a proton. 
Raclopride itself is most hydrophobic when at neutral pH, which is at first counter -intuitive as 
these are the conditions when the molecule is most charged.  However, in this state the 
molecule forms a zwitterionic internal salt which is net neutral, thus may reside deep within the 
membrane in a similar manner to the compounds described above.  This explains the lack of 
response of the FPE probe upon exposure to raclopride, described in section 5.6.1.1 (page 103): 
the introduction of a neutral, hydrophobic species in amongst many others has effectively no 
impact upon the surface charge function and similarly prompts no build-up of counter-ions upon 
the surface. 
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By contrast, this trend is reversed in the neutral D6, which aside from its lack of charge is almost 
isosteric with D1.    This may be due to it suspending at a different orientation in an amphiphilic 
membrane than in the more uniform hydrophobic environment, as the most polar bonds in the 
molecule D6 are found in the aniline moiety at the other end of the compound to the aliphatic 
region carrying the charge in D1, 2 and 7. 
The data derived from haloperidol testing reveals a crucial difference between its behaviour in 
the membrane and that of raclopride.  By virtue of either its free hydroxyl or its greater 
molecular length, haloperidol retains significantly more of its charge in the membrane, 
suggesting that the basic region floats much closer to the polar interface of the lipids.  This can 
be seen from the differences in affinity between the C18 experiments at pH 10.5 and the artificial 
membrane assay, revealing the causes behind its strong interactions with FPE, especially when 
compared to those of raclopride. 
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7.4 Hydrolytic activity 
The hydrolytic activity of the compounds described in Table 6 was assessed in the bulk phase, 
according to the protocols developed earlier in section 5: briefly, each compound was co-
lyophilised at a 1:20 molecular ratio with DOPC and hydrated with 10mM PBS buffer, before 
being homogenised via vortexing and centrifugation.  These samples were sealed and incubated 
at 37°C and analysed over a period of some 600 hours.  In early studies, samples were simply 
stored in a plastic test-tube holder, but as described in section 5.4.2 (page 72) these were found 
to give misleadingly high rates due to the partial dehydration of samples due to the thermal 
gradients formed in each vial.  As a result, the data shown in Figure 82 cannot be used to 
generate more than trend data, as the internal raclopride standard is shown to hydrolyse DOPC 
significantly faster than was observed in later, isothermal studies.  However, it can be concluded 
that small modifications to the basic moiety of the parent compound can be used to  create 
significant changes in the rate of observed hydrolysis.  Furthermore, this data suggests that the 
change from a zwitterionic species at physiological pH to a cationic species has little effect upon 
its behaviour in the membrane, promoting the theory that the drug is effectively neutral when 
sequestered in the bilayer. 
 
Figure 82: Hydrolysis of DOPC catalysed by compounds A1,  A2 and D1, compared to both the standard raclopride data 
(Figure 33, blue line) and the data gathered using raclopride under identical conditions to the two test compounds (red 
squares).  No other di-methoxy compound demonstrated any hydrolytic activity: A3 is shown for illustrative purposes. 
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Under similar conditions, D2 was the only MANT compound to demonstrate any measureable 
hydrolytic activity, at a rate approximately half as fast as that of A2 in the example above.  
Despite repeated testing, no lyso-PC was detected in the presence of any other MANT amide, 
suggesting that the additional basicity of the probe led to a change in orientation of the 
molecule relative to the bilayer normal.  This is supported by preliminary modelling studies by 
Callum Dickson (unpublished work) which appear to show the probe compounds lying parallel to 
the membrane surface at the interface.  However, these results are at a very early stage and 
caution should be exercised when drawing conclusions based upon them. 
SAXS data, prepared from samples as described above and flame-and-silicone sealed into 1.5 
mm diameter glass capillaries showed no changes of interest in the membrane packing of any of 
the MANT analogues tested over a period of some three weeks (see Figure 83, below).  This is 
unsurprising considering the lack of hydrolytic activity displayed above, but further reinforces 
the notion that all these species, including those containing strongly basic tertiary amines, are 
net neutral when sequestered in a membrane at physiological pH.  If this were not the case, 
significant swelling of the lamellae would be observed, analogous to that demonstrated in 
Figure 35 in the presence of haloperidol. 
 
Figure 83: Collated data showing the small-angle X-ray scattering of a DOPC system containing 5 mol% D1 analysed over 
the course of 600 hours.  No measurable change in long-range packing was observed. 
The implications for these findings and those from section 5.5.2 when compared to the drugs’ 
respective hydrolytic activity suggests that previous hypotheses were to a large degree 
Page | 198  
 
incorrect: while the affinity of a CAD for its proton (its effective pK a) does have a major impact 
upon its ability to trigger hydrolysis, the assumption that higher basicity  higher activity has 
been proven to be too simplistic.  This data further supports the existence of a “Goldilocks zone” 
as described previously – an insufficiently basic compound resides too deeply within the 
membrane and does not cause hydrolysis, whereas if it is too basic the CAD is unwilling to 
relinquish its proton to the ester groups and so no reaction occurs.  
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7.5 Medical imaging applications  
In the event, no PET labelling was achieved during the time of the study: a combination of 
experimental difficulties and logistical issues meant that no successful labelling experiments 
were performed upon the compounds listed in Table 6.  Experimental difficulties revolved 
around the very low nucleophilicity of the target site chosen for 11C labelling, due to its 
internally hydrogen-bonded resonance forms (shown below in Figure 84), similar to those found 
in keto-enol structures228 such as those found in curcumin229.  These resonance forms were 
important as the source of the compounds’ fluorescence, as the hydrogen-bonded structure 
forms a second delocalised ring leading to anthracene-like absorption and emission spectra230.  
However, by delocalising the electrons on the free aniline, its nucleophilicity was substantially 
reduced, making its attack by [11C]-methyl iodide or [11C]-methyl triflate unfavourable even 
when activated with a hydride reagent such as sodium hydride (see Figure 84).  
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Figure 84: One of the resonance forms of E1 that prevented efficient labelling with [
11
C] methyl iodide.  Internal 
hydrogen bonding reduced the nucleophilicity of the free aniline to the point that reactions were so slow that they 
became unsuitable for PET study. 
Repeated attempts at Aarhus University Hospital with compounds E1, 2, 6 and 7 above 95% 
purity all showed similar results: labelling could be made to proceed, but at radiochemical yields 
in single digits making them insufficient for study.  While this reaction is certainly feasible under 
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standard laboratory conditions, under the low reagent/short timescale regime of PET chemistry 
the labelling became impractical without significant optimisation work and the study was 
postponed.  In the future, however, it should be perfectly possible to create such dual-modality 
imaging agents: work is currently on-going into the creation of amide bonds directly, using an 
aryl halide, an amine and a [11C]-labelled carbon monoxide molecule over a palladium 
catalyst231.  This work will allow the direct, one-pot synthesis of compounds of interest such as 
the one above, greatly simplifying labelling protocols and allowing the direct comparison of in 
vivo, ex vivo and in vitro experimental techniques. 
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8 Conclusions 
This study has made significant steps into understanding the mechanistic processes which 
underpin the hydrolysis of lipid membranes by raclopride, a model compound which bears 
strong structural resemblance to a wide range of commonly administered drugs.  Significant 
development has been achieved in the identification and optimisation of a robust assay to 
quantify the phenomenon, and the data derived with these new techniques proved to be 
extremely reproducible across different batches of lipid, reagent and analytical conditions.  
The investigation has overturned a number of the group’s previous assumptions regarding the 
dependencies and mechanisms of reaction, leading to a very different experimental programme 
to the one originally envisioned.  While no study into such a complex environment can 
realistically hope to identify every dependency of a process, the list of potential influencing 
factors has been significantly narrowed: the results in section 6 strongly suggest that simple 
geometric and curvature stress considerations do not adequately describe the behaviour 
observed, whereas the discovery that more ordered lipid arrangements promote raclopride’s 
hydrolytic activity suggest that either diffusional timescales, drug-lipid residency or water 
penetration depth may play a significant role in determining how fast the drug can digest its way 
through a membrane.  In that regard, the first of the three working hypotheses described in 
section 4.1.5 has been fully validated, and these findings are currently being prepared in a 
format suitable for publication. 
It has also been demonstrated that, despite earlier theories to the contrary, having a fully 
protonated or very high pKa basic group on the CAD molecule is not necessarily a predictor of 
potency.  The evidence presented in sections 0, 5.6.2.2 and 7.3 strongly suggest that raclopride 
does its work as a predominantly neutral species, whereas more basic and thus more fully -
protonated compounds have shown no activity at all under the assay conditions devised.  This 
also has implications for the leaflet selectivity of the reaction: previously, it was thought that 
drugs added exogenously could only really influence the outer leaflet, as the flip -flop time for 
charged amphiphiles is so slow.  However, the equilibration time for even very  large neutral 
species such as long-chain fatty acids is very rapid61, meaning that raclopride could potentially 
be distributed equally throughout its host membrane over a timescale of seconds.  
These findings contribute to suggestions that an ideal range of overlapping physico-chemical 
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parameters, a so-called “Goldilocks” zone, exists for drug hydrolysis and therefore, if the 
working hypotheses of the project (section 4.1.5), are to be believed, for drug transport as a 
whole.  Such a concept has precedent – Lipinski’s rule of 5 has been the basis to a greater or 
lesser extent of drug discovery for a decade121.  However, the understanding of this 
phenomenon offers the prospect of a genuine theoretical framework about which to hang our 
understanding of drug transport and bioavailability, rather than the current empirical rule of 
thumb. 
Despite this promise, there is still no real consensus over whether the reaction has any influence 
over in vivo transport, or whether it is simply an interesting but fundamentally insignificant 
phenomenon when its influence is compared to diffusion and organic transporter pumps 
described in section 3.2.  If the rates observed in the bulk phase studies revealed in sections 5.5 
and 6 really are representative of those in a genuine cell membrane, then the study above can 
be nothing more than a footnote, describing an unusual and unexpected effect but one of only 
academic interest.  However, the direct microscopy results from both in previous experiments 53 
and touched upon in cell imaging experiments presented briefly in section 5.6.4.1 suggest that, 
by whatever mechanism, the membrane disruption caused by CADs in giant vesicles and native 
cell membranes is significantly faster and more universal than in condensed phase experiments.  
In both these cases, membrane shedding was catalysed by drugs which did not reveal their 
effects during the bulk-phase assays in this study, suggesting that the kinetics of reaction are 
very different between the two systems. 
This sheds light upon the third of the working hypotheses discussed: these experiments and 
others like them have demonstrated that drugs sequestered within a membrane have no 
particular inclination to leave of their own accord and must be propelled by some external force 
or agent.  In the case of raclopride and a number of other CADs, the evidence suggests that 
agent is of their own making, a detergent droplet formed from the degradation products of their 
original host.  In those compounds where hydrolysis was not observed or was impossible by 
design, no such movement was observed and instead the compounds were content to reside in 
the membrane until their eventual precipitation or metabolism. 
This provides hope that further study into the phenomenon will confirm not just whether or not 
and to what degree the process contributes to systemic transport, but also how it might be 
profitably used by pharmaceutical researchers and companies to minimise the drug dose 
Page | 203  
 
required by a patient to reach effective tissue concentrations.  In this way, research following on 
from the above might make a genuine difference to patient healthcare, shrinking the volumes of 
drug that the body must metabolise and therefore expanding each compound’s therapeutic 
window, limiting toxicity and minimising side effects. 
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